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Abstract 
Transmissible  spongiform  encephalopathies  (TSEs)  are  rare  but  fatal 
neurodegenerative diseases affecting human and animals. The prion protein which 
is the causative agent, according to “protein-only” hypothesis misfold in to rogue 
amyloid conformer. Despite several years of studies, the atomic structural details of 
the rogue conformers  have not  been clearly understood. This study focused on 
developing  an  in-vitro  conversion  method,  which  allows  us  to  monitor  the 
transition from unfolded state of prion protein to fibril state. In order to reach 
maximal unfolded state, we have used 8 M urea as chemical denaturant, pH 2 and 
prion fragment 90-230 as the model. It has been demonstrated earlier that acidic pH 
and mild denaturant induce the fibril formation. The mechanism underlying the 
structural transition from monomeric state to polymeric form is largely unknown. 
We have confirmed by EM and AFM that fibrils are formed in our conditions, 
which  resemble  to  naturally  occurring  fibrils  in  morphologies  observed.  The 
agitation accelerates the rate of fibril formation and, which allow us to do time-
resolved NMR on these preparations.  
The conformational flexibility is inherent to amyloid fibrils and has been observed 
in our preparations.  We aimed to map the important segment of prion protein, 
which forms the rigid core in its fibrillar structured form. Our time-resolved NMR 
studies allowed us to monitor the changes happening from unfolded state to fibrillar 
state. Analysis of data identified the segment between residues 145 to 223 forming 
the rigid core in these fibrils, which correspond to β strand 2, helix 2 and major part 
of helix 3 of native prion monomeric structure. Most of the point mutations which 
are associated with hereditary prion disease are part of rigid core, which undergo a 
refolding on fibril formation. The C-terminal residues from 224 to 230 displayed  
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peak shifting and therefore, indicate the adaptation to a fibril specific conformation. 
The  major  part  of  N-terminal  90-144  segment,  remains  dynamic,  which  can  be 
understood by their accessibility to amyloid specific antibodies. This provides novel 
structural insight to the amyloid formation from unfolded state of prion protein 
fragment  90-230,  which  represents  the  proteinase-K  resistant  part  naturally 
occurring  prions.  Earlier  studies  have  established  the  core  to  160-220  where 
hydrogen-deuterium exchange mass spectrometry or site-directed spin labeling EPR 
spectroscopy was used for analysis. Those studies have been initiated from either 
native-like or partially unfolded state of recombinant prion protein, and therefore, 
it is quite striking to find out that fibrils initiated from unfolded monomeric state 
share the same “amyloid core”. This structural insight has important implications 
for understanding the molecular basis of prion propagation 
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Chapter 1  
Protein Misfolding, Amyloid and Prion Diseases 
The "Central Dogma of Molecular Biology" (Crick, 1970) refers to the flow of 
genetic  information  in  biological  systems.  The  genetic  information  flows  from 
DNA  to  RNA  to  protein.  DNA  (deoxyribonucleic  acid)  encodes  the  genetic 
information for most species. In order to use this information to produce proteins, 
the DNA must first be converted into a messenger RNA (ribonucleic acid) through 
a process called transcription. The information carried by the mRNA is then used 
as information transfer to code for a specific protein (or polypeptide) through a 
process called translation. Each polypeptide then performs a specific function in the 
cell. Retroviruses, like HIV, carry an RNA genome which is converted into DNA 
prior to its insertion into the human genome. In order to carry out this conversion, 
the RNA must be reverse transcribed into DNA. Retroviruses produce a special 
enzyme called reverse transcriptase which, conveniently, performs the process of 
reverse transcription (RNA  DNA). Once the viral DNA is inserted into the 
human genome, the standard rules of the central dogma apply (Figure 1.1). 
 
Figure 1.1: Schematic representation of central dogma of molecular biology: the flow 
of biological information.  
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The  prions  as  called  by  Nobel  laureate  S.  Prusiner  to  define  “proteinaceous 
infectious agent” are protein molecules which are infectious agents. Since prions are 
proteins, they do not carry a genome. Prion diseases, such as Mad Cow, result from 
the interaction of misfolded, i.e. rogue prion proteins with normal prion proteins. 
These  interactions  result  in  the  misfolding  of  the  normal  prion  proteins  and, 
ultimately, the typical spongiform encephalopathy associated with prion diseases 
(Hunter, 1999, Keyes, 1999a, b, Morange, 2007). The native structure of protein is 
the unique, stable and kinetically accessible minimum of the free energy. How these 
proteins reach their native structure is studied as "protein folding". These prions 
exist in more than one stable conformation (prion strains) and, which defy the 
presence  of  single  minimum  energy  structure.  These  structures  are  usually 
macromolecular ordered assemblies, known as protein fibrils. It therefore, studies 
on prion proteins and alike a new field of study called “Protein misfolding and 
aggregation”. In this chapter, we discuss about understanding of protein folding, 
misfolding and aggregation, human prion protein and its conformations, structures 
of amyloid fibrils and finally NMR methods to explore amyloid fibril assemblies 
and its formation.  
Protein folding, misfolding and aggregation 
Protein  folding  is  defined  as  the  physical  process  by  which  a  newly  expressed 
nascent  polypeptide  chain  adopts  its  characteristic  and  functional  conformation. 
This process includes structural modification in the endoplasmic reticulum and the 
Golgi  in  eukaryotic  organisms.  The  stable  structural  conformation  exposes 
hydrophilic elements on the surface, while hydrophobic elements form the interior 
of  the  protein  (Crick,  1970).  This  process  is  crucial  as  the  correct  fold  is  a 
prerequisite for a protein’s stability and the functionality to make it able to interact  
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with its partner biological macromolecules (Dobson, 2003).  How do these proteins 
adopt the correct structure? What is the mechanism of folding? How is folding 
regulated in a living cell? These are the fundamental question of protein folding. In 
1968, Levinthal (Levinthal.C, 1968) was the first to notice the protein puzzle that 
even  though  proteins  have  vast  conformational  spaces,  protein  can  search  and 
converge quickly to native states, on a microsecond time scale.  The pioneering 
work of Anfinsen on protein folding in the 1970s (Anfinsen, 1973) inferred that the 
three-dimensional  structure  is  encoded  by  the  amino  acid  sequence  of  the 
polypeptide chain and this functional fold represents  a global minimum on the 
energy  landscape.  Based  on  this  finding,  enormous  effort  has  been  put  to 
understand the process of folding. How to achieve a minimum energy state and 
tracing  the  trajectory  of  folding  has  been  of  major  interest  in  protein  folding 
studies. The folding funnel hypothesis is a specific version of the energy landscape 
theory of protein folding, which assumes that a protein's native state corresponds 
to its free energy minimum under the solution conditions usually encountered in 
cells. It became evident that a random search for the right conformation cannot be 
performed  on  a  microsecond  to  a  millisecond  biological  timescale  of  protein 
folding,  and  the  protein  is  “funneled”  down  through  the  energy  landscape  by 
energy barriers, kinetic traps and narrow pathways (Figure 1.2) (Wolynes et al., 
1995,  Dill  and  Chan,  1997).  The  cross-sectional  view  of  energy  funnel;  shows 
presence  of  the  myriads  of  unfolded  states  at  the  edges  of  the  funnel,  where 
potential energy and entropy are large. The native state is found at the funnel’s 
bottom and has minimal energy and almost zero   






.   
  Figure 1.2: Schematic representation of folding energy landscapes. (a) Smooth 
funnel model: An idealized funnel landscape. As the chain forms 
increasing numbers of intrachain contacts, and lowers its internal 
free energy, its conformational freedom is also reduced (b) Bumpy 
bowl  model  which  display  that  native  structure  N  is  achieved 
through  intermediate  stages  with  kinetic  traps,  energy  barriers, 
and some narrow throughway paths (c) a cross-sectional view of 
funnel. (adapted from (Dill and Chan, 1997)).  
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entropy. Folding, therefore, advances by a trade-off between energy and entropy as 
protein  moves  down  the  energy  landscape  its  energy  decreases,  but  so  does  its 
entropy. This folding process takes place by different routes connecting unfolded 
and native state of protein. The concept of a folding funnel can be understood as 
ensembles of unfolded nascent polypeptide chain flowing through many diverse 
parallel microscopic routes to the native state ground state. Therefore the folding 
pathway  is  an  ensemble  of  multiple  microscopic  folding  trajectories  and  these 
microscopic  folding  routes  may  be  grouped  into  several  macroscopic  pathways. 
Any  state  except  the  native  (unfolded  and  intermediate)  is  an  ensemble  of 
microstates (i.e., microscopic conformations). These microstates are meta-stable and 
microscopic  trajectories  initiate  from  unfolded  ensembles.  These  conformational 
trajectories are driven either by native, nonnative or a blend of both interactions. The 
presence of nonnative interactions in the transition state is supported by all-atom 
simulations using a Charmm-based effective energy function, where it was found 
that 20%–25% of the energy in the transition state arose from nonnative contact 
(Paci et al., 2002). Recently; a computational study on β-Hairpin peptide shows that 
its folding to native structure channeled through nonnative structuring (Figure1.3). 
This is one of the examples to show the importance of nonnative interactions in 
protein folding (Thukral et al., 2009), which is in accordance to the data published 
from our group stating that nonnative contacts stabilize early formed structures to 
prevent degradation or aggregation (Klein-Seetharaman et al., 2002).  
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Figure  1.3:  Folding  of  β-Hairpin  Peptide  routing  through  nonnative  structures. 
(Adapted from (Thukral et al., 2009) 
On the other hand, the living cells are composed of very dense environment having 
about  300  g/L  of  protein  and  other  macromolecules  (Ellis,  2001b,  a).  This 
macromolecular crowding is considered as an important cause for these nonnative 
interactions  which  lead  to  intermolecular  interactions  between  the  unfolded 
domains of unstable or partially stable intermediate states. These intermolecular 
interactions  results  in  self-association  leading  to  formation  of  large  ordered  or 
disordered  assemblies  broadly  called  “aggregates”  (Dobson,  2003,  Brockwell  and 
Radford, 2007). It is necessary for a cell to avoid these aggregate formations and 
therefore  folding  should  happen  in  a  regulated  manner  to  prevent  misfolding 
(Figure  1.4).  In  biological  state,  this  is  achieved  by  molecular  chaperones  (e.g. 
Hsp/Csp) they guide protein to adopt correct functional fold while the ubiquitin 
proteasome pathway directs degradation of abnormally folded conformations (Jahn  
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and Radford, 2005). The failure or disruption of any of these safeguarding systems 
results in malfunctioning of the living organism causing the disease (Dobson, 2001, 
Horwich, 2002). The nonnative states of proteins are considered as potential entry 
points  for  folding  or  misfolding  pathways  of  protein  thus  it  is  important  to 
characterize the residual structure in these states. Nonnative states of proteins can 
be  produced  in-vitro  by  denaturizing  the  native  protein.  This  denaturation  is 
achieved by putting protein under physical or chemical stress; physical methods 
include  pressure  and  temperature  variation  while  chemical  stress  is  created  by 
varying  pH  to  highly  alkaline  or  acidic,  by  chaotropic  agents  such  as  urea  or 
guanidine hydrochloride, by detergents like sodium dodecyl sulfate and by other 
reducing agents like 2-mercaptoethanol or dithiothreitol. This denaturation process 
is often reversible.  
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Amyloidosis: a protein conformational disease.  
„Es gibt fast kein Problem in der allgemeinen und speziellen  Pathologie, das sich über 
Jahrhunderte in einer so sphinxhaften Weise verhalten hat wie die Amyloidose.“ [There is 
almost no problem in general and systemic pathology that over the centuries has behaved 
in such a sphinx-like way as amyloidosis.] From Letterer (1966)(Westermark, 2006) 
 
The term amyloidosis refers to a group of diseases caused by abnormal deposition 
of aggregated proteins in organs and/or tissues (Ghiso et al., 1986, Abrahamson et 
al., 1992, Westermark et al., 2005). Amyloidosis can be either local or systemic, 
where  the  amyloid  deposits  are  localized  to  a  particular  organ  or  found  in  the 
whole body, respectively. So far, 24 (or more) different proteins have been isolated 
from  amyloid  deposits  associated  with  different  forms  of  human  amyloidoses 
(Westermark  et  al.,  2005,  Westermark,  2005).  A  brief  summary  of  some 
amyloidogenic  proteins  and  related  amyloid  diseases  is  given  in  Table  1 
(Westermark, 2006). Among these disorders, prion diseases distinguish themselves 
by  their  transmissibility,  which  is  believed  to  be  a  serious  threat  to  the  public 
health. 
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Table 1 : Amyloid fibril proteins and their precursors in human (Westermark, 2006). 
Amyloid  Precursor protein 
Systemic (S) 
or  localized 
(L) 
Syndrome  or  involved 
tissues 
AL 
Immunoglobulin  light 
chain 
S, L  Primary myeloma associated 
AH 
Immunoglobulin  heavy 
chain 
S, L  Primary myeloma associated 
ATTR  Transthyretin 
S 
L 
Familial senile systemic 
Tenosynovium 





AA  (apo)serum AA  S  Secondary, reactive 





AApoAII  Apoliproprotein AII  S  Familial 
AGel  Gelsolin  S  Familial 
ALys  Lysozyme   S  Familial 
AFib  Fibrinogen   chain  S  Familial 
ACys  Cystatin C  S  Familial 
ABri/AD
an 
ABriPP/ADanPP  S/L 
Familial  dementia, 
British/Danish 
AApoAIV  Apoliproprotein AII  S  senile 
A   A  protein precursor  L  Alzheimer’s disease 
APrP  Prion protein  L  Spongiform encephalopathies 
ACal  (Pro)calcitonin  L  C-cell thyroid tumors 
AIAPP  Islet amyloid polypeptide  L  Islets of Langerhans insulinomas 
AANF  Atrial natriuretic factor  L  Cardiac atria 
APro  Prolactin  L  Aging pituitary prolactinomas 
AIns  Insulin  L  Iatrogenic 
AMed  Lactadherin  L  Senile arotic, media 
AKer  Kerato-epithelin  L  Cornea; familial 
ALac  Lactoferrin  L  Cornea; familial 
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Amyloid 
The  term  amyloid  was  introduced  in  1854  by  the  German  doctor  Rudolph 
Virchow  to  define  an  abnormal  macroscopic  appearance  in  cerebral  corpora 
amylacea  after  staining  with  iodine.  These  macroscopic  deposits  had  properties 
similar to cellulose and starch (Puchtler and Sweat, 1966). Virchow also detected 
proteins in these deposits, but the protein fraction was not considered to be a part 
of the amyloid. Later, it was established that main component of amyloid is protein 
(Sipe and Cohen, 2000). In 2006 the Nomenclature Committee of the International 
society of Amyloidosis  defined amyloid as intra- and extracellular protein deposits, 
mainly consisting  of protein fibrils with  typical X-ray diffraction pattern and a 
particularly affinity for the dye Congo red resulting in green birefringence. It was 
based on earlier studies using electron microscopy, which displayed that amyloids 
of different origins share similar fibrillar ultrastructure (Cohen and Calkins, 1959). 
Similarly, the optical microscopic studies of Congo red-stained amyloid revealed 
that it shows apple-green birefringence under polarized light (Puchtler and Sweat, 
1966). The following X-ray diffraction analysis of amyloid revealed that amyloid 
fibrils present characteristic “cross-β” structure, i.e. continuously stacked β strands 
are oriented perpendicular to the axis of the fibril (Eanes and Glenner, 1968). First, 
atomic level insight into this “cross-β” motif has been obtained by Nelson et al. 
using  microcrystals  formed  by  short  amyloidogenic  peptides  thought  to  reflect 
certain structural properties of amyloid fibrils (Nelson et al., 2005).  
In classical sense, amyloid is an extracellular deposit of proteinaceous fibrils, with 
specific “cross-β” structure, characterized by green birefringence after being stained 
by Congo red (Westermark et al., 2005). However, it has been shown that many 
synthetic  proteins  and  peptides  form  amyloid-like  fibrils  in  vitro.  Thus,  
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biophysically, the definition of amyloid may be extended to any ordered protein or 
peptide aggregate with a “cross-β” structure.  The concept of protein folding funnel 
was extended to “dual-funnel” to allow the aggregation states of proteins (Figure 
1.5).  Partially  folded  states  on  this  landscape  may  be  intrinsically  prone  to 
aggregation, and favorable intermolecular contacts drive their association towards 
fibrillar  state  and  eventually  to  protein-misfolding  diseases.  The  mechanisms, 
specific  to  aggregation  process  have  not  been  fully  understood.  A  general 
understanding about misfolding and aggregation is that intermolecular contacts are 
required to drive unfolded polypeptide ensembles towards many disease causing fibril 
assemblies while intramolecular contacts lead to right functional conformation.  
 
 
Figure 1.5: extension of protein funnel with addition of aggregation funnel in magenta, 
when extended ensembles trap to form aggregates or amyloids.  adapted 
from (Jahn and Radford, 2005).  
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Prion diseases 
Prion  diseases  correspond  to  pathologically  defined  transmissible  spongiform 
encephalopathies  (TSEs)  of  infectious,  genetic  or  sporadic  nature  and  are 
characterized by neurodegeneration and protein aggregation. They are known as 
TSEs because of the sponge-like holes they leave in infected brains. These diseases 
are  a  relentlessly  progressive  and  fatal  in  nature.  The  human  and  animal 
neurodegenerative conditions associated with prion diseases include the deposition 
of  abnormal  Prion  Protein  (PrP
Sc)  in  the  brain  that  affects  the  central  nervous 
system. A list of various Prion diseases is given in Table 1.2 (Prusiner, 1998). The 
pathology  of  TSE  may  vary  from  case  to  case,  but  generally  result  in  similar 
neurological features such as vacuolation, astrocytosis, and neuronal loss (Jeffrey et 
al., 1995), giving the brain a “spongy” appearance. Scrapie is the first prion disease 
ever studied, it was first described in sheep and goats more than two hundred and 
fifty  years  ago  (Woolhouse  et  al.,  2001).  In  1936,  scrapie  was  demonstrated  as 
transmissible by Cuille and Chelle (Detwiler, 1992). In 1959, Hadlow reported that 
scrapie and Kuru have common histopathological and clinical traits, making a link 
between an animal and a human form of TSE for the first time (Hadlow, 1959, 
1995). In the same year, Gajdusek managed to transmit Kuru from brain material 
of deceased humans to chimpanzees by intracerebral injection. In 1976, Gajdusek 
received the first Nobel Prize to be given to researchers in the TSE-field. The 
scrapie transmission to goats and mice successfully demonstrated a few years later 
(Chandler,  1961,  1962,  Detwiler,  1992).  In  1947,  the  second  animal  TSE, 
Transmissible Mink Encephalopathy (TME), was recognized in ranch-raised mink 
by Gaylord Hartsough (Marsh and Hadlow, 1992). In many midwestern states of 
the United States, some elk and mule deer carry a form of TSE called Chronic 
Wasting Disease (CWD) (Salman, 2003).  
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Human TSEs can be classified into three different forms: sporadic, inherited, or 
acquired by infection. Around 85% of TSE cases occur sporadically, in absence of 
any  obvious  trigger  (Sy  et  al.,  2002).  The  inherited  forms  include  Gerstmann–
Sträussler–Scheinker syndrome (GSS), fatal familial insomnia (FFI) and around 15% 
of the cases of Creutzfeldt–Jakob disease (CJD) (Eggenberger, 2007). Kuru is the 
first identified infectious human TSE; its transmissibility was linked to the practice 
of ritualistic cannibalism, confined to the Fore highlanders of Papua New Guinea 
(Liberski  and  Gajdusek,  1997).  Human-to-human  transmission  of  TSEs  was 
confirmed by iatrogenic CJD cases caused by direct contact of the central nervous 
system with contaminated material during medical treatment (Johnson and Gibbs, 
1998).  
Prion diseases are rare in humans, and until 1980s the knowledge of these diseases 
was limited to a small community of neuroscientists. Since 1986, a new form of 
TSE, Bovine Spongiform Encephalopathy (BSE), also known as “mad cow disease,” 
had started to spread in Great Britain and infected more than 180,000 cattle (Brown 
et al., 2001). BSE is also believed to have been transmitted to humans resulting in 
outbreak  of  a  new  form  of  CJD,  variant  CJD  (vCJD)  by  consumption  of 
contaminated beef products (Bruce et al., 1997). Since then, TSEs have attracted 
enormous attention from both scientists and the public. A special concern is the 
potentially long incubation period for prion diseases, infected individuals may be 
carriers (pre- and subclinical) and similarly CJD-infection can be spread by blood 
transfusion or tissue transplants. Infective rogue proteins are resilient molecules; 
they are very difficult to destroy by routine sterilization methods and carry their 
infectivity. The presence of unnoticed subclinical infections in animal and human 
populations is continuous concern for health and food control authorities.   
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Table 2: Prion Diseases of mammals  
Species    Prion Disease 
Human  Sporadic  sCJD 
  Inherited  fCJD, GSS, FFI, BPI 
  Acquired  iCJD, Kuru, vCJD 
Sheep    Scrapie 
Cattle    BSE 
Mink    TME 
Felidae    FSE 
Cervids    CWD 
 
Protein-only hypothesis 
Development of prion concept. Initially, until 1950s, scrapie, kuru, and CJD were 
studied  independently,  without  realizing  the  interconnection  among  these 
disorders. In 1959, William Hadlow pointed out the likenesses between kuru and 
scrapie, and suggested that experimental transmission of kuru should be performed 
on  chimpanzees,  since  they  are  genetically  very  close  to  humans  (Liberski  and 
Gajdusek, 1997). In 1966, Gajdusek et al. efficiently infected chimpanzees with kuru 
by  injecting  brain  homogenates  from  diseased  human  into  the  recipient’s  brain  
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(Gajdusek et al., 1966, 1967). Later, the same group (Gibbs Jr et al., 1968, Masters et 
al., 1981b, a) showed the transmissibility of sporadic CJD and some forms of GSS 
indicating that the infectivity of a TSE is not related to if it is sporadic, inherited, or 
acquired by infection. 
Once the transmissibility of TSEs was established, efforts were made to identify the 
causative  pathogen.  At  first,  based  on  the  unusually  long  incubation  periods 
between the exposure to the infectious agent and the onset of symptoms (Becker, 
1977), it was suggested that TSE diseases were caused by a “slow virus” (Gajdusek et 
al., 1966, 1967), a term coined by Bjorn Sigurdsson in 1954 while he was working 
on scrapie disease of  the sheep in Iceland (Palsson, 1994). However, subsequent 
studies showed that the infectious TSE agent might not be a virus, or any other 
known  type  of  infectious  pathogen,  because  the  minimum  agent  necessary  for 
infectivity  was  found  to  be  too  small  (Alper  et  al.,  1967).  Furthermore, 
investigations  revealed  that  the  infectious  agent  from  scrapie  had  extraordinary 
resistance to inactivation by UV and ionizing radiation, which would normally 
destroy DNA or RNA (Alper et al., 1967, Latarjet et al., 1970). Later, a similar 
resistance was found for the CJD agent (Gibbs et al., 1978).  
All these investigations led scientists to conclude that causative TSE agents were 
devoid of nucleic acid, leading to many proposals on the nature of these pathogens 
(Gibbons and Hunter, 1967, Griffith, 1967, Pattison and Jones, 1967, Hunter et al., 
1968, Field et al., 1969, Hunter, 1972). In 1967, Griffith proposed, for the first time, 
that a self-replicating protein instead of a virus was responsible for the transmission 
of scrapie (Griffith, 1967). In 1979 Stanley Prusiner started to work on the concept 
of an infectious agent completely devoid of DNA and based on his results, he 
hypothesized  that  TSE  agents  are  primarily  made  of  protein  and  called  them  
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“prion”  (Prusiner  et  al.,  1980a,  Prusiner  et  al.,  1980b,  Prusiner  et  al.,  1980c, 
Prusiner et al., 1980d).  
 
 
Figure 1.6: Prion cycle in cell. Prion proteins are synthesized and processed in ER and 
Golgi and transported to cell membrane (green) while, when they come in 
contact with rouge conformer (red), conversion of normal PrP to rouge 
conformation happened at cell surface and cell intake misfolded protein by 
endocytosis. These misfolded prions pile up in lysosome and where they 
grow in volume leading to cell death. 
“Protein-only” hypothesis. In 1982, Prusiner and his colleagues successfully isolated 
the infectious agent from scrapie-infected hamster brains (Prusiner, 1982, Prusiner 
et al., 1982a, Prusiner et al., 1982b), and concluded that the agent was devoid of any 
detectable nucleic acid and was mainly, if not entirely, composed of protein. To 
describe this unusual pathogen, Prusiner coined the term “prion,” derived from 
“proteinaceous  infectious  particle.”  Therefore,  that  protein  was  named  prion 
protein, PrP. Since then, prion diseases have been considered synonymous with 
TSEs. Later, Prusiner was awarded the Nobel Prize for his work on Prions in 
1997.   
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The studies revealed that prions often have typical amyloid features, including a 
rod-like  shape  in  electron  micrographs  and  apple-green  birefringence  under 
polarized light after staining with Congo red (Prusiner et al., 1982a, Prusiner et al., 
1983). Prions are partially resistant to proteolytic digestion by proteinase K (PK), 
and  Western  blotting  analysis  showed  the  PK-resistant  core  of  prions  shows  a 
molecular weight of 27-30 kDa, named PrP27-30 (Bolton et al., 1982, Prusiner et al., 
1982a, McKinley et al., 1983). All of the aforementioned findings were summarized 
in the revolutionary “protein-only hypothesis.” It states that the infectious particles, 
responsible for the transmissible forms of prion diseases are composed of an abnormal 
isoform of  the  normal cellular prion  protein designated  PrP
Sc. Conversion  from the 
normal form of prion protein designated PrP
C to PrP
Sc can be catalyzed by introducing 
PrP
Sc.  Therefore  a  native  prion  protein  go  through  conformational  conversion, 
when it comes in proximity with misfolded prions (Figure 1.6), those misfolded 
proteins get deposited into lysosome through endocytosis.  
Evidences supporting the protein-only hypothesis. Since prions are entirely different 
from  other  known  infectious  pathogens,  the  protein-only  hypothesis  is  very 
controversial  (Chesebro,  1998,  Manuelidis  et  al.,  2007),  but  colossal  amount  of 
biochemical data were published to support this model. Evidences in favor of the 
hypothesis include: 
1) A few years after purifying PrP27-30, the gene encoding PK-resistant PrP 
was detected and identified as a host gene, designated PRNP in humans and Prnp in 
animals (Oesch et al., 1985, Basler et al., 1986, Sparkes et al., 1986). The PRNP gene 
is mapped to the short arm of chromosome 20, and the exact location of the Prnp 
gene varies from species to species. Further, the translated product from the Prnp 
gene was found to be widely expressed, even in a noninfected host, and showed no  
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difference in the primary structure, nor did it show any posttranslational chemical 
modification  different  from  that  of  PK-resistant  PrP.  However,  the  translated 
product was highly soluble and very sensitive to PK digestion (Oesch et al., 1985, 
Basler et al., 1986, Stahl et al., 1993). 
2)  Transgenic  studies  of  mouse  provided  another  important  evidence  to 
support  protein-only  hypothesis  (Bueler  et  al.,  1992,  Prusiner  et  al.,  1993).  PrP 
knockout mice  were  resistant  to  the  scrapie  infection,  demonstrating  that  PrP
C 
expression is crucial to the propagation of prion diseases. 
3) Genetic studies of familial prion diseases also strengthened the essential 
role  of  PrP,  and  provided  important  support  to  the  protein-only  hypothesis 
(Collinge, 2001). To date, more than twenty mutations in the PRNP gene have 
been connected to inherited prion diseases. 
4) A number of studies on prion-based inheritance in yeast and fungi have 
proven the principle that proteins alone can be infectious (Uptain and Lindquist, 
2002, Chien et al., 2004). 
5) Further evidence came from the success in generating infectious PrP
Sc in 
vitro. Since the cell-free conversion of PrP
C to PrP
Sc was first reported in 1994 
(Kocisko et al., 1994), in vitro generation of prions has been studied extensively, 
which  finally  led  to  a  new  cell-free  conversion  system  called  Protein  Misfolding 
Cyclic  Amplification  (PMCA)(Soto  et  al.,  2002b,  Castilla  et  al.,  2005).  In  2004, 
Legname et al. successfully infected transgenic mice by inoculating them with in 
vitro  generated  amyloid  fibrils  from  recombinant  PrP  (Legname  et  al.,  2004). 
However, some scientists expressed reservations about the conclusions, because the 
transgenic  mice  used  in  these  studies  over-expressed  by  16  times,  the  normal  
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amount of PrP, while mice which overexpressed PrP only 10 times the normal 
amount were found to show symptoms of prion disease without any inoculation 
(Couzin, 2004, Weissmann, 2005). To date, scientists are still looking for final proof 
of  the  protein-only  hypothesis:  using  in  vitro  produced  PrP
Sc  to  infect  normal 
experimental animals. 
Prion strains and species barriers: Although many results support the protein-only 
hypothesis, there are still some arguments against it (Kimberlin, 1982, Prusiner, 
1998). One of these arguments is the existence of prion strains, where PrP
Sc can 
result in several distinct phenotypes which are  faithfully  propagated  (Bruce and 
Fraser, 1991). First noted in early interspecies transmission experiments (Pattison 
and  Millson,  1961),  prion  strains  differ  in  the  following  three  characteristics: 
incubation period, histopathological lesion profiles, and clinical symptoms (Morales et 
al., 2007). As well as these differences, prion strains can also be distinguished by 
biochemical and physical properties, such as PK resistance, to locate PK cleavage 
sites  (Bessen  and  Marsh,  1992,  1994),  and  the  ratio  of  unglycosylated, 
monoglycosylated  and  diglycosylated  PrP  within  the  infectious  PrP
Sc  aggregate 
(Khalili-Shirazi et al., 2005). Although distinct pathologies of disease are more easily 
reconciled  with  pathogens  containing  nucleic  acid,  prion  strains  can  still  be 
accounted for by the protein-only hypothesis. Recent evidence suggested that prion 
strains  are  encoded  in  the  different  conformational  forms  of  PrP
Sc  (Bessen  and 
Marsh, 1994, Aguzzi, 2004, Priola and Vorberg, 2004). Other factors that would 
likely influence the strain phenotype include PrP
C glycosylation and differential 
binding of additional components to PrP
Sc (Weissmann, 1991, Khalili-Shirazi et al., 
2005).  
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In most cross-species transmission experiments, prions transmitted between species 
resulted  in  longer  incubation  periods  and/or  weakened  pathology.  This 
phenomenon  is  called  the  “species  barrier”,  and  reflects  the  observed  limited 
infectivity  of  prions  of  one  species  towards  another  species.  To  determine  the 
molecular basis for this barrier, Prusiner et al. developed transgenic mice expressing 
Syrian hamster PrP, which were found to be highly susceptible to hamster prions 
in contrast to normal nontransgenic mice (Scott et al., 1989, Prusiner et al., 1990). 
These studies were able to link the species specificity of prions with PrP sequence. 
Later, in vitro cell-free conversion studies limited the species specificity to a couple 
of amino acid residues (Kocisko et al., 1995). 
PrP
C  
The structure of PrP
C. Mammalian PrP
C is a glycoprotein attached to the cell surface 
by a C-terminal glycosylphosphatidylinositol (GPI) anchor. The original translated 
product  consists  of  253  amino  acids.  During  processing  in  the  endoplasmic 
reticulum, residues 1-22 are cleaved as a signal peptide that targets the protein to the 
plasma membrane, and residues 232-253 are replaced by a GPI anchor (amino acid 
numbering  according  to  human  PrP),  so  mature  PrP
C  contains  209  residues 
spanning from 23 to 231. PrP
C has three types of posttranslational modifications: 
two N-glycosylation sites at Asn181 and Asn197 (Caughey et al., 1989, Haraguchi 
et al., 1989), a single disulfide bond between Cys179 and Cys214 (Turk et al., 1988), 
and  a  C-terminally  attached  GPI  anchor  (Stahl  and  Prusiner,  1991,  Stahl  et  al., 
1993). In the human brain, the molecular weight of PrP
C varies among different 
glycoforms: 27 kDa for the unglycosylated form, 29 kDa for the monoglycosylated 
form and 33-42 kDa for the diglycosylated form.  
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Before  1996,  high-resolution  structural  studies  of  PrP
C  were  hampered  by  the 
limited source of the protein. The problem was finally resolved by the successful 
expression of PrP in E. coli ((Hornemann and Glockshuber, 1996, Mehlhorn et al., 
1996, Zahn et al., 1997). Since then, the three-dimensional structures of PrP from 
different  species  have  been  determined  by  nuclear  magnetic  resonance  (NMR) 
spectroscopy (Riek et al., 1996, Donne et al., 1997, Zahn et al., 2000). All structures 
are very similar which is consistent with the fact that most known mammalian 
PrPs share a high degree of sequence identity (Wopfner et al., 1999). Different from 
the NMR structures, the crystal structure of human PrP was reported as a dimer 
(Knaus et al., 2001). However, the solution structure of human PrP (as shown in 
Figure 1.7) is believed to be more representative of the native structure in vivo. In 
this structure, full-length human PrP
C can be divided into two regions: the folded 
C-terminal segment (126-231) contains three  helices and two  -strands, while the 
N-terminal  segment  (23-125)  is  flexible  and  unstructured.  An  octarepeat  region 
between residues 51-91 contains four glycine-rich repeats (PHGGGWGQ) and one 











Figure 1.7: NMR structure of human prion protein (PDB:1QM0), C-ter 23 to 125 are 
unstructured while N-ter 126 -228 have well-defined structure having three 
-helices  and  two  -strands  forming  an  anti-parallel  sheet.  The  N-ter 
unstructured part consist of five octapeptide repeats followed by charge 
cluster (CC), hydrophobic cluster (HC), while structured part is having 
two β-strand (S1 & S2) and three α-helices (H1, H2 & H3)  
The cellular function of PrP
C: Despite many years of research, the exact physiological 
function of PrP
C remains unclear. Surprisingly, PrP knockout mice were found to 
behave normally, without any apparent defects (Bueler et al., 1992). So far, many 
hypotheses  have  been  proposed  for  the  physiological  function  of  PrP
C,  varying 
from protection against apoptotic and oxidative stress, to transmembrane signaling, 
to formation and maintenance of synapses (Hu et al., 2007, Westergard et al., 2007, 
Hu et al., 2008). Besides these proposals, the only clear feature of PrP is its ability to 
bind copper (II) ions. Most studies found the major copper-binding site was the 
octarepeat region of PrP
C, a region highly conserved in mammalian and avian PrP 
((Hornshaw et al., 1995, Viles et al., 1999, Jackson et al., 2001). All these results  
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appear to suggest the involvement of PrP in brain copper metabolism, a hypothesis 
first proposed by Brown and Kretzschmar (Brown et al., 1997). 
The  strongest evidence  for  this  hypothesis  came  from  studies  of  PrP  knockout 
mice, where the copper content in their synaptosomes was found to be much lower 
than that of wild-type mice (Brown et al., 1997, Herms et al., 1999). However, the 
above results were challenged by a following study, which proved that the amount 
of ionic copper in subcellular fractions or in whole brain were similar in the mice 
with different PrP expression levels (Waggoner et al., 2000). Taken together, a more 
likely hypothesis is that PrP
C can buffer copper ions in the synaptic cleft, so PrP
C 
can only alter the distribution of the copper content in the brain (Vassallo and 
Herms, 2003). 
 
Mutations associated with the PRNP gene.  
The  inherited  prion  diseases  are  linked  to  mutations  in  the  PRNP  gene.  These 
mutations can be classified into the three categories (Mead, 2006). 
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Figure 1.8: The pathogenic point mutations associated with hereditary prion diseases 
in PrP 27-30 region. (Prusiner, 1998, van der Kamp and Daggett, 2009) 
1) Insertions of extra octapeptide repeats. Since the octarepeat region is 
not required for prion infection (Fischer et al., 1996), the mechanisms by which 
these mutations cause the diseases remain unclear. 
2)  Point  mutations  leading  to  a  premature  stop  codon.  One  of  these 
mutations is to substitute tyrosine with a stop codon at position 145, which results 
in a familial prion disease with the deposition of prion amyloid in cerebral vessels 
(Ghetti et al., 1996) 
3) Point mutations leading to an amino acid substitution. So far, more 
than 25 of these mutations have been found within the 90-231 region of PrP (Figure 
1.8) (Prusiner, 1998, van der Kamp and Daggett, 2009).  
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The connection between mutations and diseases is not fully understood. However, 
Surewicz  lab’s  previous  stopped-flow  studies  have  revealed  the  existence  of  a 
partially folded intermediate on the pathway of PrP refolding (Apetri and Surewicz, 
2002,  Apetri  et  al.,  2004).  Compared  to  wild-type  PrP,  most  disease-associated 
mutations result in an increase of the thermodynamic stability and thus to populate 
the intermediate, suggesting its possible role in the conformational conversion of 
PrP. 
The rouge conformations: PrP
Sc 
Prion Conversion Models 
Nucleation dependent polymerization model 
  
 
Figure 1.9: Nucleation dependent polymerization model of prion propagation, early 
conversion  to  β-rich  structure  is  reversible  and  slow,  therefore  rate-
limiting step. 
The  slow  onset  of  neurodegeneration  is  a  characteristic  of  the  human  prion 
diseases (Figure 1.9).  (Jarrett and Lansbury, 1993) The prion amyloid exists as 
ordered  noncrystalline  polymers;  which  can  be  defined  as  a  one-dimensional 
crystal in which the intermolecular packing in the plane vertical to the direction 
of fibril growth is nonuniform. Amyloid is capable of forming different types of 
insoluble,  amorphous  aggregates  which  can  form  rapidly  when  the  protein 
concentration exceeds the solubility. There is a kinetic barrier to amyloid formation 
caused by a lag in forming an amyloid nucleus which can subsequently multiply. This  
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nucleation  formation  is  rate-determining  step  and  was  proposed  to  be 
mechanistically  relevant  to  that  speeded  up  by  the  presence  of  infective  agent 
during amyloid formation. This led to the hypothesis of a possible replication 
mechanism  for  converting  PrP
C  into  PrP
Sc  which  assumes  that  PrP
Sc  is  an 
aggregate in which an alternative conformer of PrP is stabilized by intermolecular 
interactions. In this model, the initial  slow reversible formation of a nucleating 
PrP
Sc multimer leads to a seeding process, during which PrP monomers are added 
to  the  growing  polymer  in  an  abnormal  PrP  conformation.  The  growing 
polymers can break apart, producing new seeds. PrP
Sc acts as a nucleation seed in 
the infectious form of disease and inherited mutations might contribute to the 
increase in affinity of the abnormal conformation of PrP for the polymer seed. 
Nucleation-dependent polymerization is common among many well-characterized 
processes  including  protein  crystallization,  flagellum  assembly,  microtubule 
assembly, sickle-cell hemoglobin fibril formation and actin polymerization. The 
process  is  similar  to  crystallization  from  a  metastable  supersaturated  solution. 
Three  distinctive  features  are  characteristic  of  a  nucleation-dependent 
polymerization mechanism. First, there is a time lag before the aggregates become 
detectable.  Second,  there  is  a  critical  concentration.  After  completion  of 
polymerization,  the  solution  contains  mainly  monomers  and  high  polymers  at 
equilibrium. The monomer concentration at this point is referred to as the critical 
concentration, below which polymerization will not occur. Third, a supersaturated 
solution  can  be  seeded  by  a  preformed  nucleus,  resulting  in  immediate 
polymerization.  In  contrast,  the  growth  of  a  linear  polymer  neither  requires 
nucleation  nor  can  be  seeded.  Linear  polymerization  is  characterized  by  the 
accumulation of intermediates in a sequential manner: no time lag is observed, and 
supersaturated solutions are unstable and rapidly aggregate.   
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Heterodimer (template assisted) model 
 
 
Figure 1.10: Template assisted model of prion propagation; first external misfolded 
conformer act as seed, which drive native PrP to misfold. 
This conformational model (Figure 1.10) (Cohen et al., 1994) proposes that random 
fluctuations in the structure of PrP
C
 result in the reversible generation of a partially 
unfolded monomer, an intermediate designated PrP*, involved in forming PrPSc. 
The  concentration  of  PrP*  would  normally  be  low  and  PrP
Sc  formed  in 
insignificant amounts. Exogenous prions containing PrP
Sc act as templates to induce 
the conversion of PrP* into PrP
Sc in the infectious form of prion disease. However, 
the insolubility of PrP
Sc renders this process irreversible and so the formation of 
PrP* followed by PrP
Sc promotes increasing concentration of PrP
Sc. Mutations in 
PrP  could  cause  destabilisation  of  PrP
C,  inducing  its  conversion  into  the 
intermediate PrP* state resulting in formation of PrP
Sc. In the case of sporadic prion 
diseases, the production of PrP
Sc could result from sufficient accumulation of PrP* 
under  rare  situations.  Indeed,  the  development  of  spongiform  degeneration  is 
observed in transgenic mice overexpressing the wild-type PrP gene(Telling, 2000, 
Castilla et al., 2003). Somatic mutations could also play a part in this form of disease 
by destabilizing PrP
C
 and promoting its conversion into PrP
Sc
 through PrP*. For 
instance, both Met and Val are commonly found at amino acid 129 in human PrP. 
Homozygosity (Met-Met) at codon 129 was found to predispose to sporadic CJD in 
these studies. Further experiments showed that those patients carrying the Asp178  
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to Asn mutation would have insomnia if the codon 129 specifies Met in the mutant 
allele; if the codon 129 specifies Val, they would have dementia.  
 
Current knowledge about PrP
Sc structure.  
Although PrP
C and PrP
Sc have identical covalent structures (Stahl et al., 1993) they 
differ markedly in biophysical properties. PrP
C is monomeric, proteinase-sensitive 
and soluble in nonionic detergents, whereas PrP
Sc is partially resistant to proteinase 
K  digestion  and  insoluble,  forming  amyloid-like  fibrils  (Prusiner,  1982,  1998, 
Caughey  and  Chesebro,  2001,  Collinge,  2001,  Polymenidou  et  al.,  2004, 
Weissmann, 2004). These differences in physical properties seem to reflect different 
conformations of the two protein isoforms. 
Indeed, low-resolution optical spectroscopic data suggests that PrP
C from normal 
brain is rich in  -helical structure, whereas PrP
Sc contains a high proportion of  -
sheet (Caughey, 1991, Pan et al., 1993). Besides, recent studies show the degree of 
polymerization affects biological properties of the protein, with infectivity residing 
in oligomeric and not monomeric forms of PrP (Silveira et al., 2005).  
According to the “protein-only” hypothesis, the conformational transition from 
PrP
C to PrP
Sc plays the central role in prion propagation. Thus, structural studies of 
PrP
Sc are the key step to understanding of the molecular basis of prion diseases. 
Unfortunately,  in  contrast  to  high-resolution  data  for  monomeric  PrP
C,  the 
understanding of the structure of PrP
Sc or synthetic PrP
Sc-like aggregates is very 
poor, which is mainly caused by the low solubility of PrP
Sc. 
New tools have recently emerged for studying the architecture of ordered protein 
aggregates (Tycko, 2004, Nelson and Eisenberg, 2006), however, these approaches  
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have not yet been used to probe the structure of mammalian prion amyloids. So far, 
very few direct observations have been made regarding the detailed structure of 
PrP
Sc. Roder and coworkers investigated the structural characteristics of the fibrils 
formed by  the fragment of the mouse  prion  protein, mPrP106-126 (Kuwata  et al., 
2003).  However,  the  relevance  of  this  short  peptide  to  PrP  conversion  is 
controversial, so further structural studies are needed to probe amyloid fibrillar 
core structures formed by different mammalian prion proteins. 
in-vitro conversion studies.  
in-vitro generation of infectious prions from recombinant PrP is considered to be 
the final proof of the “protein-only” hypothesis. In addition, compared to slow and 
costly conversion experiments in animals and cell culture (Prusiner, 1998), cell free 
conversion  systems  simplify  the  experimental  environment,  and  open  an 
opportunity to understand the mechanism of the conversion. Thus, many scientists 
endeavored to study in vitro PrP conversion, beginning with short, synthetic PrP 
peptides (Gasset et al., 1992, Forloni et al., 1993, Tagliavini et al., 1993). Although 
these short peptides were found to form amyloid fibrils under certain conditions, 
their relevance has always been questioned since these fibrils were never found to 
be infectious in vivo. 
In 2003, group of Surewicz successfully converted the recombinant protein huPrP23-
144,  which  corresponds  to  the  Y145stop  variant,  from  a  monomeric  state  to 
amyloidal fibrillar state in-vitro (Kundu et al., 2003). Furthermore, using this model 
they  demonstrated  species  barrier  and  strain  diversity  in  mammalian  prion 
propagation  (Vanik  et  al.,  2004,  Jones  and  Surewicz,  2005).  However,  the  PK-
resistant fragment of PrP
Sc, PrP 27-30, had been found to span residues ~90-231  
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(Prusiner, 1998), Y145stop, a disease-linked mutation, remains an artificial model 
for PrP conversion as it does not cover the full PK-resistant core. 
Recently, it has been shown that the recombinant prion protein (PrP23-231), or a 
biologically-relevant  fragment  PrP90-231,  can  be  converted  into  a  variety  of 
oligomeric forms that are rich in  -sheet structure and have increased resistance to 
PK digestion (Swietnicki et al., 2000, Baskakov et al., 2002, Apetri et  al., 2005, 
Bocharova et al., 2005). These aggregates include amyloid fibrils, a form of PrP 
recently reported to be infectious in a transgenic mouse model overproducing PrP
C 
(Legname et al., 2004). 
Another in-vitro conversion system, PMCA, was developed by Soto’s group (Soto 
et  al.,  2002b,  Castilla  et  al.,  2005).  This  amplification  is  equivalent  of    the 
polymerase chain reaction (PCR) for DNA and applicable to prion protein, this 
technology  replicates  the  conformation  of  PrP
Sc.  During  the  procedure,  minute 
amounts of brain-derived PrP
Sc and a large excess of cellular PrP
C are incubated 
with  brain  homogenate  and  a  low  concentration  of  detergents,  resulting  in  the 
growth  of  PrP
Sc  templates.  Then  these  PrP
Sc  aggregates  are  broken  down  by 
ultrasound to generate more units capable of replication. By the cyclic repeating of 
incubation  and  sonication,  most  PrP
C  is  rapidly  converted  into  PrP
Sc.  Healthy 
hamster brain homogenate was first used as the source of PrP
C, and the PMCA-
generated PrP
Sc shared similar PK resistance, autocatalytic conversion activity and 
biological infectivity with the brain-derived templates (Castilla et al., 2005, Weber 
et al., 2006). However, brain homogenate contains many exogenous factors which 
may play a role in generation of infectivity. Recently, Supattapone and colleagues 
were able to simplify the components present during amplication of native hamster 
PrP
C (Deleault et al., 2007). Infectious PrP
Sc-like aggregates were produced using  
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only co-purified lipid molecules and a synthetic polyanion. In addition, the authors 
found infectious PrP
Sc could also be generated without any preexisting templates, 
which  offers  an  opportunity  to  understand  the  mechanism  of  sporadic  human 
prion diseases. Although recombinant PrP from E. coli has been widely used in 
other  in-vitro  conversion  system,  it  has  been  rarely  used  as  an  amplification 
substrate  of  PMCA  since  it  lacks  glycosylation  and  the  GPI  anchor.  Lately, 
Caughey’s group succeeded in utilizing the recombinant hamster PrP as a PMCA 
substrate, and the PK digestion of the final product generated the similar bands as 
PK-digested unglycosylated scrapie PrP
Sc (Atarashi et al., 2007). 
 
Toxicity of in-vitro generated prions 
 
In  recent  reports,  bacterially  expressed  recombinant  prion  protein  has  shown 
toxicity  to  host  after  fibril  formation.  These  fibrils  were  either  formed  under 
denaturing conditions (Makarava et al., 2010) or using PMCA (Kim et al., 2010, 
Wang et al., 2010) method as shown in Figure 1.11.  Although these fibrils prepared 
from recombinant protein lacked post-translational modification they proved to be 
infectious to hamsters upon serial transmission. (Makarava et al., 2010) However, 
recent data suggest that recombinant prion fibrils have different globular structure 
than the disease associated prion fibrils (Wille et al., 2009) and it is hypothesized 
that  recombinant  prion  fibrils  undergo  a  conformational  adaptation  during  the 
process of conversion to disease-associated prions (Makarava et al., 2010). In the 
studies by Wang et al., they have used endogenous cofactors in prion conversion. 
Therefore it is likely that they probably constrain PrP structure and influence the 
properties  of  different  prion  strains  in  cells.  It  is  more  likely  that  endogenous  
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cofactors are catalyzing the formation of prions exclusively composed of PrP as it 




Figure  1.11:  Two  different  biochemical  protocols  yield  recombinant  PrP  with 
different  level  of  infectivity.  The  amyloid fibrils,  which  are  formed  by 
incubating  recombinant  PrP  with  chemical  denaturants  were  less 
infectious  (left)  while  mixing  recombinant  PrP  with  phospholipid  and 
RNA  produces  highly  infectious  prions  (right).  Adapted  from 
(Supattapone, 2010). 
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Current structural models for PrP
Sc.  
The  structure  of  PrP
Sc  is  still  unclear  since  it  is  insoluble  and  inaccessible  to 
conventional methods of protein structural biology, such as NMR spectroscopy or 
X-ray crystallography. In 2002, Cohen and coworkers used electron microscopy to 
study the structure of two-dimensional crystals of PrP 27-30, and the reconstructed 
images shown that the repetitive unit of the samples is having hexagonal symmetry 
(Wille et al., 2002). Assuming PrP
Sc had a similar structure to currently known 
proteins, the authors suggested that the hexagonal symmetry came from a trimeric 
structure, and proposed a “left handed  –helical model,” as shown in Figure 1.12 
(Govaerts et al., 2004). In this β -helix model, the N-terminus of each monomeric 
subunit  (residues  89-175)  formed  left-handed  β  -  helices  in  the  core  part  of  the 
trimer, whereas the C-terminus (residues 176-227) largely preserved the disulfide-




Figure 1.12: The left handed  –helical model adapted from (Govaerts et al., 2004).  
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At same time, DeMarco and Daggett utilized molecular dynamics to simulate PrP 
conversion,  which  resulted  in  another  theoretical  model,  the  “spiral  model”,  as 
shown in Figure 1.13 (DeMarco and Daggett, 2004). In this model, each monomeric 
subunit in PrP
Sc preserves all three   helices, but has increased β-sheet content in 
the 116-164 region, consisting of a three-stranded sheet and one isolated strand. The 
first  new  strand  proposed  (116–119)  is  N-terminal  to  the  first  β  strand,  other 
extended  structures  represent  extension  of  the  original  two  β  strands  During 
polymerization,  each  isolated  strand  is  connected  with  the  adjacent  monomer’s 
three-stranded sheet  to  form a  continuous four-stranded sheet, which leads to a 
spiraling  protofibril.  Our  findings  which  will  be  discussed  later  in  the  thesis 





Figure 1.13: spiral model of prion fibrils, adapted from (DeMarco and Daggett, 2004)  
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Fungal prions 
In 1994, Reed Wickner proposed that two non-Mendelian genetic elements of yeast 
Saccharomyces  cerevisiae,  [PSI+]  and  [URE3],  were  caused  by  a  self-propagating 
conformational conversion of protein (Wickner, 1994), and therefore it extended 
the prion concept from the infectious agent of TSEs to heritable elements of yeast. 
So far, six prions in yeast and other fungi have been identified  (Wickner et al., 
2007).  These  fungal  prions  do  not  share  amino  acid  sequence  identity  with 
mammalian  PrPs,  however  fungal  proteins  display  prion-like  mechanisms  of 
propagation. The aggregation of soluble fungal prion proteins into amyloid fibrils 
changes  the  phenotype  of cells,  and  these  characteristics  can  be  cytoplasmically 
transferred from mother to daughter cell, showing that the altered phenotype is 
heritable.  Studies  on  these  fungal  prion  proteins  have  been  proven  extremely 
valuable (Chernoff et al., 2002). For example, one of the best-studied fungal prion 
proteins,  the  translation  termination  factor  Sup35p,  can  aggregate  into  distinct 
forms of amyloid fibrils in-vitro under different experimental conditions (Glover et 
al., 1997). Infection of normal yeast cells with these distinct amyloid fibrils was 
found to generate different [PSI+] strains, providing an opportunity to understand 
the molecular basis of this phenomenon (King and Diaz-Avalos, 2004, Tanaka et al., 
2004). 
 
Methods to study protein aggregation and amyloid structure 
The biophysical investigations are aim to resolve the three fundamental questions 
linked to prion amyloid assemblies:  
1: fibril structure determination (rigid core),   
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2: the mechanism of fibril formation and  
3: understanding the kinetics of fibril formation. 
As far as the strategy of targeting protein misfolding is addressed, most preliminary 
studies are carried out in vitro both for mechanism elucidation and for inhibitors’ 
discovery. Several physical methods are available to study protein aggregation in 
vitro.  They  are  distinguished  from  being  direct  or  indirect  methods  (when  a 
property  that  is  directly  or  indirectly  involved  in  the  aggregation  process  is 
measured) and from being or not being capable of giving some information on the 
characteristics and morphology of aggregates (morphological or non morphological 
techniques). Each approach shows a few advantages and disadvantages. Therefore, 
in  order  to  get  a  complete  picture  of  the  aggregation  phenomenon,  the 
simultaneous of multiple techniques is often used to cross-validate the results. 
Direct non-morphological techniques  
The easiest direct approach is absorbance spectroscopy, which can be used if the 
monomer  shows  an  absorption  profile  somehow  different  from  the  oligomers. 
However, since this requirement is not easily met, an alternative application is to 
follow the disappearance of soluble species from the solution by monitoring the 
decrease  of  absorbance  of  an  aggregating  mixture  (e.g.  in  combination  with 
sedimentation).  Intrinsic  fluorescence  spectroscopy  is  also  a  direct  method  to 
measure  protein  aggregation.  It  is  based  on  the  measurement  of  intrinsic 
fluorophores  (e.g.  indole  side  chain  of  tryptophans)  to  gain  information  on 
conformational changes occurring in the protein upon aggregation. The advantage 
is that it is a directly applicable and sensitive methodology, which requires pM-nM 
concentration  of  peptide/protein  and  can  monitor  the  kinetics  of  aggregation. 
Another technique, which has the advantage of correlating signal and concentration  
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through the Lambert and Beer's law, is circular dichroism (CD) spectroscopy (Han 
and Hill, 2008). By measuring the selective absorbance of dextro or levo circularly 
polarized monochromatic wavelength over the range of the UV spectrum related to 
the absorption  of the  carbamidic  function  of  peptide/protein (190-230  nm), the 
secondary structure of the protein can be characterized. CD spectropolarimeters 
can monitor the formation of amyloid structures of proteins in solution in real 
time.  Therefore,  the  time  course  CD  spectrum  changes  provide  useful  kinetic 
information  on  the  conformational  transitions  over  oligomerization  and 
aggregation.  A  universally  applicable  method  for  obtaining  kinetic  data  is 
calorimetry.  The  direct  measurements  of  the  temperature  changes  (e.g. 
microtritation  calorimetry)  accompanying  protein  aggregation  can  provide 
thermodynamical  information  such  as  the  free  energy,  enthalpy,  entropy, 
equilibrium constant and heat capacity of the protein aggregation process.  
Solid-state  and  liquid  nuclear  magnetic  resonance  (NMR).spectroscopy  are 
powerful,  direct  methods  that  can  be  used  to  characterize  all  the  intermediate 
species  in  protein  aggregation.  By  solid-state  NMR,  the  amount  of  fibrils  that 
precipitate  can  be  monitored,  as  well  as  the  conformational  changes  upon 
aggregation (Tycko, 2006a, Naito and Kawamura, 2007). However, the required 
protein concentrations typically higher than that required with other techniques 
(mM versus nM). Moreover, NMR requires the use of labeled amino acid residues. 
Solution phase NMR can be used to monitor the aggregation process, however, at the 
high concentration required, proteins quickly tend to become insoluble. At this 
regard, two dimensional (2-D) and polynuclear NMR techniques are better suited. 
Concerning  fibrils  characterization,  Fourier  Transform  Infrared  spectroscopy 
(FTIR)  is  directly  used  to  characterize  the  β  -sheet  orientation  of  fibrils, 
determining whether they are in a parallel or anti-parallel configuration. However,  
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no  evidence  is  yet  available  for  intermediate  oligomeric  or  amorphous  protein 
aggregates.  
Indirect Non-morphological techniques 
Among  the  spectroscopic  techniques,  indirect  colorimetric  or  fluorometric 
methods are widely employed due to the high sensitivity of these techniques. These 
indirect  methods  involve  the  use  of  dyes  such  as  congo  red  and  thioflavin 
T(Khurana et al., 2001, Khurana et al., 2005) . By interacting with aggregates (which 
usually have a high content cross- β structure) the former gives rise to a specific 
absorption  band  in  the  visible  region  of  the  UV-Vis  spectrum,  the  latter  to  a 
fluorescence  spectrum;  whose  intensities  are  proportional  to  the  amount  of 
aggregates/fibrils  and  therefore  can  be  used  for  protein  aggregation  kinetics  in 
solution and for quantitative studies. 
Morphological methods 
Despite  being  useful  for  quantitative  studies,  the  spectroscopic  and  calorimetric 
methods  cannot  allow  the  discrimination  of  different  aggregate  species,  which  all 
together  contribute  to  the  measured  property  in  a  combined  averaged  way. 
Therefore, methods capable of defining characteristics of the oligomeric/fibrillar 
species  in  the  aggregation  kinetics  are  described.  Turbidity  directly  measures 
aggregation by revealing the particles with a hydrodynamic radius greater than the 
wavelength of the incidence light. The solution turbidity has been shown to be 
proportional to the number concentration (equal to the number of entities of a 
mixture divided by the volume of the mixture) multiplied by the length of the 
aggregates in dilute solution; consequently, turbidity is proportional to the total 
number of monomeric units in solution. Therefore, if the sample is homogeneous, 
the turbidity is directly related to the concentration, and the oligomeric size can be  
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determined.  However  limitations  exist  in  detecting  some  intermediates  if  their 
hydrodynamic radius is smaller than the wavelength and in determining the size of 
aggregates in heterogeneous samples. To follow fibril size as a function of time, 
light  scattering  has  been  extensively  used.  By  assuming  that  all  particles  are  of 
identical  size,  then  the  scattering  intensity,  R(Q),  is  dependent  upon  the  particle 
concentration, Cp (g/L), the molar mass of the particles, Mp (g/mol), the particle 
form factor, P(Q), and the structure factor of the dispersion, S(Q,Cp), according to the 
following equation:  
R(Q)=KCpMpP(Q)S(Q,Cp) 
 
where K is a constant dependent upon the instrumentation and upon the difference 
in refractive index of particles and solvent. Therefore, the molecular weight of a 




where  M  is  the  molecular  weight  of  the  polymer,  r  is  the  radius,  NA  is  the 
Avogadro's number, and υ is the partial specific volume of the polymeric molecule. 
Light scattering depends upon Brownian motion and the speed at which particles 
move, or the diffusion of the molecules, which is inversely proportional to the 
cubic root of the molecular weight. Therefore, a correlation between the extent of 
light scattering measurement and fibril size is feasible.  
Mass  spectrometry,  in  particular  matrix-assisted  laser  desorption  coupled  to 
ionization time of flight mass spectrometry (MALDI-TOF) can be used to monitor 
the  formation  of  protein  complexes  at  specific  time  intervals  (Kheterpal  et  al., 
2006). By optimizing buffer, cosolvent and matrix conditions, oligomeric and larger 
aggregate proteins can be detected and their mass derived in the molecular range up  
- 43 - 
to approximately 300,000 g/mol. X-Ray diffraction (XRD) can help in elucidating 
fibrils structure at the end of the aggregation process. Important information such 
structure  (fibrils  morphology)  and  packing  in  crystalline  fibril  sample  can  be 
acquired; however, the interesting intermediate and amorphous species cannot be 
examined by XRD. Morphology in terms of shape and dimensions of oligomers 
and fibrils can be defined by using microscopic techniques.  
The  atomic  force  microscope  (AFM)  is  a  surface  biophysical  probe  capable  of 
generating  high-resolution  topographical  images  of  surfaces  and  exploring  the 
interactions between molecules within a sample (Anderson et al., 2006, Gosal et 
al., 2006). In addition force spectroscopy experiments can be performed using the 
AFM whereby the  forces between the tip  and sample or interactions  between 
individual  molecules  can  be  investigated.  The  principle  of  AFM  imaging  is 
analogous to a record player where sound is generated when the stylus moves 
across the surface of the record. In the AFM, a stylus is attached to a flexible 
cantilever; at the end of the stylus is a sharp tip, which interacts with the surface 
of the sample. As the cantilever raster scans backwards and forwards across the 
surface of the sample, a map of the surface features is generated in the x and y 
direction. In the simplest imaging method, to build up a topographical map of the 
sample surface details of variations in the height of the surface are recorded by the 
movement of the cantilever in the z direction, thus producing a two-dimensional 
image of the surface topography (Figure 1.14). The deflections of the cantilever 
are  monitored  with  atomic-scale  sensitivity  by  an  optical  lever  system;  a  laser 
beam directed onto the cantilever is reflected via a mirror to a position sensitive 
photodiode. A piezoelectric ceramic scanner controls the motion of the cantilever 
by an electronic feedback mechanism. As the probe raster scans across the surface, 
the flexible cantilever undergoes deflections due to the attractive and repulsive  
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forces  experienced  by  the  tip  as  a  result  of  the  overlapping  electron  orbitals 
between the atoms of the sample and the tip. Consequently the deflection of the 




Figure  1.14:  schematic  diagram  of  atomic  force  microscopy  (AFM)  setup,  showing 
cantilever & tip. (Adopted from wikipedia) 
AFM cantilevers for biological imaging are very flexible structures with spring 
constants of less than 1 N/m for contact mode and 2 to 42 N/m for tapping mode 
imaging. Typically cantilevers are silicon or silicon nitride with lengths ranging  
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from  100-250  µm  and  tip  apexes  with  radii  of  curvature  of  5  to  40  nm.  The 
optimum resolution of an image is greatly affected by the shape and apex of the 
tip. Currently the most commonly used commercially available tips are oxide-
sharpened pyramid shaped. However, the low aspect ratio and shape of these tips 
may result in the contact occurring between the sides of the tip and the sample 
feature before the apex of the tip. This causes a tip broadening artifact whereby 
features  appear  larger  than  their  true  size,  in  addition  two  structures  lying 
adjacent  might  be  perceived  as  one.  A  solution  to  this  limitation  is  under 
development,  in  which  long  and  narrow  carbon  nanotubes  with  high  aspect 
ratios, replace the pyramidal tip.  
Electron  microscopy  (EM)  is  a  non  solution  method  for  visualizing  the  surface 
morphology of the fibrils being studied (Shirahama and Cohen, 1967). The EM 
(including  scanning  electron  microscopy  (SEM)  and  transmission  electron 
microscopy  (TEM))  is  capable  of  generating  very  high-resolution  images  of 
biological samples. However there are limitations to studying amyloid using the 
EM: firstly, the requirement for extensive sample preparation in which samples 
must be dried and stained before imaging, and secondly the inability to image 
dynamic processes in situ; the images generated are of dehydrated samples in their 
non-native state. The greatest advantage, that EM offer over other structural or 
morphological techniques is that it does not require samples to by crystalline, it 
enables the study of transient quaternary intermediates, it requires a small amount 
of sample relative to NMR or crystallography and there is no upper limit for the 
size of molecule to be studied. Samples are usually preserved in a heavy metal 
stain  (negative  stain)  or  in  a  hydrated  state  at  liquid  nitrogen  temperatures 
(cryoEM).  Recent  advances  in  cryo  electron  microscopy  and  image  processing 
techniques  have  enabled  detailed  structural  studies  of  large  macromolecular  
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assemblies including protofibrils and amyloid fibrils. The negative staining EM is 
a simple method which allows rapid and routine morphological and structural 
examination of biological macromolecules and macromolecular assemblies.  The 
negative staining EM offers several distinct advantages over other techniques: 1) it 
is  technically  simple  to  perform;  2)  it  produces  high  contrast  images;  3)  it  is 
relatively insensitive to damage to the specimen by the electron beam; 4) samples 
are easy to prepare and 5) it requires only a small amount of sample (couple of 
µls). In this procedure, the sample is placed on an EM grid and stained with heavy 
metal solution and dried. Contrast is introduced by interaction of the electron 
beam with the sample regions having different scattering power, macromolecules 
scatter electrons weakly and the images are of low contrast. The thin shell of 
heavy  metal  atoms  surrounding  the  sample  scatters  the  electron  beam.  The 
problems associated with negatively stained specimens are the resolution is limited 
to about 25 Å. The structure is usually flattened due to drying of sample, different 
quaternary structures exhibit differential adsorption and orientation to the grid. 
The  uneven  staining  could  result  in  some  image  artifacts  and  the  high  ionic 
strength and non physiological pH of stain might alter the specimen. The cryo 
electron microscopy overcomes most of these  limitations imposed  by negative 
staining and has been used to achieve near atomic resolution in the most favorable 
cases. In this method, samples are preserved in their hydrated state in ice by quick 
freezing in liquid nitrogen or ethane and imaged at low to moderate dose by EM 
to  minimize  damage  to  sample.  For  separating  aggregates  of  various  size,  Size 
Exclusion Chromatography (SEC), Capillary Electrophoresis (CE), sedimentation 
and  flow Field-Flow Fractionation  (FFF) in  combination with other techniques 
have been used to detect and distinguish the aggregates. However, these techniques 
suffer from intrinsic potential effects on the aggregation phenomenon. In fact, in 
sedimentation studies, centrifugation time and sample concentration would require  
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controls, while interaction with the stationary phase, flow stress and electric field 





Figure 1.15: Time scales of molecular motions for the prion (PrP) protein and linked 
NMR-techniques.  
For a protein, different dynamical features happen at different time-scale to carry 
out  necessary  biological  activity  of  the  protein.  Therefore,  protein  cannot  be 
completely rigid but should be containing flexible regions. For prion protein, these 
processes  include  formation  of  oligomers,  protofibrils  and  mature  fibrils. 
Amyloidal  fibril  formation  is  a  relatively  slow  process.  The  Figure  1.15  above 
represents the correlation between NMR observables and protein folding process.   
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Diffusion ordered spectroscopy 
 
NMR spectroscopy is best suited for carefully purified single isoform compounds. 
But the nature's most challenging problems like amyloids are presented to us as 
mixture  of  populations  as  well  as  continuously  changing  globular  shape. 
Diffusion-ordered spectroscopy (DOSY) answer to this limitation by separating 
the NMR signals of molecules of different sizes, so that the signals from different 
species can be distinguished. In DOSY, a series of experiments is performed in 
which pulsed field gradients are used to make the signals in a spectrum decay at a 
rate which depends on the rate of diffusion, and the set of spectra is then used to 
synthesize  a  two-dimensional  spectrum  in  which  Larmor  frequency  is  plotted 
against  diffusion  coefficient.  Where  different  species  have  NMR  signals  at  the 
same frequency, it is extremely difficult to distinguish the different contributions 
the individual signals make to the overall decay of signal strength as a function of 
field gradient. Rotational   and translational   diffusion coefficients are given 
by  
 
where   is an appropriate friction factor,   is the Boltzman constant and   is 
temperature. For small hard spheres, the translational friction factor is given by 
Stokes’ law as   , where   is the viscosity of the solution and   is the 
hydrodynamic radius of the sphere. The Einstein-Stokes equation is therefore: 
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H/D exchange methods 
The  aggregation  process  of  proteins  converting  them  into  amyloid  fibrils  is 
complex.  This  conversion  involves  series  of  events  during  which  various 
intermediate states are populated. The amyloid fibrils are highly dynamic in nature 
as evident from our Solid-state NMR data. Therefore hydrogen deuterium exchange 
experiments on amyloid-like fibrils are best to find out solvent accessibility in these 
fibrils. It was known more than 50 years ago that the isotopic exchange rates of 
peptide backbone amide protons are very sensitive to protein structure, which led 
to  widespread  use  of  hydrogen  deuterium  exchange  (HDX)  as  a  tool  to  probe 
protein structure, dynamics, and interactions (Engen and Smith, 2001, Hoofnagle et 
al., 2003, Englander, 2006). High-resolution multidimensional NMR is a dominant 
analyzing  method  of  HDX.  The  HDX-NMR  can  provide  direct  information 
towards structural organization of fibrils. In all polypeptides, there are three groups 
of  hydrogens:  those  attached  to  carbons  are  barely  exchangeable  under  normal 
conditions; those on the polar amino acid side chains and on the N- or C- terminus 
exchange  too  fast  to  be  trapped  for  measurement;  only  the  backbone  amide 
hydrogens have suitable exchange rates for most HDX studies. Amide hydrogens 
normally  undergo  rapid  exchange  with  solvent  hydrogens  experience  a  slower 
exchange when involved in hydrogen-bonded structures or sterically inaccessible to 
the  solvent.  The  rate  of  exchange  is  monitored  by  replacing  hydrogens  by 
deuterons. In an amyloid assembly, protein molecules assemble in repetitive arrays 
of  β  -sheets  oriented  parallel  to  the  fibril  axis.  These  arrangements  of  protein 
molecules  form  a  core  of residues,  which  becomes  solvent-shielded.  The  HDX-
NMR is a powerful tool for mapping the core structure of amyloid fibrils (Wagner 
et al., 1984, Wand et al., 1986) . Recent data have suggested that fibrils probably  
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represent a source of toxic oligomeric species that give rise to disease (Koffie et al., 
2009). The mature fibrils are best to characterize the core structure of amyloids due 
to their long-life and highly ordered structure. The exchange rates of HDX are 
minimum at about pH 2.5 (Smith et al., 1997). 
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Aim of the thesis 
There have been significant progresses made in the field of prion biology in last two 
decades.  There  has  been  significant  advancement  towards  the  final  proof  of 
“protein-only”  hypothesis.  Despite  this  progress,  the  key  questions  remain 
unanswered.  These  open  questions  are  about  transmission  and  structural 
characterization of prions  and include questions like (1) what drives monomers to 
assemble  into  oligomers;  (2)  which  segments  or  domain  of  a  long  polypeptide 
constitute the recognition motifs (3) are there any of these recognition motifs play 
key roles in amyloid fibril formation; (4) how the β-strands stack relative to one 
another; (5) what is the significance of π-π stacking; (6) there more a few possible 
arrangements  other  than  “cross-β”  architecture,  (7)  what  are  most  favored 
architecture of β-sheets and what are the intermolecular interactions between the 
layers that stabilize these; (8) what are the pathways and the intermediate states that 
are involved in seed and fibril formation; and, (9) how do strains carry structural 
information for transmission of disease? Several studies have demonstrated fibril 
formation from native-like and partially folded state of recombinant prion protein; 
however there is not much information available on fibril formation from another 
important state “the unfolded state”, while it has been postulated that protein has to 
undergo partial or complete unfolding for conformational switching as happen in 
prions. The unfolded state of the prion protein is an important conformational 
state  apart  from  the  native  state.  Urea  has  been  used  and  provided  substantial 
information of unfolded state of proteins. The main objective of my study is to 
establish  and  characterize  the  prion  fibril  formation  from  chemically  denatured 
state (8 M urea, pH 2, 25 °C) and map the structural transition of the prion protein 
segments from its unfolded state to the fibril structure. Which thus enable us to 
draw an atomic picture of dynamics and misfolding events in prion protein.   
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Chapter 2  
Material and methods 
Materials 
Plasmids 
pJCTEV: The pJCTEV vector is a pJC40-derived expression vector for high-level 
prokaryotic  expression  controlled  by  the  strong  bacteriophage  T7  promoter. 
Expression is induced by the production of T7 RNA polymerase in BL21(DE3) E. 
coli. Additionally, pJCTEV vector offers N-terminal polyhistidine (7xHis) tag for 
rapid purification with nickel-chelating resin and tobacco etch virus (TEV) protease 
cleavage site for removal of fusion tag. It is a high-copy number expression vector 
(Clos and Brandau, 1994). 
pRSET A: The  pRSET  vector is a  pUC-derived expression vector for  high-level 
prokaryotic  expression  controlled  by  the  strong  bacteriophage  T7  promoter. 
Expression is induced by the production of T7 RNA polymerase in BL21(DE3) E. 
coli.  These  cells  also  produce  T7  lysozyme  to  reduce  basal  expression  of  target 
genes.  Additionally,  pRSET  vector  offers  T7  gene  10  sequences,  which  provide 
protein stability, an N-terminal polyhistidine (6xHis) tag for rapid purification with 
nickel-chelating resin and thrombin cleavage site for removal of fusion tag. 
pKM263: The pKM263 is a pGEX-cs derived expression vector having additionally 
N-terminal GST tag for rapid purification with nickel-chelating resin and tobacco 
etch virus (TEV) protease cleavage site for removal of fusion tag   
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Construct  Coding for  Source 
pJCTEV/hPrP121-230  Human  prion  C -
terminal  s tructured 
fragment 121-230 
Kindly  provided  by  Dr. 
Susanne  Grimme,  Sanofi -
aventis  Cooperation, 
Goethe  University, 
Frankfurt 
pRSET A/hPrP90-230  Human  prion  C -
terminal  PrP  27 -30 
derived  fragment  90 -
230 
Kindly  provided  by  Dr. 
Krishna  Saxena,  Sanofi -
aventis  Co operation, 
Goethe  University, 
Frankfurt 







Following  software  were  used  for  data  acquisition,  analysis  and  visualization  of 
NMR experiments. 
Topspin 1.3, 2.1, 2.5  Bruker Biospin, Karlsruhe, Germany 
Xwin-NMR 3.5  Bruker Biospin, Karlsruhe, Germany 
Sparky 3  Goddard  and  Kneller,  University  of 
California San Francisco 
XEASY  Wüthrich group, ETH Zürich  
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CARA  Rochus  Keller,  Wüthrich  Group,  ETH 
Zürich 
Protein Dynamics Center  Bruker Biospin, Karlsruhe, Germany 
 
Buffers and solutions 
 
Lysis buffer:  
Buffer 1A: 8M Urea, 100mM NaPi, 10mM Tris, pH 8.0 
Buffer 2A: 8M Urea, 100mM NaPi, 10mM Tris, 10mM Imidazole, pH 8.0 
Buffer 3A: 8M Urea, 100mM Tris-HCl, 10mM Imidazole, pH 8.0 
Buffer 4A:100 mM Tris-HCl, 500mM NaCl, 1% Triton-X-100, pH 8.0 
 
Inclusion Body wash buffer 
50 mM Tris-HCl, 23% sucrose, 1 mM EDTA, 1 mM benzamidine-HCl, 1 % 
Triton-X-100, pH 8.5 
 
Refolding and proteolytic cleavage buffer 




Buffer 1A: 8M Urea, 100mM NaPi, 10mM Tris, 10mM Imidazole, pH 8.0  
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Buffer 1B: 8M Urea, 100mM NaPi, 10mM Tris, 50mM Imidazole, pH 8.0 
Buffer 1C: 8M Urea, 100mM NaPi, 10mM Tris, 200mM Imidazole, pH 8.0 
 
Buffer 2A: 8M Urea, 100mM Tris-HCl, 10mM Imidazole, pH 8.0 
Buffer 2B: 100mM Tris, 10mM Imidazole, pH 8.0 
Buffer 2C: 100mM Tris, 50mM Imidazole, pH 8.0 
Buffer 2D: 100mM Tris, 200mM Imidazole, pH 8.0 
 
Buffer 3A: 8M Urea, 100mM NaPi, 10mM Tris, pH 8.0 
Buffer 3B: 8M Urea, 100mM NaPi, 10mM Tris, pH 5.5 
Buffer 3C: 8M Urea, 100mM NaPi, 10mM Tris, pH 4.5 
 
Prion Protein Protocols 
Safety considerations 
The expression and purification of human prion protein constructs was carried out 
under S1 conditions, in the laboratory of Prof. Dr. Harald Schwalbe at the Institute 
for Organic Chemistry and Chemical Biology, at the Riedberg campus of Goethe 
University, Frankfurt, Germany.  
 
The following procedures were used for inactivation of prions  
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Surfaces were cleaned with 1M NaOH (final concentration) applied for a minimum 
period of 30 minutes at 20 °Celsius. Devices and articles were dipped 2.5 % sodium 
hypochlorite with at least 2% free chlorine for >1 hour or 1M NaOH for > 1 
hour. Liquids were treated by addition of a same volume 2 M NaOH and/or 5 % a 
sodium hypochlorite solution - 1h. This was followed by thermal inactivation in 
the autoclave (134 °Celsius for 5 minutes or 121 °Celsius for 20 minutes). 
 
Constructs 
Recombinant human PrP 90-230 





(From Dr. Krishna Saxena, Sanofi-aventis cooperation) 
Parent Vector: pRSETA  
Promoter: T7 
Purification: His-tag (underlined in amino acid sequence)/Ni-NTA 
Protease Site for cleavage: Thrombin 
 
Recombinant human PrP 121-230 
 
Amino acid Sequence:   





(From Dr. Sussane Grimme, Sanofi-aventis cooperation) 
ParentVector: pJCTEV  
Promoter: T7 
Purification: His-tag (underlined in amino acid sequence)/Ni-NTA 
Protease Site for cleavage: TEV 
 
Recombinant human PrP 166-230 
 




Residues  166-230  were  subcloned  from  pJCTEV  PrP121-230  construct  in  pKM263 
vector with engineered TEV protease cleavage site using forward primer with Nco1 
restriction site  
5' AAACCATGGTGGTGGGGGGCCTTGGCGGCTACATG3’ and backward 
primer with BamH1 restriction site  
5' AAACCATGGTGGTGGGGGGCCTTGGCGGCTACATG 3' 
 
Promoter: T7 
Purification: His-tag/Ni-NTA  
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Protease Site for cleavage: TEV 
 
Expression of prion protein for NMR 
 
The authenticity of the clone construct was confirmed by nucleotide sequencing. 
Independent  of  the  construct  used,  plasmid  DNA  was  freshly  transformed  into 
BL21 (DE3) and cells were grown on selective agar plates. A single colony was 
picked from the plate and a 10 ml overnight culture in Luria-Bertani (LB) broth 
medium was started at 37 °C supplemented with 100  g/ml ampicillin. Protein 
expression  was  induced  with  the  addition  of  1  mM  isopropyl  1-thio-  β  -D-
galactopyranoside  (IPTG)  when  the  OD600  reached  ~0.6.  The  culture  was 
incubated in 5-liter Erlenmeyer flask for ~4 h with aeration (160-180 rpm) at 37 °C 
before the cells were harvested by centrifugation (5,000 × g, 15 min, and 4 °C). 
 
Expression of isotope labeled protein 
 
Procedure 1: The above procedure is used with minimal M9 media in place of LB 
media. 
15N  enriched  NH4Cl  (1g/L)  & 
13C  enriched  Glucose  (2g/L)  are  used  to 
obtain uniformly labeled protein for NMR experiments.  
 
Procedure 2: BL21 (DE3) E. coli cells with hPrP(90-230) were initially inoculated 
into  two  10ml  culture  tubes  of  LB  medium  with  100µg/ml  ampicillin.  These 
cultures were grown with shaking at 37 °C for approximately 4 hours, inoculated 
into 90ml of LB/Amp each and then grown overnight for about 12 hours. One 
2000ml flask of LB/Amp medium were then inoculated with 10% of the overnight  
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culture and grown at 37 °C until the absorbance at 600nm (OD600) reach ~1.2, 
when the cells have reached the end of log phase of their growth. These cells were 
pellet down and washed twice with M9/Amp medium and then re-suspended into 
one  2000ml  flasks  containing  M9/Amp  medium  (either  with 
15N  or 
15N  & 
13C 
enriched) along with addition of 1mM isopropyl-β-D-thiogalactopyranoside (IPTG) 
to induce the expression of PrP and allowed to grow at 37 °C until the absorbance 
at 600nm (OD600) reach ~2.4. 
 
Purification of prion protein: 
 
The cells were harvested by centrifugation (5,000 × g, 15 min, 4 °C). The cell 
pellets obtained further processed by 4 different procedures to obtain the purified 
protein for NMR experiments.  
 
Purification of His-tag free protein 
Procedure 1: 
Cell pellet was dissolved in Buffer 1A and sonicated (10×, 55-s pulse on, and 180-s 
pulse off) in an ice bath. This was followed by the centrifugation at 15000 ×g, 20 
minutes, 10 °C. The cell debris was separated as pellet, while supernatant was used 
for  another  round  of  centrifugation  (20000  ×g,  20  minutes)  to  remove  urea-
insoluble  particles.  The  supernatant  containing  the  protein  was  subjected  to 
incubation with Ni-NTA resin for 30 minutes and then loaded on disposable spin 
columns. The column was washed thrice with Buffer 1A and then with buffer 1B 
having increased imidazole concentration of 50 mM, to washout non-specifically 
bound proteins. Protein was eluted with buffer 1C. The column resin was then  
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washed with 1M NaOH and 1% SDS with 4 column volume and equilibrated by 
buffer C by 10-15 column volume. Ni-NTA resin recharged with 1mM NiSO4 and 
again equilibrated by buffer 1A by 10-15 column volume. The purified protein was 
refolded by gradual dialysis against refolding buffer for 16 hours. Purified protein 
was  subjected  to  Protease  cleavage  in  dialysis  cassette  and  the  His-tag  was  then 
removed by thrombin cleavage for 1 h at room temperature in cleavage buffer, 
using  0.1  unit  thrombin/ml.  Thrombin  was  removed  using  DE52  column  and 
purified protein was pooled using 200mM NaCl gradient. This protein was again 
passed through recharged Ni-NTA column to remove residual His-tag tail, which 
gets bound to column, while cleaved protein came as flow through. The column 
was recharged again as described earlier. The protein was dialyzed against 8M Urea 
pH  8  for  about  3-4  hours  and  further  dialyzed  against  8.8  M  Urea  pH  2  for 
experimental purposes. The protein was concentrated to variable concentrations of 
200µM to ~2mM for experimental purposes. The usual concentration was ~1mM. 
. The NMR samples were prepared with addition of 10% D2O. 
 
Procedure 2: 
Procedure 2 is almost similar as 1
st but involving refolding on column as reported 
earlier (Zahn et al., 1997). This refolding is achieved by applying slow gradient from 
buffer 2A to 2B. The protein was eluted with buffer 2D. This process of refolding 
and elution was repeated thrice for maximum recovery of protein. The rest of the 
procedure was same as first.  
Fast purification of his-tag protein 
Procedure 3: 
Since  for  many  NMR  experiments,  protein  purity  of  ~95%  is  satisfactory,  a 
shorter purification protocol was developed, which effectively resulted in better  
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yield. In this method protein was purified by changing to acidic pH. (Buffer 3C). 
The  pooled  protein  was  then  dialyzed  against  8.8  M  urea,  pH  2  and  used  for 
experiments or used as same procedure as earlier to remove His-tag.  
 
Procedure 4: 
The  prion  protein  is  expressed  in  inclusion  bodies  and  resolubilzation  of  these 
inclusion bodies in NMR buffer was enough to obtain a good spectrum. In this 
procedure cell pellet was suspended in lysis buffer 4A and sonicated as described 
above.  On  centrifugation,  pellet  containing  inclusion  bodies  and  cell  debris 
separated out. This pellet was washed thrice with wash buffer and then obtained 
inclusion bodies were suspended in 8.8 M Urea, pH 2 and put on dialysis against 
same for 1 hour.  
 
Yield  of  protein  varied  from  8mg/L  to  40mg/L  of  media,  depending  on  the 
procedure.  The  concentration  of  purified  protein  was  determined 





To  form  amyloid  fibrils  for  NMR  investigations,  hPrP  (various  constructs  and 
concentrations) in 8 M urea, pH 2 was placed into 1.5 ml conical plastic tubes, each 
containing 0.5 ml. The protein concentration was determined by measuring the 
absorbance at 280 nm. The fibrillation reactions were carried out in 1.5 ml conical 
plastic tubes at a total reaction volume of 0.5 ml at 37 °C with continuous shaking 
at 600 rpm using Eppendorf plate shaker. A schematic diagram showing the fibril 
formation is shown in Figure 2.1. These samples were used for NMR measurement  
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at regular intervals. 





Figure  2.1:  Model  for  in  vitro  prion  fibrillation  in  denaturing  environment.  The 
native-like  conformer  (a)    of  recombinant  hPrP90-230  compass  three  -
helices and two  -strand forming anti-parallel sheet (PDB:1QM0) (Zahn et 
al., 2000). Addition of 8M Urea and acidic pH changes the equilibrium 
between  unfolded  extended  confirmation  (b)  and  -sheet  rich 
conformation (c)(Baskakov, 2004). These  -sheet rich monomers lead to 
either amorphous aggregate (f) or fibril formation (g) when agitated at 600 
rpm at 37°C; probably through formation of intermediate oligomer (d) 
and protofibrils (e). 
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AFM: 
The AFM images were taken by Dr. Thorsten-Lars Schimdt in the Group of Prof. 
Dr.  Alexander  Heckel  at  Center  of  Excellence  –  Macromolecular  Complexes, 
Frankfurt and taken on a Veeco (New York, NY, USA) Dimension 3100 AFM 
with  a  Nanoscope  IIIa  controller  in  dry  tapping  mode.  1  µl  of  the  completed 
amyloid fibril formation reaction solution were diluted in 99 µl of TEA-Mg buffer 
(40 mM Tris/ acetic acid pH 7.5, 2.5 mM EDTA, 12.5 mM MgCl2). From this 
solution,  2  µl  were  applied  on  freshly  cleaved  mica  (muscovite  grade,  Plano, 
Wetzlar, Germany) and incubated for ca. 2 minutes. The surface was rinsed with a 
few ml of milli-Q water and dried with a stream of nitrogen. ACT probes (25-75 
N/m)  from  APP  Nano  (Santa  Clara,  CA,  USA)  were  used  for  imaging  at  an 
amplitude set point of 0.3 V. The AFM raw data was processed with Nanoscope 
5.31 software (Veeco). 
EM: 
Electron  microscopy  has  been  performed  by  Dr.  Janet  Vonck  at  Max  Planck 
Institute for Biophysics, Frankfurt. Electron microscopic images were obtained by 
negative staining with 1% uranyl acetate, pH ~4 using a Philips CM 120 at 120kV 
under low dose conditions at a magnification of 45,000× on Kodak SO-163 electron 




Solid-state NMR spectroscopy  
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The  solid-state  NMR  experiments  have  been  done  in  the  Group  of  Prof.  Dr. 
Clemens  Glaubitz,  Institute  for  Biophysical  Chemistry,  Frankfurt.  These 
experiments have been performed by Ines Lehner, Nicole Pfleger, Jun Yang and 
Jakob Lopez. Spectra were recorded at a Bruker Avance 600 WB spectrometer using 
a 4mm DVT probehead at 25°C. Usually 1H decoupling of 90 kHz was applied and 
2048 transients were accumulated. For CP, a contact time of 2ms was used. The 
FIDs were processed using exponential line broadening of 20 Hz. 
Backbone resonance assignment 
The  backbone  assignment  is  prerequisite  for  the  analysis  of  protein  dynamics, 
interactions by NMR. The assignment of backbone residues involves the isotope 
labeling  of  protein  with  NMR  observable 
15N  and 
13C  nuclei.  Therefore  prion 
protein constructs were labeled as discussed earlier. The labeling of these nuclei 
along with abundant 






1H  and 
13C´ nuclei through scalar couplings along bonds in a 
series of three-dimensional NMR experiments, which permit to map resonances 
according to amino acid sequence of protein.  
A set of three dimensional NMR experiments (Sattler et al., 1999) were performed 
to unambiguously assignment of residues. The core experiment of assignment was 
HNCACB; this experiment correlates the 
1H, 
15N of amide with 
13C  and 
13C  of 
self and previous residue in polypeptide. The sign of   and   residues are opposite, 
and thus allow easier identification. The second experiment was CBCA(CO)NH, 
which correlates the 
1H, 
15N  of amide with 
13C  and 
13C  of previous residue in 
polypeptide. The sign of both   and   residues were same in this experiment. In an 
ideal situation, a protein backbone can be completely assigned with these two three- 
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dimensional  experiments.  However,  prion  protein  in  non-native  environment 
showed low dispersion of signals, which lead to over-lapping of several signals. For 
start point of backbone assignments, backbone amide peaks were picked in a well-
resolved 
1H 
15N  HSQC  spectrum.  The  chemical  shift  patterns  in  a  HNCACB 
spectrum, is a good indicator of residue type. The denaturing conditions of 8M urea 
creates  an  environment  where  these  shifts  are  closely  resemble  random  coil 
chemical  shifts  available  at  NMR  database  BMRB.  Few  residues  like  alanine, 
glycine,  threonine  and  serine  are  easier  to  identify  based  on  their  unique  peak 
pattern  and  chemical  shifts.  These  residues  are  suitable  candidates  for  start  of 
sequential backbone assignment. However, amino acid sequence of prion protein is 
having several repetitive sequences, which make it harder to identify them in the 
sequence,  where  each  of  these  sequence  appear  similar  due  to  high  denaturing 
environment of 8M urea.  Therefore additional three-dimensional experiments were 
performed to assign backbone residues unambiguously. Which includes HNCA, 
HN(CO)CA,  HNCO,  and  (H)CC(CO)NH  allowed  better  resolution  for 
13C  
residues while HNCO  was in particularly   useful  to resolve overlapping  amide 
peaks  in 
1H 
15N  HSQC  with  additional  resolution  from 
13C´dimension.  The 
(H)CC(CO)NH experiment 
13C of previous residue with amide in a TOCSY-type 
transfer, therefore gives a unique peak pattern, which helps in determining the spin-
system  type  for  the  residue.  Another  important  three  dimensional  NMR 
experiment was HNN (Panchal et al., 2001), which correlates amide resonance with 
amide  resonance  of  previous  and  next  residue  and  offer  another  dimension  to 
sequential assignment. All pulse programs were used from Bruker standard library, 
except HNN which was kindly provided by the group of Prof. Hosur, Mumbai.      
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MUSIC based HSQCs 
The  amino  acid  type  selective  experiments  are  developed  to  assign  the  residues 
which  are  difficult  to  assign  unambiguously  in  manual  or  automated  routine 
assignment procedure.  Most assignment procedure use a 15N–HSQC spectrum as a 
starting point and correlate the (
1H,
15 N) frequency pairs with carbon or proton 
frequencies in a third dimension to achieve a sequence-specific assignment. These 
experiments  are  based  on  the  MUSIC  (multiplicity  selective  in-phase  coherence 
transfer) (Schubert et al., 1999, Schubert et al., 2001a, b) pulse sequence building 
block, which accomplishes a coherence transfer to or from the hetero-nucleus and 
which replaces the initial INEPT transfer and is selective for X H2  or X H3  (where 
X  is either 
15N or 
13C). A distribution landscape for Cβ and Cα chemical shifts is 
shown in Figure  2.2; this specific distribution is utilized  for  selection.  It selects 
multiplicity  via  multiple-quantum  filters  and  offers  superior  suppression  of 
unwanted signals compared to sequences, which work solely by the appropriate 
tuning of delays to select for the number of coupling partners or the use of selective 
pulses.   
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Figure  2.2:  Two  dimensional  landscapes  of  Cβ  and  Cα  chemical  shifts  with 
characteristics  areas  for  different  amino  acid  types.  The  circle  shows 
approximate areas with standard deviations of the chemical shift values 
found  in  Biological  Magnetic  Resonance  Bank  database  (www. 
Bmrb.wisc.edu)  
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When MUSIC is implemented in the appropriate triple-resonance experiment, the 
signals of the desired amino acid types are selected based on the topology of the side 
chain. MUSIC does not lengthen the sequence compared to the standard triple-
resonance  experiments;  therefore  no  loss  of  intensity  occurs  due  to  relaxation. 
MUSIC HSQCs provide the information in number of HSQCs (Figure 2.3), each 
one giving for a particular type of set of residues for example, selective for Ser (S–
HSQC); Val, Ile, and Ala (VIA–HSQC); Leu and Ala (LA–HSQC); Asp, Asn, and 
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Diffusion ordered NMR spectroscopy 
 
Diffusion coefficients obtained from PFGSE measurements can be directly related 
to the geometry of species under study via the friction factors. For an amyloid 
which represents a near rod kind shape, the motion is much restricted and therefore 
the length of fibrils influence significantly to the value of diffusion coefficient. The 
friction  is  different  for  rod  shaped  and  spherical  shaped  assemblies.  The 
translational,  , and rotational,  , friction factors, preexponential factors  , and 
limiting  preexponential  functions  for  idealized  geometries.    is  the 
viscosity,  is the radius, and   is the rod length. 
 
Geometry         
Sphere         




In an amyloid sample, there will be a distribution of the leng ths of rods or the 
diameters of spheres. The lengths are observed to vary over several orders of 
magnitude. Account must be taken of this variation if the model is used to analyze 
experimental data. And therefore, a prefactor   and the Stejskal-Tanner 
factor   and the PFGSE signal intensity decay is given by 
0 0
0
0 ) ( lim ) (










The DOSY experiments were performed using pulse field gradient stimulated echo 
(PFGSE)  sequence  with  presaturation  (Bruker  pulse  sequence:ledbpgppr2s)  was 
used for diffusion experiments with p30 = 2.2 ms with variable diffusion delay   as  
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shown in Figure 3.14 (Baldwin et al., 2008) The resonances from amide and methyl 
regions were used for analysis. 
 
Deuterium exchange 
Preformed  fibrils  were  visualized  using  EM  and  then  gradually  dialyzed  against 
water, pH 2 for 2 days with 6 changes to remove urea from the solution. The 
dialyzed protein was concentrated and then divided in two parts. Those parts were 
diluted with D2O to achieve 90% H2O, 10%D2O and 70%D2O, 30% H2O final 
solvent environment. Deuterium exchange was observed constantly for a day and 
then for 2weeks and 6 months interval.  
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Chapter 3  
Results 
A complete understanding of prion misfolding and aggregation process requires the 
characterization  of  all  species  populated  along  the  aggregation  coordinate  in 
aggregation funnel, including the unfolded state, partially folded intermediate states, 
prefibrillar oligomers, protofibrils and mature amyloid fibrils. The unfolded state 
ensembles are of particularly importance as it is believed that prion or any other 
protein molecule, either partially or globally unfold in the course of misfolding 
pathway. Unfolded states of proteins, such as in high concentration of chemical 
denaturant, have been used as random coil models, where long-range interactions 
are considered to be absent and therefore local interactions of next neighbor amino 
acids dominate the conformational behavior. However, the high-resolution NMR 
studies with unfolded lysozyme (acid denatured with or without urea) in our group 
has been significant in providing evidence that unfolded states are not completely 
random (Klein-Seetharaman et al., 2002). The parameters and time-scales of these 
NMR  experiments  can  provide  considerable  information  about  the  ensemble-
averaged structural properties of unfolded proteins. The most common structure 
element found in unfolded state is the presence of hydrophobic cluster. The studies 
on hen egg white lysozyme (HEWL) showed that the polypeptide chains contain 
residual  structure  involving  long-range  interactions  between  aromatic  residues, 
importantly  tryptophane  residues.  It  has  been  also  established  that  single-point 
mutations  of  the  hydrophobic  residue  in  the  residual  structure  modulated  the 
compactness and long-range interactions of reduced lysozyme (Wirmer et al., 2004),  
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resulting in the production of mutant HEWLs possessing various degrees of residual 
structure;  these  studies  have  contributed  significantly  in  understanding  of 
fibrillation of  lysozyme.  The  heat-denatured  (65  °C)  HEWLs  reported  to  form 
fibrils  at  acidic  pH  readily  (Krebs  et  al.,  2000,  Xu  et  al.,  2005)  and  established 
importance of denatured state in amyloidal path of protein conformations.  
Prion diseases are one of most lethal amyloid related disease and the spontaneous 
amyloid formation from recombinant prion protein has been studied extensively in 
recent years. The methods of choice utilized mild denaturing conditions at acidic 
pH. Under those conditions, the protein misfolds and misfolding is driven through 
both native and non-native contacts. The mechanism, therefore, appears complex, 
while the unfolded state should minimize the effect of native-like interactions and 
therefore  allow  us  to  get  a  better  understanding  of  importance  of  non-native 
contacts in the process. Our result shows that fibrils can be formed from highly 
denatured  state  in  8M  Urea,  pH  2  with  and  without  agitation,  which  clearly 
demonstrate the presence of mechanism of self-aggregation in highly denaturing 
environment.  This  mechanism  may  involve  formation  of  fluctuating  local 
structures which promotes intermolecular aggregation or long range interactions 
which define the architecture for aggregation. These contacts might be initiation 
site for misfolding eventually leading to amyloid formation. There are not many 
reports showing amyloid formation in highly denaturing conditions. 
Assignments of recombinant prion fragments 
The structural characterization of the unfolded state of recombinant prion protein 
by NMR is been most challenging due to complex nature of protein. In general, the 
NMR characterization is difficult due to the poor dispersion of amide and carbon 
resonances in unfolded or partially folded states. The aggregation process of prion  
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protein hampered  the  backbone  resonance  assignments  severely.  The  3D  NMR 
experiments usually require 3 to 4 days of NMR measurement time, in which the 
ratio of monomer-oligomer population in NMR sample changes. The use of HNN 
(Panchal et al., 2001)- and MUSIC-based (multiplicity selective in-phase coherence 
transfer)  HSQCs  (Schubert  et  al.,  1999,  Schubert  et  al.,  2001a,  b)  helped  in 
unambiguously  identifying  and  assigning  the  amide  backbone  resonances.  The 
initial assignment of backbone amide resonances was performed using a series of 
triple  resonance  backbone  experiments  (HNCACB,  CBCA(CO)NH,  HNCA, 
HN(CO)CA,  HNCO,  HCCCONH)  (Sattler  et  al.,  1999).  There  have  been 
significant numbers of overlap, which have been resolved using combination of two 
or more experiments.  
Almost  complete  H
N  and 
15N  backbone  resonance  assignments  of  recombinant 
prion protein fragments 90-230, 121-230 and 166-230 in 8 M urea at pH 2, 25 °C 
were obtained. Figure 3.1 shows comparative dispersion for amide resonances in 
1H 
15N  HSQC  spectrum  with  respect  to  spectrum  at  lower  urea  concentration  or 
without urea. Figure 3.6 shows an illustrative sequential walk for the palindrome 
sequence 113-120 AGAAAAGA using HNN corresponding CBCA(CO)NH and 
strips  are  plotted  in  HNCACB  in  Figure  3.7.    The  complete  backbone  amide 
resonance assignments for unfolded recombinant prion protein is shown in Figure 
3.2, all of 
1H amide resonance are distributed in narrow range of ~0.8ppm. Despite 
the  small  chemical  shift  dispersion  and  dynamic  nature  of  protein,  the  almost 
complete  assignment  of  disordered  protein  is  satisfying.    MUSIC  (multiplicity 
selective in-phase coherence transfer) pulse sequence based HSQCs were helpful in 
determining the residues and i+1 selective manner for a number of amino acids 
(Figures 3.3, 3.4, 3.5) and helped in correct assignment of these residues.   
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Figure  3.1: 
1H 
15N  HSQC  spectra  for  various  urea  concentrations  recorded  with 
recombinant  human  prion  protein  121-230,  the  spectra  for  4  M  urea 
concentrations  display  line  broadening  and  disappearance  of  signals, 
indicating  molten  globule  state  of  protein,  while  spectra  in  8  M  urea, 
shows characteristics low dispersion of signals.  
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For  a  native  protein  structure,  the 
13Cα  resonances  for  α-helices  are  shifted 
downfield typically by an average of 3.1 ± 1.0 ppm, while in β-sheets; they are 
shifted upfield typically by − 1.5 ± 1.2 ppm. However, for the unfolded states of 
proteins,  where  conformational  averaging  takes  place,  the  observed  NMR 
parameters  are  a  population-weighted  average  of  all  structures  in  the 
conformational ensemble; therefore the observed secondary shifts are considerably 
smaller. Nevertheless, deviations of chemical shifts from random coil values reflect 
the relative  population  of dihedral angles in  α  and β regions of conformational 
space. The chemical shifts and J coupling constants are the two most sensitive NMR 
parameters to detect small conformational propensities of the protein backbone in 
unfolded  states,  which  otherwise  cannot  be  detected  by  NOEs.  Recently,  also 
residual  dipolar  couplings  have  been  utilized  to  derive  local  conformational 
preferences (Shortle and Ackerman, 2001). The cumulative chemical shift deviations 
(Kumar  et  al.,  2008)  indicate  slight  preference  for  -sheet  propensities  in  urea-
unfolded state (Figure 3.8); while random coil index analysis and TALOS+ analysis 
predict the non-native state in 8 M urea as random coil with very little  -sheet 
preferences near to C-terminus residues (Figure 3.9 and 3.10).  
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Figure 3.6: Strip plots for three dimensional HNN experiments for 10 residues long 
sequence (111-120) including palindrome sequence AGAAAAGA . (next 
page)  
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Figure 3.8: Chemical shift deviation plots for recombinant human prion protein 90-
230 (previous page). The cumulative (Kumar et al., 2008) shift indicates 

































































































































































































































































































































































































C  carbon shifts 
 
C  carbon shifts 
CO carbon shifts 
Cumulative carbon shifts 
(C
cum)=  (C )/25 -  (C )/25+ (CO)/10 
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Figure  3.9:  Chemical  shift  Index  (CSI)  (Berjanskii  and  Wishart,  2005)  plots  for 
recombinant human prion protein 90-230. The CSI values shows  -sheet 




Figure 3.10: TALOS+ analysis; S
2  and  -sheet propensity  (Shen et al., 2009) plots for 
recombinant human prion protein 90-230. The RCI values shows  -sheet 
preferences for residues 208-210 and 213-214, rest of chain shows random 
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Amyloiodal core residues in prion fibrils 
We  have  analyzed  the  structural  rearrangements  of  the  urea-denatured  state  of 
recombinant human prion protein (residues 90-230) hPrP90-230   to the fibrillar state 
by liquid-state NMR. This fragment is of particular importance as it represents the 
proteinase-K  resistant  core  of  prion  protein  and  includes  the  widely  studied 
amyloidogenic determinant 106-126 (Forloni et al., 1993, Gu et al., 2002, Singh et 
al., 2002). Over a period of seven days, protein preparations form high molecular 
weight  fibrils. Their  formations  have been  observed by  subjecting the  fibrils to 
electron  microscopy  (EM)  (Figure  3.11).  Consistently  the  observed  images  are 
similar to those described previously (Anderson et al., 2006). 
 
Figure 3.11: Electron micrograph of the hPrP90-230 sample showing long straight fibrils. 
Scale bar: 500 nm.   
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The 
1H 
15N HSQC of hPrP90-230 with intact disulfide bond recorded immediately 
after purification under urea denaturing conditions (8M urea, pH 2.0) revealed the 
typical  dispersion  and  narrow  line  width  comparable  to  spectra  of  unfolded 
proteins (Figure 3.12a). The spectra for the same sample acquired after constant 
agitation  on  the  4
th  and  7
th  day  showed  a  non-uniform  loss  of  intensity  of 
resonances,  some  of  them  disappeared  (Figure  3.12b  and  3.12c).  By  comparison 
with spectra of a construct containing residues 166-230 only, we can show that the 
disappearing signals originate mainly from residues corresponding to this region of 




Figure  3.12:  Solution  NMR  of  human  prion  fibrils.  (a)  1H,15N-HSQC  spectra  of 
hPrP90-230 at 298K in 8M urea, pH 2 at a concentration of 200 M in 10% 
D2O.  Spectrum  acquired  30  minutes  after  dissolving  hPrP90-230.  The 
spectrum  is  well  resolved  and  135  out  of  136  cross  peaks  are  assigned 
(Figure  3.2).  Spectra acquired  (b)  4  days  and  (c)  7  days  after dissolving 
hPrP90-230 under constant agitation.   
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Figure 3.13: Disappearing signals include the region comprising the residues 166-230 of 
hPrP  sequence.  (a) 
1H, 
15N-HSQC  spectrum  of  hPrP90-230  acquired 
immediately after dissolving the protein in the denaturing conditions (8 M 
urea, pH 2.0, 25°C). (b) Overlay of the spectra in (a) acquired on the 4
th 
day (blue) and the construct hPrP166-230 (8 M urea, pH 2.0, 25°C) acquired 
immediately  after  sample  preparation.  The  disappearing  signals  in  the 
hPrP90-230 include region 166-230, * represents signals for the palindrome 
sequence AGAAAAGA (113-120). 
 
Apparently, even under conditions where fibrils form as evidenced by EM and 
AFM,  we  can  observe  some  well -resolved  resonances  in  solution -state  NMR 
spectra. The observation of NMR signals from a high molecular weight fibril state 
has previously been attributed to either a residual monomer population (Platt et al., 
2009) and/or has been thought to be due to the dynamic nature of the individual 
sub-domains  stemming  from  the  residues  not  rigidified  in  the  amyloid  fibrils   
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(Baldwin et al., 2008). The presence of fibrillar species in solution can be ascertained 
by pulse-field gradient (PFG) NMR quantifying rotational diffusion(Baldwin et al., 
2008). These experiments when performed for the seven days old sample of hPrP90-
230  confirmed the presence of fibrillar species (Figure 3.14).  
 
Figure  3.14:  Integrated  PFGSE  profiles  for  prion  protein  in  fibril  state  as  a 
function of field strength. Data is plotted for a range of Δ.(in grey) 
with  a  lysozyme  monomer  (black).  These  values  are  in  accordance 
with  earlier  reported  values  for  SH3  fibrils  (Baldwin  et  al.,  2008) 
supporting the presence of large molecular structures like the fibrils, in 
solution. 
 
We assigned the NMR backbone resonances of the hPrP 90-230  under  denaturing 
conditions of 8M urea and pH 2. The assignment was complete with all the residues 
except for residues near Cys214 (Figure 3.2).  The gradual loss of the intensities 
observed in the HSQC spectra between the 1
st, 4th,
 and the 7
th day is plotted against 
the residue numbers in Figure 3.15. The relative intensities observed can be broadly 
classified into three different categories: (I) peaks with a slow decrease (90-144), (II)  
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peaks  with  the  fast  decrease  that  finally  disappeared  (145-223).  A  few  residues, 
namely 149, 150, 151, 177, decreased slower than others in this region until 4
th day 
while residues 180 and 208 are still observable on the 7
th day, and (III) peaks that 
change chemical shifts during the aggregation process (224-230) (Figure 3.18). The 
loss of signal intensities is caused by slow rotational reorientation, arising from the 
rigid parts of the fibrils while the signals that are still NMR observable stem from 
mobile regions of the fibrils. The presence of rigid and flexible regions in the fibrils 
is further supported by solid-state NMR experiments (Figure 3.16).  
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The  region  between  residues  145-223  showed  a  significant  decrease  in  signal 
intensities, indicating a major role in fibril formation. Although signal intensities 
for residues 144-156 ( -helix-I) are decreased, it has been reported that this region 
promotes  aggregation  but  is  not  converted  to  -sheet  (Watzlawik  et  al.,  2006). 
Recently, using mass spectrometry (Lu et al., 2007) and EPR spectroscopy, it has 
been  proposed  that the residues ranging  from  Gln160–Lys220  form the core  of 
amyloid made of parallel in-register  -sheets (Cobb et al., 2007, Cobb et al., 2008). 
The  amyloid  form  of  the  recombinant  mouse  prion  protein  of  the  full  length 
mPrP23-231  displays  only  two  regions  that  are  highly  protected  from  hydrogen 
exchange (residues (24-98) and (182-212)) showing that the region in between is still 
flexible (residues 99-180) (Nazabal et al., 2009).  We investigated the role of the 
residues 166-230. 
1H 
15N HSQC of hPrP166-230 acquired immediately after the protein 
was dissolved in denaturing conditions (8M urea, pH 2) revealed line widths and 
chemical shifts comparable to the hPrP90-230 (Figure 3.17). The HSQC acquired after 
six  hours  already  showed  remarkable  disappearance  of  most  of  the  signals, 
indicating formation of oligomers. This sample resulted in a thick gel, which when 
subjected  to  electron  microscopy  revealed  an  un-resolvable  dense  mass  of 
amorphous aggregates. We concluded that a polypeptide chain comprising residues 
166-230 does not form fibers under the denaturing conditions employed here. These 
residues, although being part of the amyloid core in our hPrP90-230 preparations, do 
not  form  fibers  in  the  shorter  construct.  We  concluded  that  the  aggregation 
promoting sequence in  the 90-166 region  seems to  be required for  the amyloid 
formation.  





Figure 3.16: 1D 
13C MAS (magic angle spinning) spectra of hPrP90-230 fibrillar 
state. hPrP90-230 aggregates into fibres and forms with time a sample 
of gel-like texture. This sample was transferred from the liquid-state 
NMR tube into a 4mm MAS NMR rotor by centrifugation. At a 
spinning  rate  of  10  kHz, 
13C  spectra  were  recorded  using  direct 
polarization (DP) and cross polarisation (CP). The DP spectrum (a) 
reveals  well-resolved  resonances  with  line  widths  of  down  to 
0.5ppm.  A  signal  loss  is  observed  under  CP  conditions.  This 
indicates  high  molecular  mobility,  which  makes  dipolar-based 
magnetization transfer as in CP inefficient. Spectra were recorded at 
a  Bruker  Avance  600WB  spectrometer  using  a  4mm  DVT 
probehead at 25°C. In both cases, 
1H decoupling of 90 kHz was 
applied and 2048 transients were accumulated. For CP, a contact 
time of 2ms was used. The FIDs were processed using exponential  
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Figure  3.17:  Overlay  of 
1H 
15N  HSQC  spectrum  of  hPrP90-230  (green)  and 
hPrP166-230 (black) acquired in the denatured state at 8 M urea, pH  
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2.0, 25°C.  
 
 
Figure  3.18:  Structural  properties  of  Tyr-Tyr-Arg  (YYR)  motifs.  (a)  Secondary 
structure representation of hPrP90-230 showing the distribution of tyrosine 
residues.  Tyrosines  appearing  in  pairs  have  been  encircled.  (b) 
1H 
15N 
HSQC spectra of hPrP90-230 at 298K in 8M urea, pH 2 at a concentration of 
200 M in 10% D2O. The signals correspond to the Tyr225-Tyr226-Gln227 
in α-helix-3 of hPrP. The changes in the chemical shift are indicated by the 
arrow. The graph in the inlay shows changes in the intensity of the signals 
observed with respect to the first day of sample preparation (normalized to 
internal phthalimide). 
Residues 90-126 are unstructured in the native form (Zahn et al., 2000) and have 
been proposed as key region for the amyloidal and toxic nature of PrP (Weissmann  
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and Flechsig, 2003). This region comprises a hydrophobic core (residues 106-126) 
and  within  this  core  an  amyloidogenic  palindrome  sequence  AGAAAAGA 
(residues 113-120). Our data show that the peak intensities of residues within the 90-
126 region decrease only by 30-40% after day 4 and remain largely visible even after 
day 7 in comparison to the other regions  of the protein, except  for the region 
around  the  Pro102  and  Pro105,  which  show  complete  decrease  in  NMR  signal 
intensity  (Figure  3.13b).  The  palindrome  sequence  (Gasset  et  al.,  1992)  remains 
visible in the NMR spectra (Figure 3.13) indicating that this region is flexible in the 
fibrillar state after the 7
th day. Previously, solid state NMR investigations on hPrP23-
144  (a  Gerstmann-Sträussler-Scheinker  (GSS)  syndrome-related  Y145stop  variant) 
identified a rigid core comprising of residues 112-141 (Helmus et al., 2008), while in 
our studies, residues 113-140 in hPrP90-230 remain flexible. The palindromic sequence 
is not part of the rigid core of fibrils but likely promotes fibril formation. The 
amyloidogenic region comprising the residues 106-126 remains solvent accessible in 
the  fibril  state,  which  could  explain  for  the  specificity  of  the  recently  reported 
monoclonal  antibody  (variant-CJD  (Creutzfeldt-Jakob  disease)  monoclonal 
antibody 3F4 (Barry and Prusiner, 1986) binds to epitope with residues from 109-
112) against this region of the pathogenic prion protein. 
The prion protein comprises 13 tyrosines and 11 of these tyrosine residues are in 
the structured domain (Figure 3.18). 6 tyrosines appear in pairs and are conserved 
across mouse, human, sheep, bovine and human PrP (Paramithiotis et al., 2003). 
Two tyrosine pairs, located in  -helix-1 and  -strand 2, are found in conjunction 
with  a  C-terminal  arginine  (hPrP  residues  149-151  and  162-164,  respectively), 
whereas the tyrosine pair at the C-terminus of  -helix-3 (residues 225-227) is flanked 
by a C-terminal aspartate in mouse and hamster or a glutamine in sheep, bovine and 
human PrP (Figure 3.18) (Paramithiotis et al., 2003). Several antibodies against Tyr- 
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Tyr-X motifs have been developed as a diagnostic tool specific to the prion protein, 
based on the assumption that these tyrosine residues are solvent exposed in the 
fibril state (Paramithiotis et al., 2003, Li et al., 2009). The same antibodies do not 
bind to the native PrP presumably because these tyrosine motifs are concealed to 
antibody recognition by tertiary structure elements (Riek et al., 1996, Liu et al., 
2000,  Zahn  et  al.,  2000)  and  native  post-translational  modifications.  Our  data 
provide direct evidence for the solvent exposure of these tyrosine motifs in the 
fibril state by NMR. In the 
1H 
15N HSQC spectrum of the fibril state of the hPrP90-
230 signals for Tyr149-Tyr150-Arg151 in  -helix-1 can be observed, indicating that 
this motif remains flexible and solvent exposed (Figure 3.13). The disappearance of 
the signals for Tyr162-Tyr163-Arg164 in  -strand 2 shows that this motif is in the 
core of the fibril. Changes in the chemical shift observed for the residues Tyr225-
Tyr226-Gln227  in  -helix-3  (Figure  3.18)  indicates  that  this  motif  undergoes 
structural rearrangement during the formation of the fibrils. We conclude that two 
of the three tyrosine motifs are solvent-exposed in the fibril state. 
 
 
Figure  3.19:  Schematic  presentation  of  fibril  core  of  recombinant  prion  hPrP90-230 
amyloid  fibrils  as  investigated  by  mass  spectrometry  (Lu  et  al.,  2007), 
electron paramagnetic resonance (EPR) spectroscopy (Cobb et al., 2007, 
Cobb et al., 2008) and solution-NMR spectroscopy (our data). The charged 
cluster (CC), hydrophobic core (HC), helices (H1, H2 and H3) and single 
disulfide bridge (S-S) from native structure (Zahn et al., 2000) are indicated.  
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In  summary,  the  recombinant  human  prion  fibrils  formed  under  denaturing 
conditions (from 8 M urea at pH 2) comprise both rigid and dynamic parts and the 
NMR data presented here allows us to delineate these regions of the fibrils. Within 
hPrP90-230, residues 145-223 (comprising from helix-1 to helix-3 in the native state) 
form  the  rigid  core  of  the  fibrils.  Previous  studies  using  fibrils  prepared  in 
denaturing  conditions  mapped  the  core  region  to  168-223  using  H/D  exchange 
(mass spectrometry) (Lu et al., 2007), whereas, the fibrils prepared in native-like 
environment at acidic pH (pH 4.0) mapped the core region to 160-220 using EPR 
spectroscopy (Cobb et al., 2007, Cobb et al., 2008) (Figure 3.19). It is striking that 
recombinant  prion  fibrils  formed  under  the  highly  denaturing  and  native-like 
environment  share  a  common  core  region.  This  information  has  a  strong 
implication for presence of common fibril forming mechanism in variable chemical 
environments. Furthermore, recently it has been shown that recombinant hamster 
prion  fibril  induces  disease  in  hamsters  on  serial  transmission  (Makarava  et  al., 
2010). It has been hypothesized that recombinant fibrils undergo conformational 
adaptation in the process. Importantly these recombinant fibrils carry structural 
information to recruit native PrP
C and thus causing the disease (Makarava et al., 
2010).  Therefore,  despite  being  potentially  structurally  different  from  infectious 
prion  (Wille  et  al.,  2009),  these  recombinant  prion  fibrils  are  having  all  the 
structural  information  for  seeding  and  transmission  of  disease  (Makarava  et  al., 
2010). We further show that the amyloidogenic region around residues 106-126 is 
not part of the rigid core but remains flexible, a finding further supporting its role 
as aggregation promotor. The solvent accessibility of tyrosine motifs known in the 
fibrils is in line with the antibody binding specific to prion protein.  
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Polymorphism in prion fibrils 
Understanding the molecular and high order architectural structural heterogeneity 
of amyloid fibrils is a major challenge to present day science. It is well known that 
for amyloid fibrils, nucleation and kinetics depend not only on inherent features 
such  as  the  amino  acid  composition,  sequence,  and  length,  but  also  on 
environmental  conditions  such  as  temperature,  concentration,  pH,  ionic 
concentration, agitation, and enhanced aggregation. Despite the knowledge about 
these factors, the self-assembly mechanism which leads to ordered fibril formation 
is not well understood. There are a number of open questions like (1) how the 
monomers  assemble  into  oligomers;  (2)  which  segments  or  domain  of  a  long 
polypeptide constitute the recognition motifs and are there any of them play key 
roles  in  amyloid  fibril  formation;  (3)  how  the  β-strands  stack  relative  to  one 
another; (4) are there favored organizations between the β-sheets or there more a 
few possible arrangements, (5) what are the most favored architecture of β-sheets 
and what are the intermolecular interactions between the layers that stabilize these; 
and, (6) what are the pathways and the intermediate states that are involved in seed 
and  fibril  formation.  The  combination  of  these  contribute  to  one  of  the  most 
difficult problem in the field of protein aggregation which is known as aggregate or 
fibril polymorphism; the aggregates can have different preferred fibril architectures 
depending  on  (even  slight)  changes  in  any  of  these  sequence  or  environmental 
factors.  In  our  studies,  where  we  started  to  observe  fibril  formation  in  highly 
denaturing  environment  of  8  M  urea,  pH  2;  which  essentially  unfold  the 
polypeptide chain, we were able to observe fibril formation. The fibrils formed 
under  these  conditions  display  structural  polymorphism  as  reported  for  under-
glycosylated scrapie prion fibrils. The different morphologies of fibrils (Figure 3.20) 
are suppose to be initiated from different molecular structures and may be lead to  
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formation of different prion strains. Therefore, an understanding is necessary for 
gaining an insight into the phenomenon of prion strains, wherein the same prion 
protein adopts a range of infectious conformations differing in their specificity and 
transmission barrier. In this section, we try to bring together the data from electron 
microscopy (EM), atomic force microscopy (AFM), solid-state NMR spectroscopy 
(SS-NMR) and solution-NMR spectroscopy.  
 
Figure 3.20: an example of a-  polymorphism observed. Cryo-EM reconstructions of 
12 individual a-β(1-40) fibrils. (a) Electron micrographs of the 12 individual 
a-β (1-40) fibrils from the same sample. (b and c) Side (b) and top (c) views 
of  the  reconstructed  fibrils  shown  in  (a);  the  image  is  adapted  from 
(Fandrich et al., 2009, Meinhardt et al., 2009). 
Electron microscopic images: Polymorphism among preparations 
The TEM is a powerful method to gain structural information about the amyloid 
fibrils. The EMgraphs were generated by staining with uranyl acetate and placed on 
carbon grid to observe the morphologies. The samples were diluted 5 to 100 times, 
depending on the viscosity of the preparation, which increase with the rise of fibril  
- 102 - 
population.    These  images  display  presence  of  multiple  morphologies  in  same 
preparation.  They  include  long  sheeted  assemblies  along  with  other  subtype  of 
fibrils. In a number of grids (Figure 3.27), these amyloids appeared to be clustered 
together,  which  make  it  difficult  to  identify  individual  characteristics  of  fibrils. 
These  fibrils  show  different  morphologies  for  non-agitated  and  agitated 
preparations. The short peptide 174-184 forms instantaneously (Figure 3.29) and 
only  one  which  gave  electron  diffraction  map  (Figure  3.30).  Non-agitated 
preparations shows majorly long twisted fibrils, with other thinner fibrils can also 
be observed (Figure 3.21, 3.22 and 3.23). The samples prepare with agitation, mostly 
showed cluster of long straight fibrils (Figure 3.24 and 3.25) but often also seen as 
bundle of thin fibres (Figure 3.26). The fibrils formed in 8 M urea pH 2, shows 
stability  when  they  are  dialyzed  against  water  pH  2  (Figure  3.28),  but  the 
morphological appearance is changed.  
    





  Figure 3.21: EMgraph of recombinant prion protein fibrils, these fibrils formed on 
long incubation at room temperature, and samples were not agitated. 
The  EMgraphs  clearly  display  a  population  of  long  twisted  fibrils, 
which are having twisted about every 80nm and 20 nm in diameter. 





  Figure 3.22: The EMgraph of freshly prepared recombinant prion fibrils, samples 
were non-agitated and clearly display that sample is full of small worm-
like  fibrils,  the  length  of  these  fibrils  are  relatively  short  and  about 
100nm.   





  Figure 3.23: The EMgraph of recombinant prion fibrils (non-agitated) display the 
presence of classic rod-like fibrils along with some twisted fibrils.  
 
 
  Figure 3.24: The EMgraph of recombinant prion protein fibrils (agitated) displaying 
long-straight  fibrils  appearing  in  bunches  for  low  protein 
concentration.   





  Figure 3.25: The EMgraph is showing a possible presence of high-order oligomers in 





  Figure  3.26:  These  EMgraphs  reveal  the  presence  of  very-thin  fibrils  which  are 
bundled  together.  These  images  are  in  accordance  with  the  fibrils 
morphology observed for unglycosylated mouse prion fibrils (Sim and 
Caughey, 2009).   










  Figure  3.28:  The  EMgraph  for  fibrils, 
which  were  dialyzed  against 
water,  pH2.  These  are  long 
unbranched straight fibrils 
 
Figure  3.29:  The  EMgraph  for  fibrils 
generated from a synthetic peptide 
containing residues from 174-184.   
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  Figure 3.30: The electron diffraction pattern for fibrils formed of hPrP peptide 174-
184.  
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The diffraction data of peptide (174-184) fibril suggest that these fibrils differ from 
the usual cross-  structure. The β stacks are arranged 4.4 to 4.5 Å apart, which 
suggest a tilt of 15 to 20 ° in stacking pattern, while regular cross-  sheets are, 
arranged at 4.7 Å.  
Atomic force microscopy: another view of prion polymorphism  
The AFM is a powerful technique to provide topological information about the 
amyloid fibrils. The AFM images usually have height information on left panel and 
amplitude  data  on  right  one.  These  results  help  in  identifying  the  existence  of 
multiple morphologies in individual preparations, which explains the complexity of 
fibril structures, produced from simplistic conditions. The topological studies were 
done by diluting parent preparations in Tris buffer (40 mM Tris/ Acetic acid pH 
7.6, 12.5 mM MgCl2, 2 mM EDTA) to avoid crowding in AFM images.  The images 
were recorded at the end-point of NMR experiments.  
AFM images display broad morphological diversity of fibrils as seen by EM as well; 
the populations within same preparations vary with respect to their width, height 
and twisting patterns. The protein seems to cluster and then fibrils are woven out 
of these clusters. These fibrils are quite long and regular with minor population of 
small  fragmented  straight  fibrils.  A  much  closer  look  of  these  reveals  the 
arrangement of fibrils in bead-like manner, which is an indication of either a base 
polymerizing unit for fibrils or regular twist in this architecture. 
The fibril subtypes included straight or slightly curvy ribbon like fibril, rod-shaped 
fibrils, and bundles and with beaded nature (Figure 3.31 and 3.32). Most of the time, 
these amyloids appeared to be clustered together, which make it difficult to identify 
individual characteristics of fibrils (Figure 3.33). One of the striking facts about  
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these fibrils was that they were disassembled into smaller oligomers with no or very 
little fibrils, when urea got crystallized at 4 °C (Figure 3.34). It is most likely urea 
crystal dissects these fibrils into smaller oligomers as observed with super cooled 
water, which dissociate mature fibrils (Kim et al., 2008). A few of such preparations 
also shows dense amorphous aggregate or a low number of fibrils present with 





  Figure 3.31: The high –resolution AFM images of recombinant human prion  
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fibrils at two different magnifications (5 µm and 1.5 µm). The 
left panel shows height data, while amplitude images are shown 
on  right  panel.  The  upper  image  shows  couple  of  non-fibril 
aggregates, and fibrils are branching out from there in spun and 
woven  manner.  The  dense  fibrils  show  variable  heights.  The 
detailed  view  in  lower  panel  shows  that  most  of  fibrils  are 
straight but different diameters. A small population of oligomers 
is also visible.  
 
 
  Figure 3.32: The high resolution AFM images of recombinant human prion 
fibrils at a high magnification (700 nm). The left panel shows 
height  data,  while  amplitude  images  are  shown  on  the  right 
panel.  The  image  shows  fibrils  of  variable  length  but  similar 
height profile. Interestingly, the fibrils are arranged in bead like 
manner, which probably reflect twist in fibrils.  
    





  Figure 3.33: The high –resolution AFM images of recombinant human prion 
aggregates; there are curvy fibril weaving out from those clusters 
of protein.   





  Figure 3.34: The high –resolution AFM images of recombinant human prion 
aggregates, which were dissected by urea crystal formed at 4 °C, 
two different dilution of preparations shows presence of large 
number of oligomeric species.  





  Figure 3.35: The high – resolution AFM images of recombinant human prion 
aggregates, the upper image shows amorphous aggregate formed, 
oligomers are visible in high number as well. The lower image 
shows a single straight fibril with a number of oligomers around.   
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Solid state NMR of PrP fibrils:  
SS-NMR is one of the major techniques available today to understand the structure 
of solid or semi-solid substances of crystalline/non-crystalline nature. Magic-angle 
spinning  became  very  relevant  to  study  membrane  proteins,  macromolecular 
assemblies  and  amyloid  fibrils  (Tycko,  2000,  2003,  Siemer  et  al.,  2005,  Tycko, 
2006b, c, van der Wel et al., 2007, Heise, 2008, Lange et al., 2009, Bayro et al., 2010, 
Van Melckebeke et al., 2010). The two dimensional solid-state NMR spectroscopy 
allowing solving structure of these biologically important samples with the very 
low amount needed. However, there is not much have been achieved on structure 
of disease-associated fibrils due to inherent nature of amyloid preparations. These 
preparations are heterogeneous in nature and often irreproducible. A distribution 




Figure 3.36: The distribution of carbon chemical shift in a typical solid state spectrum. 
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For our studies, samples were prepared by centrifuging the solution-NMR sample 
to fit in 4mm MAS-NMR rotor. The solid-state NMR spectra of PrP fibrils show 
characteristic heterogeneity of prion fibril assemblies. These preparations were not 
completely rigid and much more appear to have gel-like texture. We have recorded 
13C direct polarization and cross-polarization spectra for three of these preparations 
(Figure  3.37).  Cross-polarization  spectra  shows  loss  of  signals,  while  direct-
polarization  spectra  display  resolved  peaks,  which  indicate  that  despite  gel-like 
texture, these samples are containing highly mobile regions. Therefore dipole based 
magnetization transfer is not enough to have cross-polarization in sample.  
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Figure 3.37: The carbon chemical shift for recombinant human prion fibrils, A) and B) 
HP-MAS spectra of fibrils in water and urea respectively while C) D) and 
E) are decoupled spectra. The spectra A) and C) are for same sample and 
display flexible threonine C  and aromatic side chain C atoms, the signals 
in MAS spectra are weak, indicating flexible nature of fibrils. Spectra A) C) 
and  E  are  of  fibrils  in  8  M  urea,  displaying  highly  flexible  nature  of 
residues in fibrils.   
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Hydrogen/Deuterium exchange of fibril core 
Due  to  their  size,  insolubility,  and  noncrystalline  nature,  the  structural  and 
dynamic  characteristics  of  amyloid  fibrils  have  been  difficult  to  elucidate  using 
traditional  methods  such  as  crystal  diffraction.  Hydrogen− deuterium  exchange 
(HDX) experiments are based on solvent accessibilities and provide information to 
characterize the structure and kinetics of proteins. When this method is subjected 
to  amyloids,  one  can  gather  information  about  inaccessible  buried  residues  and 
relatively  more  accessible  residues,  which  can  be  suitable  drug  targets.  The 
backbone amide protons usually undergo fast exchange with solvent protons, while 
hydrogen-bonded or buried amide protons show much slower exchange.  
 
 
Figure 3.38: The schematic presentation of sample preparation for HDX experiments.   




We dialyzed the fibrils, which were formed in 8 M urea, pH 2 against water, pH 2 
and then buffer exchanged with 70% D2O pD 2 (Figure 3.38), to observe deuterium 
exchange in these already formed fibrils. Presence of fibrils after dialysis and buffer 
exchange  was  verified  by  electron  microscopy.  In  contrast  to  common 
understanding  of  amyloid  fibrils  being  rigid  and  sterically  constraint,  recent 
developments show that these are not completely rigid and continuous reformation 
of fibrils happens all the time. Therefore, the amyloid fibril assemblies are not static 
but dynamic structures. The two-dimensional 
1H 
15N HSQCs are used to observe 
the protection factor of protons. Figure 3.39 shows percentage of protection for 
fibrils incubated over 6 months in D2O, bar represents protection for individual 
residues, while red line shows average over 7 residues. Most of residues show about 
protection around 40%, while residues 120-123, 144-149, 174-180 and 187-194 shows 
a low protection and therefore these residues are solvent accessible. The region 187-
194 is relatively striking as it shows complete loss of signals. This region is rich in 
theronine residues HTVTTTTK and shows high degree of mobility. The relative 
higher accessibility of these residues was also observed by solid-state spectra, where 
C  of theronine residues are seen (Figure 3.37). The fibrils formed from ovine prion 
protein fragment helix2 and helix3 also display similar behavior for these residues, 
which makes a rigid helical hairpin structure (Adrover et al., 2010). This piece of 
information  indicates  that  fibrils  undergo  structural  rearrangement  on  solvent 
exchange and the core of amyloid is not entirely rigid and allows residues to adopt 
conformation according to solvent. These fibrils are made of residues 90-230, which  
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represents proteinase-K resistant core of naturally occurring prions; therefore the 
solvent  accessibility  of  residues  give  relative  information  about  the  exposure  to 
solvent, even though they are part of amyloid core.  
 
 
Figure  3.39:  Protection  plot  for  deuterium  (70%)  exchanged  fibrils.  Most  of  the 
residues  show  about  40%  protection.  There  is  a  dip  around  TTTT 
sequence  (189-192)  showing  that  these  amide  protons  are  completely 
exchangeable.  
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Chapter 4  
Outlook 
 
Figure 4.1: outline of various fibrillation studies performed with unfolded recombinant 
prion protein constructs. 
The prion proteins have been studied widely in the last two decades, despite the 
advancement in our understanding of prion protein, there are a few key questions 
remain unanswered. One of these crucial questions is structural characterization of 
the  soluble  PrP  oligomers  and  insoluble  PrP
Sc  fibrils.  The  complete  structural 
characterization  of  the  soluble  oligomeric  intermediates  is  very  unlikely  and 
difficult because these intermediate are typically having short lives and display a 
wide range of conformational landscape and degrees of aggregation. In our studies  
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we used recombinant prion protein constructs (90-230, 121-230,174-184 and 166-
230)  in  the  highly  denaturing  environment  (Figure  4.1).    The  longer  construct 
forms fibril in non-agitated and agitated conditions, the core of the amyloid was 
identified starting from 145 to 223 residues. The 121-230 construct does not form 
fibrils in non-agitated conditions when purified under oxidized environment while 
it forms fibril when construct retains 7 x His-tag, and purified in presence of 5mM 
DTT.  The 166-230 construct form aggregates faster under these conditions; these 
aggregates contain irresolvable mass, when subjected to EM. The short polypeptide 
segment 174-184 forms fibrils almost instantaneously, the diffraction data shows 
that these fibrils are different from known fibrils characteristics; they are ~4.5Å 
rather than usual 4.7Å, which indicate that fibrillar   sheets are tilted at the angle of 
20°.  
The Association prone monomers can lead multiple pathways and therefore end up 
in formation of either amorphous aggregates, annular or globular oligomers or a 
number of morphologically different fibrils (Figure 4.2). The complexity of fibril 
conformations is another interesting and intriguing phenomenon associated with 
prions; it termed as “prion strains”. These strains were originally characterized by 
incubation time and the neuropathology observed in the host. The transgenic mice, 
which are homozygous for the PrP gene (Prnp) allowed to propagated most of the 
strains indefinitely and provided a laboratory model for studies. The protein-only 
hypothesis assumes that each strain is associated with different conformer of PrP
Sc, 
which indicate the presence of multiple stable conformations. The mouse model 
allows  propagating  about  15  different  strains;  therefore,  we  should  have 
approximately  15  different  conformations  for  PrP
Sc.    The  cell-free  conversion 
experiments allowed auto-catalytic replication of PrP to PrP
Sc-like conformations. 
These experiments supported the template assisted model of prion propagation,   




Figure  4.2:  Paths  of  molecular  assemblies  in  a  cell,  a  native  monomer  adopt  to 
association prone monomer conformations in the suitable environments, 
these monomers then assemble into early oligomers with variable lag time 
in  the  formation  of  oligomers,  and  finally  lead  to  end  product  like 
amorphous  aggregates,  globular  oligomers,  annular  oligomers  or  to 
amyloids through the formation of nucleus.   
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which  got  extended  by  development  of  protein  misfolding  cyclic  amplification 
assay (Soto et al., 2002a). These allowed mimicking PrP
Sc like conformations, in 
vitro.  The  in-vitro  preparation  of  fibrils  from  recombinant  prion  protein  is 
inherently  heterogeneous,  which  reflects  the  characteristic  nature  of  prions. 
However,  it  makes  difficult  for  routine  structural  investigations  using  NMR  or 
crystallography. An isolated single strain would probably allow gaining insight to 
conformational switching on fibril formation.   
The  unfolded  state  of  protein  represents  minimal  constrained  structure  and 
therefore,  our  observation  of  fibril  formation  in  denaturing  environment  is 
significantly  important.  It  shows  that  fibrils  can  be  formed  from  the  extended 
unfolded  state  of  prion  protein.  Therefore,  our  data  fill  the  empty  space  of 
information  about  fibril  formation  from  unfolded  state.  From  initial  unfolded 
extended conformations, these monomers adapt association-prone structures. This 
lead to oligomerization and the end product of these associations can be amorphous 
aggregates, globular oligomers, annular oligomers or amyloid fibrils. These amyloid 
fibrils usually adopt more than one conformation in same preparation, and  the 
observations are done on a pool of strains, than a single isolated amyloid strain. 
Most of the studies of fibril-kinetics are performed using dyes congo red (Khurana 
et al., 2001), thioflavin-T (Khurana et al., 2005) or thioflavin-S; however, accuracy 
of  these  dyes  were  always  questioned.  Recent  studies  clearly  demonstrated  that 
existence of non thioflavin-T binding fibrils for mouse prion strains(Colby et al., 
2009),  while  others  have  shown  significantly  different  lag  time  for  same 
recombinant protein in identical conditions (Krebs et al., 2005). These definitely 
question the use of thioflavin-T as the right candidate to understand the dynamics 
of  fibril  formation.  Here  we  present  that  real  time  analysis  using  the  NMR  
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spectroscopy offer the best method for kinetic observations; which does not reflect 
variability due to different binding mode of dye.   
The PrP 27-30 which represents the amyloid core of naturally occurring prions, 
starts either from 89/90 or 111/112 residue in amino acid sequence and therefore, 
the residues from 90 to 124 plays a crucial role, although they are unstructured in a 
native-like environment. PrP
Sc models, which  were  calculated  based  on  electron 
microscopic images varies in secondary structural details while the experimental 
data from HDX, MALDI  (Cobb et al., 2007, Lu et al., 2007), EPR (Cobb et al., 
2008)  and  our  NMR  studies  agree  on  the  common  core  region.  The  solvent 
inaccessible or rigid core is identified from residue 145 to 223, while  last seven 
residues at C-terminus show the conformational transition on fibril formation.  
The new evidence suggested Darwinian evolution of prion strains, suggesting that 
strains  adopt  conformations  with  environment  variation  and  develop  drug 
resistance(Figure 4.3) (Li et al., 2010). The improved energy landscape for prion 
amyloidal  formation  will  represent  the  view  that  sub-strains  are  distinguishable 
collectives  of  prions  that  can  interconvert  reproducibly  and  relatively  readily 
because they are separated by relatively low activation energy barriers. The new 
scheme  also  implies  that  the  properties  of  a  strain  vary  depending  on  the 
environment  in  which  it  replicates,  because  the  proportions  of  the  component 
substrains may change to favor the one replicating most rapidly.  
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Figure 4.3: With new knowledge about strains and substrains, the energy landscape of 
amyloid formation should be broaden to include substrain phenomena of 
amyloid, which is largely depending upon the local environment.   
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The  prion  protein  has  a  highly  conserved  native  structure,  which  may  be  the 
central to the abilities of prions to transfer infection across species. Initially, these 
differences in primary structure have been thought to support the concept of a 
barrier to cross-species infection, but now it has been demonstrated that the "strain-
ness" of a prion is fundamental to its ability to infect a new species. Therefore, two 
prion  strains,  which  propagate  in  one  species,  carry  the  abilities  to  cross  a 
transmission barrier. In the context with this knowledge “conformational selection 
model” (Collinge, 1999) have been proposed, which state that the possible PrP
Sc 
strains that can overcome natural clearance and propagate effectively in mammals, 
only  a  subset  is  compatible  with  a  given  host  PrP
C  structure,  and  can  thereby 
propagate  in  that  host.  With  this  new  piece  of  information  about  the  prion 
transmission, the species barriers can be explained by the degree of overlap between 
strain  types  that  are  permissible  in  the  two  species  concerned.  However,  it  is 
possible that these prions do not maintain their identity when propagate in a new 
host  but  switch  structural  properties,  causing  strain  "mutation"  on  crossing 
between  species,  or  intraspecies  transmission  due  to  PrP  polymorphism  or  the 
effect of genetic  background. The pathogenicity of  new strain may be different 
from its progenitor, and may be more toxic. Therefore, these strain mutations has 
potential  public  and  animal health implications. One  of  the interesting findings 
about prions is that shows conformational adaptability (Bartz et al., 2000, Jones and 
Surewicz, 2005, Surewicz et al., 2006, Meyerett et al., 2008, Cobb and Surewicz, 
2009, Colby et al., 2009, Angers et al., 2010), when environment or host is changed. 
It was astonishing that fibrils formed in 8 M Urea pH 2, could demonstrate this 
conformational switching when fibrils were transferred from highly viscous urea 
solution to water, pH 2 by dialysis. The EMgraph confirms the presence of long 
well ordered fibrils and the 
1H
 15N HSQC spectrum of fibrils in water pH 2 shows  
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very similar distribution and dispersion of residues. However, HDX experiments 
show that TTTT sequence (189-192) becomes solvent accessible on this transition 
demonstrating the strain adaptation and mutation, when the local environment is 
changed.  The  high-resolution  NMR  spectroscopy  is  the  method  of  choice  to 
investigate the prion kinetics as it can differentiate among different prion strains, as 
they will exhibit different NMR spectra, due to change in their architecture. The 
changes can be followed in a time-dependent manner, though may require dedicated 
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Appendix 
Chemical shift values for recombinant prion protein90-230 
Residue    Ca  Cb  C'  N  HN  Ha 
G  90    44.99    173.99  110.94  8.531   
Q  91    55.89  29.19  176.39  119.74  8.291   
G  92    44.99    174.39  110.14  8.491   
G  93    44.99    174.49  108.64  8.301   
G  94    45.09    174.19  108.74  8.311   
T  95    61.99  69.79  174.49  113.24  8.141   
H  96    54.99  28.49  174.19  120.64  8.611   
S  97    58.49  63.89  174.29  117.34  8.381   
Q  98    56.19  29.09  175.39  122.34  8.511   
W  99    56.99  29.19  175.69  121.94  8.161   
N  100    52.79  38.79  175.89  120.74  8.251   
K  101    52.79  37.99    119.64  8.481   
P  102    62.59  31.79  176.69       
S  103    58.19  63.99  173.99  117.04  8.451  4.461 
K  104    54.29  32.59    124.04  8.381  4.341 
P  105    62.69  31.59  176.29       
K  106    60.69  37.89  175.79  122.14  8.281  4.331 
T  107    61.99  69.59  173.89  118.14  8.151  4.291 
N  108    52.89  38.59  174.89  121.44  8.571  4.761 
M  109    54.29  32.29  175.89  122.64  8.101  4.481 
K  110    56.09  32.79  176.19  122.74  8.391  4.421 
H  111    54.99  28.49  174.19  120.34  8.651  4.721 
M  112    55.09  32.89  175.49  123.14  8.541  4.521 
A  113    52.59  18.99  177.79  126.04  8.481  4.371 
G  114    44.79    173.49  108.54  8.361  3.821 
A  115    52.49  19.19  177.39  123.74  8.141  4.321 
A  116    52.39  18.79  177.39  123.34  8.291  4.321 
A  117    52.39  18.79  177.29  123.44  8.201  4.311 
A  118    52.49  18.89  177.99  123.34  8.221  4.291 
G  119    44.79    173.39  108.04  8.261  3.821 
A  120    52.39  19.19  177.49  123.54  8.041  4.361 
V  121    62.29  32.39  176.09  120.04  8.161  4.141 
V  122    62.29  32.59  176.39  124.94  8.281  4.141 
G  123    44.89    174.19  113.04  8.471   
G  124    44.99    173.99  108.44  8.211   
L  125    55.39  42.19  177.79  121.54  8.261  4.381 
G  126    45.09    174.29  109.44  8.441  4.201 
G  127    44.99    173.59  108.44  8.171   
Y  128    57.69  38.49  175.49  120.14  8.051  4.571  
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M  129    55.49  32.59  175.69  122.34  8.331  4.381 
L  130    55.29  42.19  177.59  123.64  8.221  4.531 
G  131    44.99    173.89  109.94  8.411  3.801 
S  132    58.09  63.99  174.39  115.44  8.181  4.421 
A  133    52.69  18.69  174.69  125.94  8.421  4.361 
M  134    55.49  32.79  176.09  118.94  8.251  4.471 
S  135    58.19  63.89  173.79  117.14  8.231  4.451 
R  136    54.19  30.09    123.64  8.341  4.411 
P  137        174.69       
I  138    60.89  38.29  175.79  121.94  8.251  4.411 
I  139    60.29  38.49  175.39  126.14  8.201  4.071 
H  140    54.59  28.79  173.69  123.44  8.541  4.731 
P  141    57.79  39.59  176.79  122.94  8.451  4.661 
G  142    44.79    173.89  110.54  8.481   
S  143    58.49  63.89  174.29  115.44  8.261  4.441 
D  144    52.89  37.69  174.79  120.74  8.551  4.731 
Y  145    58.59  38.19  175.59  120.84  8.091  4.451 
E  146    55.79  28.29  175.79  120.94  8.111  4.481 
D  147    52.69  37.89  174.89  119.74  8.471  4.671 
R  148    56.29  30.29  175.49  121.34  8.161  4.281 
Y  149    57.69  38.39  175.29  120.34  8.031  4.741 
Y  150    57.79  38.69  175.49  122.14  8.021  4.341 
R  151    56.09  30.29  175.19  120.24  8.031  4.481 
E  152    55.89  28.49  175.49  121.44  8.291  4.711 
N  153    58.29  27.59  174.99  121.34  8.491  4.731 
M  154    55.59  32.39  175.49  121.04  8.311  4.311 
H  155    52.89  38.29  174.99  120.14  8.511  4.711 
R  156    55.89  30.89  175.99  122.84  8.301  4.441 
Y  157    55.59  32.59    122.04  8.441  4.341 
P  158    63.49  31.79  176.29       
N  159    53.19  38.49  175.59  118.54  8.461  4.701 
Q  160    55.99  29.19  175.19  120.64  8.261  4.681 
V  161    62.09  32.49  175.19  121.74  8.131  4.031 
Y  162    57.49  39.09  174.89  124.24  8.231  4.291 
Y  163    57.59  38.99  174.59  123.64  8.181  4.291 
R  164    53.59  30.29  175.39  124.94  8.241  4.511 
P  165               
M  166        175.39       
D  167    52.89  37.69  175.39  119.54  8.271  4.681 
E  168    60.99  38.59  175.59  121.64  8.161  4.241 
Y  169    57.59  38.59  175.59  120.44  8.131  4.591 
S  170    57.89  63.99  173.99  116.84  8.191  4.411 
N  171    52.99  38.19  175.09  121.14  8.461  4.731 
Q  172    57.59  28.89  175.29  120.24  8.091  4.531 
N  173    53.19  38.59  174.59  119.14  8.391  4.641 
N  174    55.29  0  176.09  118.84  8.241  4.471  
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F  175               
V  176    62.29  32.49  175.59  121.54  8.021  4.481 
H  177    54.99  28.59  173.59  122.34  8.581  4.761 
D  178    52.89  37.99  174.49  121.14  8.601  4.751 
C  179    58.59  27.79  174.09  120.44  8.461  4.731 
V  180    61.99  28.29  175.29  122.14  8.201  4.711 
N  181    52.89  38.59  175.49  122.84  8.491  4.631 
I  182    56.19  38.29  175.99  121.14  8.171  4.261 
T  183    61.89  69.59  174.19  119.04  8.301  4.351 
I  184    61.99  38.49  175.79  124.44  8.201  4.581 
K  185    56.09  32.79  175.59  126.34  8.431  4.331 
Q  186    55.89  32.59  173.99  122.34  8.351  4.371 
H  187        174.19  120.44  8.741  4.741 
T  188        174.09  117.34  8.381  4.381 
V  189    62.19  32.79  175.99  123.04  8.401  4.281 
T  190    61.89  69.79  174.49  118.74  8.371  4.501 
T  191    61.79  69.69  174.39  116.44  8.221  4.351 
T  192    61.49  69.89  174.39  116.14  8.261  4.501 
T  193    61.59  69.89  174.39  116.74  8.281  4.471 
K  194    56.49  32.69  176.69  124.04  8.381  4.341 
G  195    44.79    173.69  110.24  8.411   
E  196    55.79  28.59  175.29  119.54  8.171  4.341 
N  197    52.89  38.39  174.69  119.94  8.471  4.711 
F  198    57.69  39.19  175.69  121.24  8.261  4.701 
T  199    61.89  69.89  174.19  115.84  8.151  4.351 
E  200    55.89  28.49  176.49  122.64  8.341  4.411 
T  201    62.09  69.69  173.89  114.94  8.191  4.331 
D  202    52.89  37.99  174.79  121.24  8.461  4.761 
V  203    62.49  32.39  175.89  120.84  8.041  4.571 
K  204        176.39  124.94  8.321  4.111 
M  205        174.89  122.04  8.361  4.341 
M  206    55.69  32.69  175.89  121.44  8.371  4.431 
E  207    55.89  29.39  175.79  122.24  8.471   
R  208        175.89  125.04  8.291  4.511 
V  209    62.09  32.59  170.79  122.74  8.281   
V  210    62.29  32.39  175.89  122.04  8.661   
E  211               
Q  212    55.59  28.49  176.39  124.74  8.451   
M  213    53.29  38.39  174.89  118.44  8.461  4.651 
C  214    55.99  28.99  175.49  120.24  8.321  4.371 
I  215        176.69  120.64  8.301  4.671 
T  216    61.49  69.99  176.59  115.24  8.211  4.381 
Q  217    56.29  32.59  175.39  122.34  8.531  4.341 
Y  218    55.89  37.89  173.99  122.24  8.411  4.361 
E  219               
R  220    55.79  28.29  176.29  121.84  8.201  4.231  
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E  221    55.69  28.59  175.89  121.24  8.381  4.431 
S  222    58.39  63.79  174.39  116.94  8.331  4.431 
Q  223    55.89  28.89  175.49  121.84  8.381  4.421 
A  224    52.69  18.79  177.19  124.44  8.201  4.301 
Y  225    57.99  38.59  175.29  119.44  8.021  4.411 
Y  226    57.79  38.59  175.09  121.64  7.941  4.511 
Q  227    55.59  29.19  175.59  122.54  8.201  4.321 
R  228    55.89  30.59  176.59  123.04  8.431  4.291 
G  229    44.79    173.49  110.44  8.451   




    
- 132 - 
LiteratureLiterature 
 
Abrahamson M, Jonsdottir S, Olafsson I, Jensson O, Grubb A (Hereditary cystatin 
C amyloid angiopathy: identification of the disease-causing mutation and 
specific diagnosis by polymerase chain reaction based analysis. Hum Genet 
89:377-380.1992). 
Adrover M, Pauwels K, Prigent S,  de Chiara  C, Xu Z, Chapuis C,  Pastore A, 
Rezaei H (Prion Fibrillization Is Mediated by a Native Structural Element 
That  Comprises  Helices  H2  and  H3.  Journal  of  Biological  Chemistry 
285:21004-21012.2010). 
Aguzzi A (Understanding the diversity of prions. Nat Cell Biol 6:290-292.2004). 
Alper T, Cramp WA, Haig DA, Clarke MC (Does the agent of scrapie replicate 
without nucleic acid? Nature 214:764-766.1967). 
Anderson M, Bocharova OV, Makarava N, Breydo L, Salnikov VV, Baskakov IV 
(Polymorphism and ultrastructural organization of prion protein amyloid 
fibrils: an insight from high resolution atomic force microscopy. J Mol Biol 
358:580-596.2006). 
Anfinsen CB (Principles that govern the folding of protein chains. Science 181:223-
230.1973). 
Angers  RC,  Kang  H-E,  Napier  D,  Browning  S,  Seward  T,  Mathiason  C, 
Balachandran  A,  McKenzie  D,  Castilla  J,  Soto  C,  Jewell  J,  Graham  C, 
Hoover  EA,  Telling  GC  (Prion  Strain  Mutation  Determined  by  Prion 
Protein  Conformational  Compatibility  and  Primary  Structure.  Science 
328:1154-1158.2010). 
Apetri AC, Surewicz K, Surewicz WK (The effect of disease-associated mutations 
on the folding pathway of human prion protein. J Biol Chem 279:18008-
18014.2004). 
Apetri  AC,  Surewicz  WK  (Kinetic  intermediate  in  the  folding  of  human  prion 
protein. J Biol Chem 277:44589-44592.2002). 
Apetri AC, Vanik DL, Surewicz WK (Polymorphism at residue 129 modulates the 
conformational conversion of the D178N variant of human prion protein 
90-231. Biochemistry 44:15880-15888.2005). 
Atarashi R, Moore RA, Sim VL, Hughson AG, Dorward DW, Onwubiko HA, 
Priola  SA,  Caughey  B  (Ultrasensitive  detection  of  scrapie  prion  protein 
using seeded conversion of recombinant prion protein. Nat Methods 4:645-
650.2007).  
- 133 - 
Baldwin AJ, Anthony-Cahill SJ, Knowles TP, Lippens G, Christodoulou J, Barker 
PD, Dobson CM (Measurement of amyloid fibril length distributions by 
inclusion of rotational motion in solution NMR diffusion measurements. 
Angew Chem Int Ed Engl 47:3385-3387.2008). 
Barry RA, Prusiner SB (Monoclonal antibodies to the cellular and scrapie prion 
proteins. Journal of Infectious Diseases 154:518-521.1986). 
Bartz JC, Bessen RA, McKenzie D, Marsh RF, Aiken JM (Adaptation and Selection 
of Prion Protein Strain Conformations following Interspecies Transmission 
of Transmissible Mink Encephalopathy. J Virol 74:5542-5547.2000). 
Baskakov IV (Autocatalytic conversion of recombinant prion proteins displays a 
species barrier. J Biol Chem 279:7671-7677.2004). 
Baskakov  IV,  Legname  G,  Baldwin  MA,  Prusiner  SB,  Cohen  FE  (Pathway 
complexity of prion protein assembly into amyloid. J Biol Chem 277:21140-
21148.2002). 
Basler K, Oesch B, Scott M, Westaway D, Walchli M, Groth DF, McKinley MP, 
Prusiner SB, Weissmann C (Scrapie and cellular PrP isoforms are encoded 
by the same chromosomal gene. Cell 46:417-428.1986). 
Bayro MJ, Maly T, Birkett NR, Macphee CE, Dobson CM, Griffin RG (High-
resolution  MAS  NMR  analysis  of  PI3-SH3  amyloid  fibrils:  backbone 
conformation and implications for protofilament assembly and structure. 
Biochemistry 49:7474-7484.2010). 
Becker LE  (Slow infections  of the  central nervous system. Canadian Journal  of 
Neurological Sciences 4:81-88.1977). 
Berjanskii MV, Wishart DS (A simple method to predict protein flexibility using 
secondary  chemical  shifts.  Journal  of  the  American  Chemical  Society 
127:14970-14971.2005). 
Bessen RA, Marsh RF (Biochemical and physical properties of the prion protein 
from two strains of the transmissible mink encephalopathy agent. J Virol 
66:2096-2101.1992). 
Bessen RA, Marsh RF (Distinct PrP properties suggest the molecular basis of strain 
variation in transmissible mink encephalopathy. J Virol 68:7859-7868.1994). 
Bocharova  OV,  Breydo  L,  Parfenov  AS,  Salnikov  VV,  Baskakov  IV  (In  vitro 
conversion of full-length mammalian prion protein produces amyloid form 
with physical properties of PrP(Sc). J Mol Biol 346:645-659.2005). 
Bolton DC, McKinley MP, Prusiner SB (Identification of a protein that purifies 
with the scrapie prion. Science 218:1309-1311.1982). 
Brockwell  DJ,  Radford  SE  (Intermediates:  ubiquitous  species  on  folding  energy 
landscapes? Curr Opin Struc Biol 17:30-37.2007). 
Brown DR, Qin K, Herms JW, Madlung A, Manson J, Strome R, Fraser PE, Kruck 
T, von Bohlen A, Schulz-Schaeffer W, Giese A, Westaway D, Kretzschmar  
- 134 - 
H  (The  cellular  prion  protein  binds  copper  in  vivo.  Nature  390:684-
687.1997). 
Brown  P,  Will  RG,  Bradley  R,  Asher  DM,  Detwiler  L  (Bovine  spongiform 
encephalopathy  and  variant  Creutzfeldt-Jakob  disease:  Background, 
evolution, and current concerns. Emerging Infectious Diseases 7:6-16.2001). 
Bruce  ME,  Fraser  H  (Scrapie  strain  variation  and  its  implications.  Curr  Top 
Microbiol Immunol 172:125-138.1991). 
Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, Suttie A, McCardle 
L,  Chree  A,  Hope  J,  Birkett  C,  Cousens  S,  Fraser  H,  Bostock  CJ 
(Transmissions to mice indicate that 'new variant' CJD is caused by the BSE 
agent. Nature 389:498-501.1997). 
Bueler H, Fischer M, Lang Y, Bluethmann H, Lipp HP, DeArmond SJ, Prusiner 
SB, Aguet M, Weissmann C (Normal development and behaviour of mice 
lacking the neuronal cell-surface PrP protein. Nature 356:577-582.1992). 
Castilla J, Gutierrez Adan A, Brun A, Pintado B, Ramirez MA, Parra B, Doyle D, 
Rogers M, Salguero FJ, Sanchez C, Sanchez-Vizcaino JM, Torres JM (Early 
detection of PrPres in BSE-infected bovine PrP transgenic mice. Arch Virol 
148:677-691.2003). 
Castilla J, Saa P, Hetz C, Soto C (In vitro generation of infectious scrapie prions. 
Cell 121:195-206.2005). 
Caughey  B  (In  vitro  expression  and  biosynthesis  of  prion  protein.  Curr  Top 
Microbiol Immunol 172:93-107.1991). 
Caughey  B,  Chesebro  B  (Transmissible  spongiform  encephalopathies  and  prion 
protein interconversions. Adv Virus Res 56:277-311.2001). 
Caughey  B,  Race  RE,  Ernst  D,  Buchmeier  MJ,  Chesebro  B  (Prion  protein 
biosynthesis in scrapie-infected and uninfected neuroblastoma cells. J Virol 
63:175-181.1989). 
Chandler  RL  (ENCEPHALOPATHY  IN  MICE  PRODUCED  BY 
INOCULATION  WITH  SCRAPIE  BRAIN  MATERIAL.  The  Lancet 
277:1378-1379.1961). 
Chandler RL (ENCEPHALOPATHY IN MICE. The Lancet 279:107-108.1962). 
Chernoff  YO,  Uptain  SM,  Lindquist  SL  (Analysis  of  prion  factors  in  yeast. 
Methods Enzymol 351:499-538.2002). 
Chesebro B (BSE and prions: uncertainties about the agent. Science 279:42-43.1998). 
Chien P, Weissman JS, DePace AH (Emerging principles of conformation-based 
prion inheritance. Annu Rev Biochem 73:617-656.2004). 
Cobb NJ, Apetri AC, Surewicz WK (Prion Protein Amyloid Formation under 
Native-like Conditions Involves Refolding of the C-terminal {alpha}-Helical 
Domain. J Biol Chem 283:34704-34711.2008).  
- 135 - 
Cobb NJ, Sonnichsen FD, McHaourab H, Surewicz WK (Molecular architecture of 
human  prion  protein  amyloid:  a  parallel,  in-register  beta-structure.  Proc 
Natl Acad Sci U S A 104:18946-18951.2007). 
Cobb  NJ,  Surewicz  WK  (Prion  Diseases  and  Their  Biochemical  Mechanisms‟. 
Biochemistry 48:2574-2585.2009). 
Cohen AS, Calkins E (Electron microscopic observations on a fibrous component 
in amyloid of diverse origins. Nature 183:1202-1203.1959). 
Cohen FE, Pan KM, Huang Z, Baldwin M, Fletterick RJ, Prusiner SB (Structural 
clues to prion replication. Science 264:530-531.1994). 
Colby DW, Giles K, Legname G, Wille H, Baskakov IV, DeArmond SJ, Prusiner 
SB (Design and construction of diverse mammalian prion strains. Proc Natl 
Acad Sci U S A 106:20417-20422.2009). 
Collinge J (Variant Creutzfeldt-Jakob disease. Lancet 354:317-323.1999). 
Collinge J (Prion diseases of humans and animals: their causes and molecular basis. 
Annu Rev Neurosci 24:519-550.2001). 
Couzin J (Biomedicine. An end to the prion debate? Don't count on it. Science 
305:589.2004). 
Crick F (Central dogma of molecular biology. Nature 227:561-563.1970). 
Deleault NR, Harris BT, Rees JR, Supattapone S (Formation of native prions from 
minimal  components  in  vitro.  Proc  Natl  Acad  Sci  U  S  A  104:9741-
9746.2007). 
DeMarco ML, Daggett V (From conversion to aggregation: protofibril formation of 
the prion protein. Proc Natl Acad Sci U S A 101:2293-2298.2004). 
Detwiler LA (Scrapie. Rev Sci Tech 11:491-537.1992). 
Dill KA, Chan HS (From Levinthal to pathways to funnels. Nat Struct Biol 4:10-
19.1997). 
Dobson CM (Protein folding and its links with human disease. Biochem Soc Symp 
1-26.2001). 
Dobson CM (Protein folding and misfolding. Nature 426:884-890.2003). 
Donne DG, Viles JH, Groth D, Mehlhorn I, James TL, Cohen FE, Prusiner SB, 
Wright PE, Dyson HJ (Structure of the recombinant full-length hamster 
prion protein PrP(29-231): the N terminus is highly flexible. Proc Natl Acad 
Sci U S A 94:13452-13457.1997). 
Eanes  ED,  Glenner  GG  (X-ray  diffraction  studies  on  amyloid  filaments.  J 
Histochem Cytochem 16:673-677.1968). 
Eggenberger E (Prion disease. Neurol Clin 25:833-842, viii.2007). 
Ellis  RJ  (Macromolecular  crowding:  an  important  but  neglected  aspect  of  the 
intracellular environment. Curr Opin Struct Biol 11:114-119.2001a). 
Ellis  RJ  (Macromolecular  crowding:  obvious  but  underappreciated.  Trends 
Biochem Sci 26:597-604.2001b).  
- 136 - 
Engen JR, Smith DL (Investigating protein structure and dynamics by hydrogen 
exchange MS. Anal Chem 73:256A-265A.2001). 
Englander  SW  (Hydrogen  exchange  and  mass  spectrometry:  A  historical 
perspective. J Am Soc Mass Spectrom 17:1481-1489.2006). 
Fandrich M, Meinhardt J, Grigorieff N (Structural polymorphism of Alzheimer A 
beta and other amyloid fibrils. Prion 3:89-93.2009). 
Field EJ, Farmer F, Caspary EA, Joyce G (Susceptibility of scrapie agent to ionizing 
radiation. Nature 222:90-91.1969). 
Fischer M, Rulicke T, Raeber A, Sailer A, Moser M, Oesch B, Brandner S, Aguzzi 
A,  Weissmann  C  (Prion  protein  (PrP)  with  amino-proximal  deletions 
restoring susceptibility of PrP knockout mice to scrapie. EMBO J 15:1255-
1264.1996). 
Forloni G, Angeretti N, Chiesa R, Monzani E, Salmona M, Bugiani O, Tagliavini F 
(Neurotoxicity of a prion protein fragment. Nature 362:543-546.1993). 
Gajdusek DC, Gibbs Jr CJ, Alpers M (Experimental transmission of a kuru-like 
syndrome to chimpanzees. Nature 209:794-796.1966). 
Gajdusek DC, Gibbs Jr CJ, Alpers M (Transmission and passage of experimenal 
"kuru" to chimpanzees. Science 155:212-214.1967). 
Gasset  M,  Baldwin  MA,  Lloyd  DH,  Gabriel  JM,  Holtzman  DM,  Cohen  F, 
Fletterick  R,  Prusiner  SB  (Predicted  alpha-helical  regions  of  the  prion 
protein when synthesized as peptides form amyloid. Proc Natl Acad Sci U S 
A 89:10940-10944.1992). 
Ghetti B, Piccardo P, Spillantini MG, Ichimiya Y, Porro M, Perini F, Kitamoto T, 
Tateishi J, Seiler C, Frangione B, Bugiani O, Giaccone G, Prelli F, Goedert 
M,  Dlouhy  SR,  Tagliavini  F  (Vascular  variant  of  prion  protein  cerebral 
amyloidosis with tau-positive neurofibrillary tangles: the phenotype of the 
stop  codon  145  mutation  in  PRNP.  Proc  Natl  Acad  Sci  U  S  A  93:744-
748.1996). 
Ghiso  J,  Jensson  O,  Frangione  B  (Amyloid  fibrils  in  hereditary  cerebral 
hemorrhage with amyloidosis of Icelandic type is a variant of gamma-trace 
basic protein (cystatin C). Proc Natl Acad Sci U S A 83:2974-2978.1986). 
Gibbons  RA,  Hunter  GD  (Nature  of  the  scrapie  agent.  Nature  215:1041-
1043.1967). 
Gibbs CJ, Jr., Gajdusek DC, Latarjet R (Unusual resistance to ionizing radiation of 
the viruses of kuru, Creutzfeldt-Jakob disease, and scrapie. Proc Natl Acad 
Sci U S A 75:6268-6270.1978). 
Gibbs Jr CJ, Gajdusek DC, Asher DM, Alpers MP, Beck E, Daniel PM, Matthews 
WB (Creutzfeldt-Jakob disease (spongiform encephalopathy): Transmission 
to the chimpanzee. Science 161:388-389.1968).  
- 137 - 
Glover JR, Kowal AS, Schirmer EC, Patino MM, Liu JJ, Lindquist S (Self-seeded 
fibers  formed  by  Sup35,  the  protein  determinant  of  [PSI+],  a  heritable 
prion-like factor of S. cerevisiae. Cell 89:811-819.1997). 
Gosal WS, Myers SL, Radford SE, Thomson NH (Amyloid under the atomic force 
microscope. Protein Pept Lett 13:261-270.2006). 
Govaerts C, Wille H, Prusiner SB, Cohen FE (Evidence for assembly of prions 
with  left-handed  beta-helices  into  trimers.  Proc  Natl  Acad  Sci  U  S  A 
101:8342-8347.2004). 
Griffith JS (Self-replication and scrapie. Nature 215:1043-1044.1967). 
Gu Y, Fujioka H, Mishra RS, Li R, Singh N (Prion peptide 106-126 modulates the 
aggregation of cellular prion protein and induces the synthesis of potentially 
neurotoxic transmembrane PrP. J Biol Chem 277:2275-2286.2002). 
Hadlow WJ (SCRAPIE AND KURU. The Lancet 274:289-290.1959). 
Hadlow WJ (Neuropathology and the Scrapie-Kuru connection. Brain Pathology 
5:27-31.1995). 
Han S, Hill AF (2008) Analysis of PrP Conformation Using Circular Dichroism. 
In: Prion Protein Protocols, vol. 459 (Hill, A. F., ed), pp 145-159: Humana 
Press. 
Haraguchi T, Fisher S, Olofsson S, Endo T, Groth D, Tarentino A, Borchelt DR, 
Teplow D, Hood L, Burlingame A, et al. (Asparagine-linked glycosylation 
of  the scrapie and cellular prion proteins. Arch Biochem Biophys 274:1-
13.1989). 
Heise H (Solid-state NMR spectroscopy of amyloid proteins. Chembiochem 9:179-
189.2008). 
Helmus  JJ,  Surewicz  K,  Nadaud  PS,  Surewicz  WK,  Jaroniec  CP  (Molecular 
conformation  and  dynamics  of  the  Y145Stop  variant  of  human  prion 
protein in amyloid fibrils. Proc Natl Acad Sci U S A 105:6284-6289.2008). 
Herms J, Tings T, Gall S, Madlung A, Giese A, Siebert H, Schurmann P, Windl O, 
Brose N, Kretzschmar H (Evidence of presynaptic location and function of 
the prion protein. J Neurosci 19:8866-8875.1999). 
Hoofnagle AN, Resing KA, Ahn NG (Protein analysis by hydrogen exchange mass 
spectrometry. Annu Rev Biophys Biomol Struct 32:1-25.2003). 
Hornemann S, Glockshuber R (Autonomous and reversible folding of a soluble 
amino-terminally truncated segment of the mouse prion protein. J Mol Biol 
261:614-619.1996). 
Hornshaw  MP,  McDermott  JR,  Candy  JM  (Copper  binding  to  the  N-terminal 
tandem  repeat  regions  of  mammalian  and  avian  prion  protein.  Biochem 
Biophys Res Commun 207:621-629.1995). 
Horwich A (Protein aggregation in disease: a role for folding intermediates forming 
specific multimeric interactions. J Clin Invest 110:1221-1232.2002).  
- 138 - 
Hu W, Kieseier B, Frohman E, Eagar TN, Rosenberg RN, Hartung HP, Stuve O 
(Prion proteins: physiological functions and role in neurological disorders. J 
Neurol Sci 264:1-8.2008). 
Hu W, Rosenberg RN, Stuve O (Prion proteins: a biological role beyond prion 
diseases. Acta Neurol Scand 116:75-82.2007). 
Hunter GD (Scrapie: a prototype slow infection. J Infect Dis 125:427-440.1972). 
Hunter  GD,  Kimberlin  RH,  Gibbons  RA  (Scrapie:  a  modified  membrane 
hypothesis. J Theor Biol 20:355-357.1968). 
Hunter  N  (Prion  diseases  and  the  central  dogma  of  molecular  biology.  Trends 
Microbiol 7:265-266.1999). 
Jackson GS, Murray I, Hosszu LL, Gibbs N, Waltho JP, Clarke AR, Collinge J 
(Location and properties of metal-binding sites on the human prion protein. 
Proc Natl Acad Sci U S A 98:8531-8535.2001). 
Jahn TR, Radford SE (The Yin and Yang of protein folding. FEBS J 272:5962-
5970.2005). 
Jarrett JT, Lansbury PT, Jr. (Seeding "one-dimensional crystallization" of amyloid: 
a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73:1055-
1058.1993). 
Jeffrey M, Goodbrand IA, Goodsir CM (Pathology of the transmissible spongiform 
encephalopathies with  special emphasis on ultrastructure. Micron 26:277-
298.1995). 
Johnson  RT,  Gibbs  CJ,  Jr.  (Creutzfeldt-Jakob  disease  and  related  transmissible 
spongiform encephalopathies. N Engl J Med 339:1994-2004.1998). 
Jones EM, Surewicz WK (Fibril conformation as the basis of species- and strain-
dependent seeding specificity of mammalian prion amyloids. Cell 121:63-
72.2005). 
Keyes ME (The prion challenge to the 'central dogma' of molecular biology, 1965-
1991.  Studies  in  History  and  Philosophy  of  Science  Part  C  30:181-
218.1999a). 
Keyes ME (The prion challenge to the `central dogma' of molecular biology, 1965-
1991. Studies in History and Philosophy of Science Part C 30:1-19.1999b). 
Khalili-Shirazi  A,  Summers  L,  Linehan  J,  Mallinson  G,  Anstee  D,  Hawke  S, 
Jackson GS, Collinge J (PrP glycoforms are associated in a strain-specific 
ratio in native PrPSc. J Gen Virol 86:2635-2644.2005). 
Kheterpal  I,  Cook  KD,  Wetzel  R  (2006)  Hydrogen/Deuterium  Exchange  Mass 
Spectrometry Analysis of Protein Aggregates. In: Methods in Enzymology, 
vol.  Volume  413  (Indu,  K.  and  Ronald,  W.,  eds),  pp  140-166:  Academic 
Press.  
- 139 - 
Khurana R, Coleman C, Ionescu-Zanetti C, Carter SA, Krishna V, Grover RK, 
Roy  R,  Singh  S  (Mechanism  of  thioflavin  T  binding  to  amyloid  fibrils. 
Journal of Structural Biology 151:229-238.2005). 
Khurana R, Uversky VN, Nielsen L, Fink AL (Is Congo Red an Amyloid-specific 
Dye? Journal of Biological Chemistry 276:22715-22721.2001). 
Kim HY, Cho MK, Riedel D, Fernandez CO, Zweckstetter M (Dissociation of 
amyloid fibrils of alpha-synuclein in supercooled water. Angew Chem Int 
Edit 47:5046-5048.2008). 
Kim JI, Cali I, Surewicz K, Kong Q, Raymond GJ, Atarashi R, Race B, Qing L, 
Gambetti P, Caughey B, Surewicz WK (Mammalian prions generated from 
bacterially  expressed  prion  protein  in  the  absence  of  any  mammalian 
cofactors. J Biol Chem 285:14083-14087.2010). 
Kimberlin RH (Scrapie agent: prions or virinos? Nature 297:107-108.1982). 
King CY, Diaz-Avalos R (Protein-only transmission of three yeast prion strains. 
Nature 428:319-323.2004). 
Klein-Seetharaman J, Oikawa M, Grimshaw SB, Wirmer J, Duchardt E, Ueda T, 
Imoto  T,  Smith  LJ,  Dobson  CM,  Schwalbe  H  (Long-range  interactions 
within a nonnative protein. Science 295:1719-1722.2002). 
Knaus KJ, Morillas M, Swietnicki W, Malone M, Surewicz WK, Yee VC (Crystal 
structure  of  the  human  prion  protein  reveals  a  mechanism  for 
oligomerization. Nat Struct Biol 8:770-774.2001). 
Kocisko  DA,  Come  JH,  Priola  SA,  Chesebro  B,  Raymond  GJ,  Lansbury  PT, 
Caughey B (Cell-free formation of protease-resistant prion protein. Nature 
370:471-474.1994). 
Kocisko DA, Priola SA, Raymond GJ, Chesebro B, Lansbury PT, Jr., Caughey B 
(Species specificity in the cell-free conversion of prion protein to protease-
resistant forms: a model for the scrapie species barrier. Proc Natl Acad Sci U 
S A 92:3923-3927.1995). 
Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-
Alloza M, Micheva KD, Smith SJ, Kim ML, Lee VM, Hyman BT, Spires-
Jones TL (Oligomeric amyloid beta associates with postsynaptic densities 
and correlates with excitatory synapse loss near senile plaques. Proc Natl 
Acad Sci U S A 106:4012-4017.2009). 
Krebs  MR, Bromley EH, Donald AM  (The  binding of thioflavin-T to amyloid 
fibrils: localisation and implications. J Struct Biol 149:30-37.2005). 
Krebs MR, Wilkins DK, Chung EW, Pitkeathly MC, Chamberlain AK, Zurdo J, 
Robinson CV, Dobson CM (Formation and seeding of amyloid fibrils from 
wild-type hen lysozyme and a peptide fragment from the beta-domain. J 
Mol Biol 300:541-549.2000).  
- 140 - 
Kumar D, Kumar A, Misra JR, Chugh J, Sharma S, Hosur RV (1H, 15N, 13C 
resonance  assignment  of  folded  and  8  M  urea-denatured  state  of  SUMO 
from Drosophila melanogaster. Biomol NMR Assign 2:13-15.2008). 
Kundu  B,  Maiti  NR,  Jones  EM,  Surewicz  KA,  Vanik  DL,  Surewicz  WK 
(Nucleation-dependent conformational conversion of the Y145Stop variant 
of human prion protein: structural clues for prion propagation. Proc Natl 
Acad Sci U S A 100:12069-12074.2003). 
Kuwata K,  Matumoto  T, Cheng H, Nagayama K, James TL,  Roder H (NMR-
detected hydrogen exchange and molecular dynamics simulations provide 
structural insight into fibril formation of prion protein fragment 106-126. 
Proc Natl Acad Sci U S A 100:14790-14795.2003). 
Lange A, Gattin Z, Van Melckebeke H, Wasmer C, Soragni A, van Gunsteren WF, 
Meier BH (A combined solid-state NMR and MD characterization of the 
stability  and  dynamics  of  the  HET-s(218-289)  prion  in  its  amyloid 
conformation. Chembiochem 10:1657-1665.2009). 
Latarjet R, Muel B, Haig DA, Clarke MC, Alper T (Inactivation of the scrapie 
agent by near monochromatic ultraviolet light. Nature 227:1341-1343.1970). 
Legname G, Baskakov IV, Nguyen HO, Riesner D, Cohen FE, DeArmond SJ, 
Prusiner SB (Synthetic mammalian prions. Science 305:673-676.2004). 
Levinthal.C (Are There Pathways for Protein Folding. J Chim Phys Pcb 65:44-
&.1968). 
Li J, Browning S, Mahal SP, Oelschlegel AM, Weissmann C (Darwinian evolution 
of prions in cell culture. Science 327:869-872.2010). 
Li L, Guest W, Huang A, Plotkin SS, Cashman NR (Immunological mimicry of 
PrPC-PrPSc  interactions:  antibody-induced  PrP  misfolding.  Protein  Eng 
Des Sel 22:523-529.2009). 
Liberski  PP,  Gajdusek  DC  (Kuru:  Forty  years  later,  an  historical  note.  Brain 
Pathology 7:555-560.1997). 
Liu  A,  Riek  R,  Wider  G,  von  Schroetter  C,  Zahn  R,  Wuthrich  K  (NMR 
experiments for resonance assignments of 13C, 15N doubly-labeled flexible 
polypeptides:  application  to  the  human  prion  protein  hPrP(23-230).  J 
Biomol NMR 16:127-138.2000). 
Lu  X,  Wintrode  PL,  Surewicz  WK  (Beta-sheet  core  of  human  prion  protein 
amyloid fibrils as determined by hydrogen/deuterium exchange. Proc Natl 
Acad Sci U S A 104:1510-1515.2007). 
Makarava  N,  Kovacs  GG,  Bocharova  O,  Savtchenko  R,  Alexeeva  I,  Budka  H, 
Rohwer  RG,  Baskakov  IV  (Recombinant  prion  protein  induces  a  new 
transmissible prion disease in wild-type animals. Acta Neuropathol 119:177-
187.2010).  
- 141 - 
Manuelidis  L,  Yu  ZX,  Barquero  N,  Mullins  B  (Cells  infected  with  scrapie  and 
Creutzfeldt-Jakob  disease  agents  produce  intracellular  25-nm  virus-like 
particles. Proc Natl Acad Sci U S A 104:1965-1970.2007). 
Marsh  RF,  Hadlow  WJ  (Transmissible  mink  encephalopathy.  OIE  Revue 
Scientifique et Technique 11:539-550.1992). 
Masters CL, Gajdusek DC, Gibbs CJ, Jr. (Creutzfeldt-Jakob disease virus isolations 
from the Gerstmann-Straussler syndrome with an analysis of the various 
forms  of  amyloid  plaque  deposition  in  the  virus-induced  spongiform 
encephalopathies. Brain 104:559-588.1981a). 
Masters CL, Gajdusek DC, Gibbs CJ, Jr. (The familial occurrence of Creutzfeldt-
Jakob disease and Alzheimer's disease. Brain 104:535-558.1981b). 
McKinley MP, Bolton DC, Prusiner SB (A protease-resistant protein is a structural 
component of the scrapie prion. Cell 35:57-62.1983). 
Mead S (Prion disease genetics. Eur J Hum Genet 14:273-281.2006). 
Mehlhorn  I,  Groth  D,  Stockel  J,  Moffat  B,  Reilly  D,  Yansura  D,  Willett  WS, 
Baldwin M, Fletterick R, Cohen FE, Vandlen R, Henner D, Prusiner SB 
(High-level  expression  and  characterization  of  a  purified  142-residue 
polypeptide of the prion protein. Biochemistry 35:5528-5537.1996). 
Meinhardt J, Sachse C, Hortschansky P, Grigorieff N, Fandrich M (A beta(1-40) 
Fibril  Polymorphism  Implies  Diverse  Interaction  Patterns  in  Amyloid 
Fibrils. Journal of Molecular Biology 386:869-877.2009). 
Meyerett C, Michel B, Pulford B, Spraker TR, Nichols TA, Johnson T, Kurt T, 
Hoover EA, Telling GC, Zabel MD (In vitro strain adaptation of CWD 
prions by serial protein misfolding cyclic amplification. Virology 382:267-
276.2008). 
Morales R, Abid K, Soto C (The prion strain phenomenon: molecular basis and 
unprecedented features. Biochim Biophys Acta 1772:681-691.2007). 
Morange  M  (What  history  tells  us  VIII.  The  progressive  construction  of  a 
mechanism for prion diseases. Journal of Biosciences 32:223-227.2007). 
Naito  A,  Kawamura  I  (Solid-state  NMR  as  a  method  to  reveal  structure  and 
membrane-interaction of amyloidogenic proteins and peptides. Biochimica 
et Biophysica Acta (BBA) - Biomembranes 1768:1900-1912.2007). 
Nazabal A, Hornemann S, Aguzzi A, Zenobi R (Hydrogen/deuterium exchange 
mass spectrometry identifies two highly protected regions in recombinant 
full-length prion protein amyloid fibrils. J Mass Spectrom 44:965-977.2009). 
Nelson  R,  Eisenberg  D  (Structural  models  of  amyloid-like  fibrils.  Adv  Protein 
Chem 73:235-282.2006). 
Nelson R, Sawaya MR, Balbirnie M, Madsen AO, Riekel C, Grothe R, Eisenberg D 
(Structure  of the  cross-beta  spine of  amyloid-like  fibrils. Nature 435:773-
778.2005).  
- 142 - 
Oesch B, Westaway D, Walchli M, McKinley MP, Kent SB, Aebersold R, Barry 
RA, Tempst P, Teplow DB, Hood LE, et al. (A cellular gene encodes scrapie 
PrP 27-30 protein. Cell 40:735-746.1985). 
Paci E, Vendruscolo M, Karplus M (Validity of Go models: comparison with a 
solvent-shielded  empirical  energy  decomposition.  Biophys  J  83:3032-
3038.2002). 
Palsson PA (Dr. Bjorn Sigurdsson (1913-1959). A memorial tribute. Ann N Y Acad 
Sci 724:1-5.1994). 
Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A, Groth D, Mehlhorn I, Huang 
Z, Fletterick RJ, Cohen FE, et al. (Conversion of alpha-helices into beta-
sheets features in the formation of the scrapie prion proteins. Proc Natl 
Acad Sci U S A 90:10962-10966.1993). 
Panchal SC, Bhavesh NS, Hosur RV (Improved 3D triple resonance experiments, 
HNN and HN(C)N, for HN and 15N sequential correlations in (13C, 15N) 
labeled proteins: application to unfolded proteins. J Biomol NMR 20:135-
147.2001). 
Paramithiotis E, Pinard M, Lawton T, LaBoissiere S, Leathers VL, Zou WQ, Estey 
LA,  Lamontagne  J,  Lehto  MT,  Kondejewski  LH,  Francoeur  GP, 
Papadopoulos  M,  Haghighat  A,  Spatz  SJ,  Head  M,  Will  R,  Ironside  J, 
O'Rourke K, Tonelli Q, Ledebur HC, Chakrabartty A, Cashman NR (A 
prion  protein  epitope  selective  for  the  pathologically  misfolded 
conformation. Nat Med 9:893-899.2003). 
Pattison IH, Jones KM (The possible nature of the transmissible agent of scrapie. 
Vet Rec 80:2-9.1967). 
Pattison IH, Millson GC (Scrapie produced experimentally in goats with special 
reference to the clinical syndrome. J Comp Pathol 71:101-109.1961). 
Platt GW, Xue WF, Homans SW, Radford SE (Probing dynamics within amyloid 
fibrils using a novel capping method. Angew Chem Int Ed Engl 48:5705-
5707.2009). 
Polymenidou M, Heppner FL, Pellicioli EC, Urich E, Miele G, Braun N, Wopfner 
F, Schatzl HM, Becher B, Aguzzi A (Humoral immune response to native 
eukaryotic prion protein correlates with anti-prion protection. Proc Natl 
Acad Sci U S A 101 Suppl 2:14670-14676.2004). 
Priola SA, Vorberg I (Molecular aspects of disease pathogenesis in the transmissible 
spongiform encephalopathies. Methods Mol Biol 268:517-540.2004). 
Prusiner SB (Novel proteinaceous infectious particles cause scrapie. Science 216:136-
144.1982). 
Prusiner SB (Prions. Proc Natl Acad Sci U S A 95:13363-13383.1998).  
- 143 - 
Prusiner SB, Bolton DC, Groth DF, Bowman KA, Cochran SP, McKinley MP 
(Further purification and characterization of scrapie prions. Biochemistry 
21:6942-6950.1982a). 
Prusiner SB, Cochran SP, Groth DF (Measurement of the scrapie agent using an 
incubation time interval assay. Annals of neurology 11:353-358.1982b). 
Prusiner SB, Garfin DE, Cochran SP, McKinley MP, Groth DF, Hadlow WJ, Race 
RE, Eklund CM (Experimental scrapie in the mouse: electrophoretic and 
sedimentation  properties  of  the  partially  purified  agent.  J  Neurochem 
35:574-582.1980a). 
Prusiner SB, Groth D, Serban A, Koehler R, Foster D, Torchia M, Burton D, Yang 
SL,  DeArmond  SJ  (Ablation  of  the  prion  protein  (PrP)  gene  in  mice 
prevents scrapie and facilitates production of anti-PrP antibodies. Proc Natl 
Acad Sci U S A 90:10608-10612.1993). 
Prusiner  SB,  Groth  DF,  Bildstein  C,  Masiarz  FR,  McKinley  MP,  Cochran  SP 
(Electrophoretic properties of the scrapie agent in agarose gels. Proc Natl 
Acad Sci U S A 77:2984-2988.1980b). 
Prusiner SB, Groth DF, Cochran SP, Masiarz FR, McKinley MP, Martinez HM 
(Molecular properties, partial purification, and assay by incubation period 
measurements  of  the  hamster  scrapie  agent.  Biochemistry  19:4883-
4891.1980c). 
Prusiner  SB,  Groth  DF,  Cochran  SP,  McKinley  MP,  Masiarz  FR  (Gel 
electrophoresis and glass permeation chromatography of the hamster scrapie 
agent  after  enzymatic  digestion  and  detergent  extraction.  Biochemistry 
19:4892-4898.1980d). 
Prusiner  SB,  McKinley  MP,  Bowman  KA  (Scrapie  prions  aggregate  to  form 
amyloid-like birefringent rods. Cell 35:349-358.1983). 
Prusiner SB, Scott M, Foster D, Pan KM, Groth D, Mirenda C, Torchia M, Yang 
SL, Serban D, Carlson GA, et al. (Transgenetic studies implicate interactions 
between homologous PrP isoforms in scrapie prion replication. Cell 63:673-
686.1990). 
Puchtler  H,  Sweat  F  (A  review  of  early  concepts  of  amyloid  in  context  with 
contemporary  chemical  literature  from  1839  to  1859.  J  Histochem 
Cytochem 14:123-134.1966). 
Riek R, Hornemann S, Wider G, Billeter M, Glockshuber R, Wuthrich K (NMR 
structure of the mouse prion protein domain PrP(121-321). Nature 382:180-
182.1996). 
Salman MD (Chronic wasting disease in deer and elk: Scientific facts and findings. 
Journal of Veterinary Medical Science 65:761-768.2003). 
Sattler  M,  Schleucher  J,  Griesinger  C  (Heteronuclear  multidimensional  NMR 
experiments  for  the  structure  determination  of  proteins  in  solution  
- 144 - 
employing pulsed field gradients. Progress in Nuclear Magnetic Resonance 
Spectroscopy 34:93-158.1999). 
Schubert M, Oschkinat H, Schmieder P (MUSIC and aromatic residues: amino acid 
type-selective (1)H-(15)N correlations, III. J Magn Reson 153:186-192.2001a). 
Schubert M, Oschkinat H, Schmieder P (MUSIC, selective pulses, and tuned delays: 
amino acid type-selective (1)H-(15)N correlations, II. J Magn Reson 148:61-
72.2001b). 
Schubert  M,  Smalla  M,  Schmieder  P,  Oschkinat  H  (MUSIC  in  triple-resonance 
experiments:  amino  acid  type-selective  (1)H-(15)N  correlations.  J  Magn 
Reson 141:34-43.1999). 
Scott M, Foster D, Mirenda C, Serban D, Coufal F, Walchli M, Torchia M, Groth 
D, Carlson G, DeArmond SJ, Westaway D, Prusiner SB (Transgenic mice 
expressing hamster prion protein produce species-specific scrapie infectivity 
and amyloid plaques. Cell 59:847-857.1989). 
Shen Y, Delaglio F, Cornilescu G, Bax A (TALOS plus : a hybrid method for 
predicting  protein  backbone  torsion  angles  from  NMR  chemical  shifts. 
Journal of Biomolecular Nmr 44:213-223.2009). 
Shirahama T, Cohen AS (HIGH-RESOLUTION ELECTRON MICROSCOPIC 
ANALYSIS OF THE AMYLOID FIBRIL. The Journal of Cell Biology 
33:679-708.1967). 
Shortle  D,  Ackerman  MS  (Persistence  of  native-like  topology  in  a  denatured 
protein in 8 M urea. Science 293:487-489.2001). 
Siemer AB, Ritter C, Ernst M, Riek R, Meier BH (High-resolution solid-state NMR 
spectroscopy  of  the  prion  protein  HET-s  in  its  amyloid  conformation. 
Angew Chem Int Ed Engl 44:2441-2444.2005). 
Silveira JR, Raymond GJ, Hughson AG, Race RE, Sim VL, Hayes SF, Caughey B 
(The most infectious prion protein particles. Nature 437:257-261.2005). 
Sim VL, Caughey B (Ultrastructures and strain comparison of under-glycosylated 
scrapie prion fibrils. Neurobiol Aging 30:2031-2042.2009). 
Singh N, Gu Y, Bose S, Kalepu S, Mishra RS, Verghese S (Prion peptide 106-126 as 
a model for prion replication and neurotoxicity. Front Biosci 7:a60-71.2002). 
Sipe JD, Cohen AS (Review: history of the amyloid fibril. J Struct Biol 130:88-
98.2000). 
Smith DL, Deng Y, Zhang Z (Probing the non-covalent structure of proteins by 
amide hydrogen exchange and mass spectrometry. J Mass Spectrom 32:135-
146.1997). 
Soto  C,  Saborio  GP,  Anderes  L  (Cyclic  amplification  of  protein  misfolding: 
application to prion-related disorders and beyond. Trends in Neurosciences 
25:390-394.2002a).  
- 145 - 
Soto  C,  Saborio  GP,  Anderes  L  (Cyclic  amplification  of  protein  misfolding: 
application to prion-related disorders and beyond. Trends Neurosci 25:390-
394.2002b). 
Sparkes RS, Simon M, Cohn VH, Fournier RE, Lem J, Klisak I, Heinzmann C, 
Blatt  C,  Lucero  M,  Mohandas  T,  et  al.  (Assignment  of  the  human  and 
mouse prion protein genes to homologous chromosomes. Proc Natl Acad 
Sci U S A 83:7358-7362.1986). 
Stahl N, Baldwin MA, Teplow DB, Hood L, Gibson BW, Burlingame AL, Prusiner 
SB (Structural studies of the scrapie prion protein using mass spectrometry 
and amino acid sequencing. Biochemistry 32:1991-2002.1993). 
Stahl N, Prusiner SB (Prions and prion proteins. FASEB Journal 5:2799-2807.1991). 
Supattapone S  (Biochemistry. What makes  a  prion infectious? Science 327:1091-
1092.2010). 
Surewicz  WK,  Jones  EM,  Apetri  AC  (The  Emerging  Principles  of  Mammalian 
Prion  Propagation and  Transmissibility Barriers:  Insight from Studies in 
Vitro. Accounts of Chemical Research 39:654-662.2006). 
Swietnicki W, Morillas M, Chen SG, Gambetti P, Surewicz WK (Aggregation and 
fibrillization  of  the  recombinant  human  prion  protein  huPrP90-231. 
Biochemistry 39:424-431.2000). 
Sy MS, Gambetti P, Wong BS (Human prion diseases. Med Clin North Am 86:551-
571, vi-vii.2002). 
Tagliavini  F,  Prelli  F,  Verga  L,  Giaccone  G,  Sarma  R,  Gorevic  P,  Ghetti  B, 
Passerini F, Ghibaudi E, Forloni G, et al. (Synthetic peptides homologous to 
prion protein residues 106-147 form amyloid-like fibrils in vitro. Proc Natl 
Acad Sci U S A 90:9678-9682.1993). 
Tanaka M, Chien P, Naber N, Cooke R, Weissman JS (Conformational variations 
in an infectious protein determine prion strain differences. Nature 428:323-
328.2004). 
Telling  GC  (Prion  protein  genes  and  prion  diseases:  studies  in  transgenic  mice. 
Neuropathol Appl Neurobiol 26:209-220.2000). 
Thukral L, Smith JC, Daidone I (Common folding mechanism of a beta-hairpin 
peptide  via  non-native  turn  formation  revealed  by  unbiased  molecular 
dynamics simulations. J Am Chem Soc 131:18147-18152.2009). 
Turk E, Teplow DB, Hood LE, Prusiner SB (Purification and properties of the 
cellular and scrapie hamster prion proteins. Eur J Biochem 176:21-30.1988). 
Tycko R (Solid-state NMR as a probe of amyloid fibril structure. Curr Opin Chem 
Biol 4:500-506.2000). 
Tycko  R  (Insights  into  the  amyloid  folding  problem  from  solid-state  NMR. 
Biochemistry 42:3151-3159.2003).  
- 146 - 
Tycko R (Progress towards a molecular-level structural understanding of amyloid 
fibrils. Curr Opin Struct Biol 14:96-103.2004). 
Tycko R (Molecular structure of amyloid fibrils: insights from solid-state NMR. 
Quarterly Reviews of Biophysics 39:1-55.2006a). 
Tycko R (Molecular structure of amyloid fibrils: insights from solid-state NMR. Q 
Rev Biophys 39:1-55.2006b). 
Tycko  R  (Solid-state  NMR  as  a  probe  of  amyloid  structure.  Protein  Pept  Lett 
13:229-234.2006c). 
Uptain  SM,  Lindquist  S  (Prions  as  protein-based  genetic  elements.  Annu  Rev 
Microbiol 56:703-741.2002). 
van der Kamp MW, Daggett V (The consequences of pathogenic mutations to the 
human prion protein. Protein Eng Des Sel 22:461-468.2009). 
van der Wel PC, Lewandowski JR, Griffin RG (Solid-state NMR study of amyloid 
nanocrystals  and  fibrils  formed  by  the  peptide  GNNQQNY  from  yeast 
prion protein Sup35p. J Am Chem Soc 129:5117-5130.2007). 
Van Melckebeke H, Wasmer C, Lange A, Ab E, Loquet A, Bockmann A, Meier 
BH  (Atomic-Resolution  Three-Dimensional  Structure  of  HET-s(218-289) 
Amyloid Fibrils by Solid-State NMR Spectroscopy. J Am Chem Soc.2010). 
Vanik DL, Surewicz KA, Surewicz WK (Molecular basis of barriers for interspecies 
transmissibility of mammalian prions. Mol Cell 14:139-145.2004). 
Vassallo N, Herms J (Cellular prion protein function in copper homeostasis and 
redox signalling at the synapse. J Neurochem 86:538-544.2003). 
Viles JH, Cohen FE, Prusiner SB, Goodin DB, Wright PE, Dyson HJ (Copper 
binding  to  the  prion  protein:  structural  implications  of  four  identical 
cooperative binding sites. Proc Natl Acad Sci U S A 96:2042-2047.1999). 
Waggoner DJ, Drisaldi B, Bartnikas TB, Casareno RL, Prohaska JR, Gitlin JD, 
Harris DA (Brain copper content and cuproenzyme activity do not vary 
with prion protein expression level. J Biol Chem 275:7455-7458.2000). 
Wagner  G,  Stassinopoulou  CI,  Wuthrich  K  (Amide-proton  exchange  studies  by 
two-dimensional correlated 1H NMR in two chemically modified analogs of 
the basic pancreatic trypsin inhibitor. Eur J Biochem 145:431-436.1984). 
Wand  AJ,  Roder  H,  Englander  SW  (Two-dimensional  1H  NMR  studies  of 
cytochrome  c: hydrogen exchange in the N-terminal helix. Biochemistry 
25:1107-1114.1986). 
Wang F, Wang X, Yuan CG, Ma J (Generating a prion with bacterially expressed 
recombinant prion protein. Science 327:1132-1135.2010). 
Watzlawik J, Skora L, Frense D, Griesinger C, Zweckstetter M, Schulz-Schaeffer 
WJ,  Kramer  ML  (Prion  protein  helix1  promotes  aggregation  but  is  not 
converted into beta-sheet. J Biol Chem 281:30242-30250.2006).  
- 147 - 
Weber P, Giese A, Piening N, Mitteregger G, Thomzig A, Beekes M, Kretzschmar 
HA (Cell-free formation of misfolded prion protein with authentic prion 
infectivity. Proc Natl Acad Sci U S A 103:15818-15823.2006). 
Weissmann C (A 'unified theory' of prion propagation. Nature 352:679-683.1991). 
Weissmann C (The state of the prion. Nat Rev Microbiol 2:861-871.2004). 
Weissmann C  (Birth of a prion: spontaneous  generation revisited. Cell 122:165-
168.2005). 
Weissmann  C,  Flechsig  E  (PrP  knock-out  and  PrP  transgenic  mice  in  prion 
research. Br Med Bull 66:43-60.2003). 
Westergard L, Christensen HM, Harris DA (The cellular prion protein (PrP(C)): its 
physiological function and role in disease. Biochim Biophys Acta 1772:629-
644.2007). 
Westermark P (ed.) (2006) Amyloidosis and Amyloid Proteins: Brief History and 
Definitions. 
Westermark  P,  Benson  MD,  Buxbaum  JN,  Cohen  AS,  Frangione  B,  Ikeda  S, 
Masters CL, Merlini G, Saraiva MJ, Sipe JD (Amyloid: toward terminology 
clarification.  Report  from  the  Nomenclature  Committee  of  the 
International Society of Amyloidosis. Amyloid 12:1-4.2005). 
Wickner RB ([URE3] as an altered URE2 protein: evidence for a prion analog in 
Saccharomyces cerevisiae. Science 264:566-569.1994). 
Wickner  RB,  Edskes  HK,  Shewmaker  F,  Nakayashiki  T,  Engel  A,  McCann  L, 
Kryndushkin D (Yeast prions: evolution of the prion concept. Prion 1:94-
100.2007). 
Wille  H,  Bian  W,  McDonald  M,  Kendall  A,  Colby  DW,  Bloch  L,  Ollesch  J, 
Borovinskiy AL, Cohen FE, Prusiner SB, Stubbs G (Natural and synthetic 
prion  structure  from X-ray fiber diffraction. Proc Natl Acad Sci U S A 
106:16990-16995.2009). 
Wille H, Michelitsch MD, Guenebaut V, Supattapone  S, Serban A, Cohen  FE, 
Agard DA, Prusiner SB (Structural studies of the scrapie prion protein by 
electron crystallography. Proc Natl Acad Sci U S A 99:3563-3568.2002). 
Wirmer J, Schlorb C, Klein-Seetharaman J, Hirano R, Ueda T, Imoto T, Schwalbe 
H  (Modulation  of  compactness  and  long-range  interactions  of  unfolded 
lysozyme by single point mutations. Angew Chem Int Ed Engl 43:5780-
5785.2004). 
Wolynes PG, Onuchic JN, Thirumalai D (Navigating the folding routes. Science 
267:1619-1620.1995). 
Woolhouse ME, Coen P, Matthews L, Foster JD, Elsen JM, Lewis RM, Haydon 
DT,  Hunter  N  (A  centuries-long  epidemic  of  scrapie  in  British  sheep? 
Trends Microbiol 9:67-70.2001).  
- 148 - 
Wopfner F, Weidenhofer G, Schneider R, von Brunn A, Gilch S, Schwarz TF, 
Werner T, Schatzl HM (Analysis of 27 mammalian and 9 avian PrPs reveals 
high  conservation  of  flexible  regions  of  the  prion  protein.  J  Mol  Biol 
289:1163-1178.1999). 
Xu M, Ermolenkov VV, He W, Uversky VN, Fredriksen L, Lednev IK (Lysozyme 
fibrillation:  deep  UV  Raman  spectroscopic  characterization  of  protein 
structural transformation. Biopolymers 79:58-61.2005). 
Zahn R, Liu A, Luhrs T, Riek R, von Schroetter C, Lopez Garcia F, Billeter M, 
Calzolai L, Wider G, Wuthrich K (NMR solution structure of the human 
prion protein. Proc Natl Acad Sci U S A 97:145-150.2000). 
Zahn  R,  von  Schroetter  C,  Wuthrich  K  (Human  prion  proteins  expressed  in 




    
- 149 - 
Ausführliche Deutschsprachige Zusammenfassung 
Einleitung 
Neurodegenerative  Krankheiten,  die  im  Zusammenhang  mit  dem  humanen 
Prionprotein stehen, sind durch die strukturelle Umordnung von Domänen des 
monomeren  zellulären  Prionproteins  (PrP
C)  in  eine  oligomere  -Struktur-reiche 
fibrilläre  Form  charakterisiert.  Natives  PrP
C  besitzt  einen  unstrukturierten  N-
Terminus und eine strukturell wohl definierte C-terminale Domäne, die aus drei  -
Helices  und  einem  zweisträngigen  kurzen  antiparallelen  -Faltblatt  besteht.  Die 
Strukturen  rekombinanter  Prionproteine  aus  Säugern,  Vögeln,  Reptilien  und 
Amphibien zeigen ähnliche globuläre Faltungen. Weil die nativen Strukturen der 
Prionproteine  sehr  ähnlich  sind,  erklären  sie  basierend  auf  dem  aktuellen 
Wissenstand  die  beobachteten  sequenzspezifischen  Speziesbarrieren  sowie 
Unterschiede im Zeitpunkt des Ausbruchs der Krankheit(en) nicht. 
Der  Mechanismus,  der  der  strukturellen  Umwandlung  eines  weitestgehend  -
helikalen  Proteins  in  die  `cross- ´-Struktur  des  fibrillären  Zustands  zu  Grunde 
liegt,  ist  unbekannt.  Modelle  für  den  Mechanismus  sind  auf  der  Basis  von 
elektronenmikroskopischen Daten sowie MD-Simulationen vorgeschlagen worden. 
Jedoch  sind  hoch  auflösende  strukturelle  Daten  für  den  fibrillären  Zustand  des 
Prionenproteins  nicht  verfügbar,  was  möglicherweise  auf  die  konformationelle 
Heterogenität der amyloiden Fibrillen zurück zu führen ist. Diese Fibrillen werden 
typischerweise  unter  denaturierenden  Bedingungen  generiert  (1M  GdnCl,  3M 
Harnstoff, 20mM Natriumacetat pH 5,0 bei 37°C). Unlängst wurde gezeigt, dass 
Fibrillen, die aus rekombinantem PrP gewonnen werden, für Hamster toxisch sind.  
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Obwohl  sie  posttranslational  nicht  modifiziert  waren,  erwiesen  sie  sich  in 
Hamstern im Zuge serieller Übertragung als infektiös.  
Werden  Fibrillen  unter  denaturierenden  Bedingungen  generiert,  vollzieht  das 
Prionprotein  eine  konformationelle  Umwandlung.  So  entsteht  ein  Ensemble 
entfalteter  Konformationen,  aus  dem  sich  bei  einem  kontinuierlichen 
Schüttelvorgang  Fibrillen  oder  amorphe  Aggregate  bilden.  Amyloide  Fibrillen, 
besonders  die  des  humanen  Prionproteins,  sind  konformationell  heterogen.  Die 
Heterogenität der Fibrillen könnte auch für die Vielfältigkeit der Prionenstämme 
verantwortlich  sein.  Im  Licht  der  oben  diskutierten  Experimente,  bei  denen 
Fibrillen  aus  rekombinantem  PrP  in  Hamster  eingebracht  wurden,  kann  die 
Hypothese  aufgestellt  werden,  dass  Prionenstämme  durch  verschiedene 
Konformationen  in  ihren  protofibrillären  und  fibrillären  Zuständen 
gekennzeichnet sind und dass die Konformation in vivo durch Lipidverankerung 
oder  Interaktion  mit  polyanionischen  Spezies  wie  RNA  beeinflusst  wird.  Die 
konformationelle Heterogenität  könnte außerdem mit verschiedenen  Pfaden der 
Fibrillenbildung  in  Verbindung  stehen.  Allen  Pfaden,  die  zur  Fibrillenbildung 
führen, wird es jedoch gemeinsam sein, dass sich die Polypeptidkette des nativen 
Proteins während der Fibrillenbildung lokal oder aber global entfaltet. Bisher ist 
nur  wenig  bekannt  über  die  Fibrillenbildung  unter  hoch  denaturierenden 
Bedingungen.  
Ziel der Arbeit 
Maßgebliche Fortschritte wurden im Bereich der Prionenbiologie in den letzten 
zwanzig  Jahren  erzielt.  So  gab  es  bedeutende  Fortschritte  auf  dem  Weg  zum 
endgültigen  Beweis  der  `Protein-only´-Hypothese.  Trotz  dieser  Fortschritte 
bleiben  essentielle  Fragen  unbeantwortet.  Einige  Untersuchungen  haben  die  
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Bildung  von  Fibrillen  ausgehend  von  nativ-ähnlichen  und  partiell  gefalteten 
Zuständen des rekombinanten Prionproteins gezeigt. Über die Fibrillenbildung aus 
dem entfalteten Zustand ist hingegen nur begrenzte Information verfügbar, wobei 
postuliert wurde, dass sich PrP partiell oder gar vollständig entfalten muss, damit 
das  konformationelle  „Umschalten“  stattfinden  kann.  Harnstoff  wurde  in  der 
Vergangenheit  zur  Entfaltung  von  Proteinen  benutzt  und  hat  umfangreiche 
Informationen über entfaltete Zustände von Proteinen geliefert. Das wesentliche 
Ziel  meiner  Arbeit  war,  die  Fibrillenbildung  des  Prionenproteins  aus  seinem 
chemisch denaturierten Zustand (8M Harnstoff pH 2,0 bei 25°C) zu etablieren und 
zu  charakterisieren  sowie  die  strukturelle  Umwandlung  einzelner 
Polypeptidsegmente vom entfalteten Zustand in den fibrillären Zustand abzubilden. 
Dies hat uns erlaubt, ein atomares Bild der Dynamik und der Missfaltungsereignisse 
des Prionproteins zu zeichnen.  
Ergebnisse 
   Zuordnung 
Ein  umfassendes  Verständnis  des  Missfaltungs-  und  Aggregationprozesses  des 
Prionproteins erfordert die Charakterisierung aller Spezies, die auf dem Weg durch 
den – thermodynamisch gesprochen – Aggregationstrichter populiert werden. Diese 
beinhalten  den  entfalteten  Zustand,  partiell  gefaltete  Intermediate,  präfibrilläre 
Oligomere,  Protofibrillen  und  ausgereifte  amyloide  Fibrillen.  Das  Ensemble  des 
entfalteten Zustands ist von besonderer Wichtigkeit, weil gemeinhin angenommen 
wird,  dass  das  Prionprotein  bzw.  jedes  andere  Protein  sich  im  Verlauf  der 
Missfaltung  partiell  oder  vollständig  entfalten  muss.  Die  strukturelle 
Charakterisierung  des  entfalteten  Zustands  des  rekombinanten  Prionproteins 
mittels NMR ist auf Grund der komplexen Natur des Proteins außerordentlich  
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herausfordernd  gewesen.  Grundsätzlich  ist  die  NMR-spektroskopische 
Untersuchung  wegen  der  geringen  Dispersion  der  Amid-  und 
Kohlenstoffresonanzen in entfalteten oder partiell gefalteten Proteinen schwierig. 
Der  Aggregationsprozess  des  Prionproteins  erschwerte  die  Zuordnung  des 
Proteinrückgrats  beträchtlich.  Ein dreidimensionales  NMR-Experiment  erfordert 
üblicherweise  drei  bis  vier  Tage  Messzeit;  Zeit,  in  der  sich  das  Verhältnis  von 
Monomer zu Oligomer in der NMR-Probe verändert. Mit Hilfe von HNN- und 
MUSIC-basierten  HSQC-Experimenten  konnten  die  Amidrückgratresonanzen 
eindeutig  identifiziert  und  zugeordnet  werden.  Die  anfängliche  Zuordnung  der 
Amidrückgratresonanzen  wurde  mittels  herkömmlicher 
Tripelresonanzexperimente  (HNCACB,  CBCA(CO)NH,  HNCA,  HN(CO)CA, 
HNCO, HCCCONH) vorgenommen. In einer bedeutenden Anzahl von Fällen 
wurde Resonanzüberlapp festgestellt, der durch die Kombination von zwei oder 
mehr Experimenten behoben werden konnte. Die nahezu vollständige Zuordnung 
der H
N und 
15N Proteinrückgratresonanzen der rekombinanten PrP-Fragmente 90-
230, 121-230 und 166-230 in 8M Harnstoff pH 2,0 bei 25°C konnte erzielt werden.   
   Aminosäuren des Fibrillenkerns 
Das rekombinante Prionprotein bildet Amyloid-ähnliche Fibrillen in einer hoch 
denaturierenden Umgebung, was durch EM und AFM bestätigt werden konnte. 
Wir  haben  die  Veränderungen  während  der  Fibrillenbildung  mit  NMR-
Spektroskopie verfolgt und können die Resonanzen basierend auf ihrem Verhalten 
grob in drei Kategorien einteilen: (I) Resonanzen mit einer langsamen Abnahme der 
Signalintensität  (90-144),  (II)  Resonanzen  mit  einer  schnellen  Abnahme  der 
Intensität,  die  zum  Schluss  vollständig  verschwinden  (145-223),  wobei  einige 
Aminosäuren (149, 150, 151 und 177) bis zum vierten Tag in dieser Region eine 
langsamere Abnahme zeigen und die Aminosäuren 180 und 208 am siebten Tag  
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noch  beobachtbar  sind,  und  (III)  Resonanzen,  die  während  des 
Aggregationsprozesses  eine  Veränderung  in  ihrer  chemischen  Verschiebung 
erfahren.  Der  Verlust  an  Signalintensität  kommt  auf  Grund  langsamer  durch 
Molekülrotation  bedingter  Reorientierung  zustande,  ausgelöst  durch  die  rigiden 
Bereiche der Fibrillen. Auf der anderen Seite stammen die Signale, die beobachtbar 
bleiben, von beweglichen Bereichen der Fibrillen. Das Vorhandensein rigider und 
beweglicher Fibrillenbereiche wird außerdem durch Festkörper-NMR-Experimente 
unterstützt. Somit bildet das Segment zwischen den Aminosäuren 145 und 223 den 
rigiden Kern der Fibrille, was  -Strang 2, Helix 2 und dem wesentlichen Teil von 
Helix  3  der  nativen  monomeren  Struktur  entspricht.  Die  C-terminalen 
Aminosäuren von 224 bis 230 weisen Signalverschiebungen auf und deuten deshalb 
die Anpassung an eine spezifische Fibrillenkonformation an. Der hauptsächliche 
Teil  des  N-terminalen  Segments  90-144  verbleibt  dynamisch,  was  durch  seine 
Zugänglichkeit für Amyloid-spezifische Antikörper verstanden werden kann. Dies 
liefert neuartigen strukturellen Einblick in die Amyloid-Bildung ausgehend vom 
entfalteten Zustand des Fragmentes 90-230, welches den Proteinase K-resistenten 
Teil natürlich vorkommender Prionen darstellt. Frühere Untersuchungen auf der 
Basis von H/D-Austausch-MS- sowie EPR-spektroskopischen Experimenten hatten 
für den Fibrillenkern den Aminosäureabschnitt 160-220 etabliert. In diesen Studien 
erfolgte die Fibrillenbildung ausgehend von entweder nativ-ähnlichen oder partiell 
entfalteten Zuständen des rekombinanten Prionproteins. Deshalb ist es durchaus 
bemerkenswert, dass Fibrillen, die ausgehend vom monomeren entfalteten Zustand 
gebildet werden, den gleichen Amyloid-Kern aufweisen. 
   Polymorphismus 
Die  auf  der  molekularen  sowie  auf  der  Quartärstrukturebene  zu  findende 
strukturelle  Heterogenität  amyloider  Fibrillen  zu  verstehen,  ist  eine  große  
- 154 - 
Herausforderung an die Wissenschaft von heute. Es ist allgemein bekannt, dass die 
Kernbildung  als  Vorstufe  und  die  Kinetik der  Bildung  von amyloiden Fibrillen 
nicht nur von inhärenten Eigenschaften wie Aminosäurezusammensetzung bzw. –
sequenz  oder  Polypeptidkettenlänge,  sondern  auch  von  experimentellen 
Bedingungen  wie  Temperatur,  Konzentration(en)  an  Ionen  und/oder 
Denaturantien,  pH,  der  Anwendung  von  Schüttelbewegungen  und  dem 
Vorhandensein von Aggregationskeimen abhängt. Trotz der Kenntnis über diese 
Faktoren ist der Mechanismus der Selbstassemblierung, der zur Bildung geordneter 
Fibrillen führt, nicht gut verstanden. Die Kombination dieser Faktoren trägt zu 
einer  der  schwierigsten  Fragestellungen  im  Bereich  der  Proteinaggregation  bei, 
welche  das  Auftreten  des  Aggregat-  bzw.  Fibrillenpolymorphismus’  behandelt. 
Aggregate können verschiedene Vorzugsarchitekturen aufweisen, was teilweise von 
nur  geringfügigen  Änderungen  in  der  Aminosäuresequenz  oder  den 
experimentellen Bedingungen abhängt. In unseren Studien waren wir in der Lage, 
die Fibrillenbildung in einer hoch denaturierenden Umgebung (8M Harnstoff pH 
2,0)  zu  beobachten.  Die  so  gebildeten  Fibrillen  zeigen  strukturellen 
Polymorphismus, was mittels EM, AFM und NMR festgestellt wurde, und sind 
unterglykosylierten Scrapie-Fibrillen ähnlich. Die verschiedenen Morphologien der 
Fibrillen  sollen  in  verschiedenen  molekularen  Strukturen  begründet  sein  und 
könnten  zur  Entstehung  verschiedener  Prionenstämme  führen.  Deshalb  ist  es 
notwendig, Einblick in das Phänomen der Prionenstämme zu gewinnen, wo ein 
und  dasselbe  Prionprotein  eine  Auswahl  infektiöser  Konformationen  annehmen 
kann, die sich hisichtlich ihrer Spezifität und Übertragungsbarriere unterscheiden.  
   Adaptierung 
Fibrillen  wurden  gegen  Wasser  pH  2,0  dialysiert  und  anschließend  ein 
Pufferaustausch mit 70% D2O pD 2,0 vorgenommen, um Deuteriumaustausch zu  
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beobachten.  Fibrillen  wurden  nach  Dialyse  und  Pufferaustausch  mittels  EM 
verifiziert.  Im  Gegensatz  zum  allgemeinen  Verständnis,  dass  amyloide  Fibrillen 
rigide sind, zeigen neue Studien, dass diese nicht vollständig rigide sind, sondern 
kontinuierlich  umgebildet  werden.  Aus  diesem  Grund  sind  amyloide  Fibrillen 
nicht statische, sondern dynamische Strukturen. Die meisten Aminosäuren zeigen 
Schutz vor Austausch von gut 40%, wohingegen die Sequenzabschnitte 120-123, 
144-149,  174-180  und  187-194  geringen  Austauschschutz  aufweisen  und  somit 
lösungsmittelzugänglich sind. Die Region 187-194 ist relativ bemerkenswert, weil 
die  zugehörigen  Signale  vollständig  verschwinden.  Sie  ist  reich  an 
Threoninseitenketten (HTVTTTTK) und zeigt ein hohes Maß an Beweglichkeit. 
Die Fibrillen, die mit einem Fragment des Prionproteins aus Schaf (Helices 2 und 3) 
gebildet wurden, weisen für diese Aminosäuren ein ähnliches Verhalten auf. Dies 
deutet  darauf  hin,  dass  sich  Fibrillen  als  Reaktion  auf  veränderte 
Lösungsbedingungen  strukturell  umordnen  und  dass  der  Amyloid-Kern  nicht 
vollständig  rigide  ist  und  bestimmten  Aminosäuren  erlaubt,  eine  den 
Lösungsbedingungen entsprechende Konformation anzunehmen.  
   Ausblick 
Eine der Ausschlag gebenden Fragestellungen im Bereich der Prionenbiologie ist die 
strukturelle Charakterisierung löslicher PrP-Oligomere sowie unlöslicher Fibrillen 
(PrP
Sc).  Die  vollständige  strukturelle  Charakterisierung  löslicher  oligomerer 
Intermediate ist schwierig auf Grund ihrer kurzen Lebensdauern und weil sie eine 
große  Anzahl  an  Konformationen  und  Aggregationsgraden  aufweisen. 
Aggregationsanfällige  Monomere  können  verschiedene  Pfade  einschlagen  und 
deshalb  zur  Bildung  von  amorphen  Aggregaten,  ringförmigen  oder  globulären 
Oligomeren oder einer Anzahl morphologisch unterschiedlicher Fibrillen führen.  
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Der entfaltete Zustand stellt die am wenigsten eingeschränkte Struktur dar, weshalb 
unsere Beobachtung der Fibrillenbildung in einer hoch denaturierenden Umgebung 
bedeutsam  und wichtig ist.  Dies zeigt, dass Fibrillen  ausgehend vom  entfalteten 
Zustand des Prionproteins gebildet werden können. Unsere Daten füllen deshalb 
den bisher kahlen Informationsraum über die Fibrillenbildung aus dem entfalteten 
Zustand. Der lösungsmittelunzugängliche und rigide Kern erstreckt sich über den 
Sequenzbereich  145-223,  während  die  letzten  sieben  C-terminalen  Aminosäuren 
eine  konformationelle  Umwandlung  im  Zuge  der  Fibrillenbildung  durchlaufen. 
Hochauflösende NMR-Spektroskopie ist die Methode der Wahl zur Untersuchung 
der  Prionenbildungskinetik,  weil  sie  zwischen  verschiedenen  Prionenstämmen 
unterscheiden  kann,  die  auf  Grund  von  Änderungen  in  ihrer  Architektur 
unterschiedliche  NMR-Spektren  aufweisen  werden.  Diese  Änderungen  können 
zeitabhängig  verfolgt  werden,  wenngleich  wegen  großer  Variabilität  in  der 






    
- 157 - 
Acknowledgements  
It is my pleasure to extend my sincere gratitude and appreciation to all the people 
who made this dissertation possible.  
First  and  foremost,  I  would  like  to  express  my  deep  sense  of  gratitude  to  my 
supervisor,  Prof.  Dr.  Harald  Schwalbe,  who  has  an  attitude  and  substance  of  a 
genius,  for  his  persistent  help,  encouragement  and  valuable  guidance.  He 
continuously and convincingly conveyed a spirit of adventure in research. He has 
supported  me  throughout  my  thesis  with  his  patience  and  knowledge  whilst 
allowing me to grow as an independent researcher. I shall always remain indebted 
to  him.  I  am  also  thankful  to  him  for  providing  unrestricted  access  to  the 
laboratory facilities. 
Words are not enough to convey my sincerest thanks to my “zwietgutachter” Prof. 
Dr. Clemens Glaubitz for his encouragement, support, suggestions and continuing 
interaction, which provided me with a deeper insight into my research area. I am 
also thankful to Dr. Ines Lehner, Nicole Pfleger, Dr. Jakob Lopez and Dr. Jun 
Yang; who spent many hours to get the worthy spectrum from flexible fibrils.  
I  would  like  to  thank  Dr.  Janet  Vonck  for  helping  me  out  with  electron 
microscopy by capturing beautiful images of fibrils. Deep appreciation should be 
made  to  Dr.  Khashti  Ballabh  Joshi,  Dr.  Thorsten-Lars  Schmidt  and  Prof.  Dr. 
Alexander Heckel for their contribution on capturing and analyzing the atomic 
force microscopic images of fibrils. I would like to thank Prof. Dr. Bernd Brutschy 
and  Mihaela  Cazacu  for  trying  out  the  LILBID  measurements  and  wonderful 
discussions on amyloids.   
I express my sincere thanks to Prof. Dr. Walter Volknandt, Dr. Monika Schneider, 
and Dr. Krishna Saxena, who kept me aware of biosafety during this research.  
My warm thanks are due to Dr. Christian Richter and Dr. Johannes Gottfried 
Zimmermann, for all the help at the spectrometers and rescuing at difficult times. 
My heartiest thank goes to Dr. Karin Abarca-Heidemann for giving me aspirations 
and  courage,  when  I  needed  it  most.  Her  cheerful  and  lively  nature  was  an 
instrumental and driving force many a times.   
- 158 - 
I wish to express my warm and sincere thanks to Dr. Henry Jonker, who shared 
the  bench  next  to  me  in  biolab,  for  his  friendship  and  stimulating  interactions 
during the long hours in the lab.  
Dr. Stephan Rehm, my special thanks goes to him; he has been a helping hand, 
whenever I look for one, whether it is moving in to new apartment or in office. 
Huge, huge thanks to Anna Paulus and Elena Hartmann for making life easier. It 
would have been impossible for things to work out properly without being them 
around. I express my heartfelt and deep sense of gratitude to you. 
I would like to thank Dr. Christian Gerum, Dr. Kai Schalepow, and Dr. Sridahr 
Sreeramulu for proof reading of my thesis. 
I extend my thanks to Dr. Karin Abarca-Heidemann, Janina Buck and Dr. Kai 
Schalepow for German translations.  
Best regards to all the past and present members of our lab for providing a very 
good atmosphere: Dr. Karin Abarca Heidemann, Dr. Nuria Aboitiz, Dr. Katrin 
Ackermann,  Dr.  Aphrodite  Anastasiadis-Pool,  Marie  Anders-Maurer,  Tomislav 
Argirevic, Neda Bakhtiari, Katja Barthelmes, Dr. Holger Berk, Anna Bischoff, Dr. 
Janina Buck, Florian Buhr, Dr. Aleksejs Cerepanov, Dr. Emily Collins, Dr. Elke 
Duchardt-Ferner, Dr. Jan-Peter Ferner, Dr. Boris Fürtig, Dr. Christian Gerum, Dr. 
Artur Gieldon, Dr. Jürgen Graf, Dr. Steffen Grimm, Martin Hähnke, Friederike 
Heinicke, Fabian Hiller, Dr. Serge Ilin, Dr. Henry Jonker, Deep Chatterjee, Dr. 
Mirko Cevec, Hannah  Steinert, Irene Bessi, Ajit Paul Kaur, Melanie  Koschinat, 
Anna Lena Lieblein, Tanja Machnik, Dr. Vijayalaxmi Manoharan, Daniel Mathieu, 
Sarah Mensch, Hillary Moberly, Dr. Muruga Poopathi Raja, Dr. Hamid Nasiri, 
Gerd Nielsen, Dr. Jonas Noeske, Senada Nozinovic, Anke Reining, Dr. Christian 
Richter, Jörg Rinnenthal, Dr. Sridhar Sreeramulu, Dr. Santosh Lakshmi Gande, Dr. 
Kai Schlepckow, Dr. Christian Schlörb, Dr. Nicole Schmut, Robert Silvers, Dr. 
Stephan Rehm, Max Stadler, Jochen Stehle, Elke Stirnal, Anna Wacker, Dominic 
Wagner, Dr. Karla Werner, Dr. Julia Wirmer-Bartoschek, Prof. Jens Wöhnert, Dr. 
Johannes Gottfried Zimmermann. 
I  am  also  grateful  to  Dr.  Markus  Fandrich,  Dr.  Ritu  Khurana,  Dr.  Ashutosh 
Kumar, Dr. Neel Sarovar Bhavesh, Dr. Navaratna Vajpayee and Prof. Dr. Raja Roy 
for fruitful discussions during conferences.   
- 159 - 
I thank my younger brother Mr. Arun Kumar Singh, for helping with complex 
mathematical problems using MATLAB.  
There are many others who have encouraged me and supported my work. I would 
like to thank them all. I thank Dr. Neeraj Tiwari, my dear old friend, for being 
there for me in my happy and sad moments. Thanks to Dr. Khalid Siddiqui and Dr. 
Sridhar  Sreeramulu  for  their  deep  and  sincere  friendship,  modest  support,  and 
motivation. I thank Dr. Radhan Ramadass and Dr. Muruga Poopathi Raja for their 
honesty and for their ways to share science and for their sense of humor. I thank 
Indian students in the campus for making it homely. A special gratitude goes to 
Jagdeep Kaur, Dr. Sarika Shastri, Dr. Santosh Kumar Mishra, Dr. Taslimarif Saiyed 
and Dr. Sanjeev Baniwal for being an extremely diverse crowd of people and at the 
same time being helpful and exciting friends. 
My  special  thanks  to  Dr.  Pankaj  Singh,  who  is  always  there,  whenever  I  have 
problem with eyes. I thank his wife Sapna Singh and little wonder “Shaurya”, who 
included me as part of their family. I also like to thank to Indian community in 
Frankfurt, especially to Bhatnagar and Srivastava families. Mr. Gagan Srivastava and 
Mrs. Renu Srivastava were like uncle and aunt, during my whole stay in Frankfurt. 
I  found  the  sweetest  cousin  in  Avanti  and  Udit.  I  also  like  to  thank  “meine 
deutschen Schwiegereltern Gudrun und Christian” and “Oma Gisela”.  
My  deepest  gratitude  goes  to  my  family  for  their  unflagging  love  and  support 
throughout my life. This work has come to completion with the blessings of my 
parents and my in-laws. I cannot express my feelings in words for my wife “Jagriti” 
who has always been a constant source of encouragement and help throughout. I 
would like to acknowledge my elder brother Shri Sanjeev Kumar Singh, who had 
been a role model for me to follow unconsciously when I was a teenager and has 
always been one of my best counselors, and sister-in-law Nilay Singh’s constant 
support and encouragement. I owe my loving thanks to me nephew Aalind; he has 
been a constant source of love.  
I gratefully acknowledge International Max Planck research school on structure and 
function of biological membranes and EU for the finance support.  
Last but not the least; I thank God for being so generous and kind to me.  
- 160 - 
Curriculum vitae   
Jitendra Kumar 
Am Brückengarten 9a 
60431, Frankfurt am Main 
 
Personal Data 
Date of Birth:   01 June 1976 
Place of Birth:   Aligarh 
Nationality:   Indian 
Family Status:   Married to Jagriti Kumar 
 
School Education: 
07/80 – 06/86  Primary  Education  at  Jugaldevi  Saraswati  Shishu  Mandir, 
Kanpur 
07/86 – 06/91  High School at Ramkrishna Mission Higher Secondary School, 
Kanpur 




07/93 – 06/96  B.Sc.  in  Physics,  Chemistry  and  Mathematics  at  Vikramajit 
Singh Sanatan Dharam College, Kanpur 
08/96 – 05/99  M.Sc. in Biotechnology at University of Calicut 
  Dissertation on “Overexpression, Purification and Characterization of Yeast 
Hexokinase  P1”  under  the  guidance  of  Prof.  Dr.  Gotam  K  Jarori, 




02/03 –   Under the supervision of Prof. Dr. Harald Schwalbe at Goethe 
University, Frankfurt  
   
Achievements: 
2003:   International Max Planck Research School Fellowship  
- 161 - 
2001:   Council  of  Scientific  and  Industrial  Research  (CSIR)  India  – 
Junior Research Fellow  
2000:    Council  of  Scientific  and  Industrial  Research  (CSIR)  India  – 
National Eligibility Test for Lectureship in Life Sciences  
1996:    Department  of  Biotechnology  (DBT),  Govt.  of  India, 
Fellowship for M. Sc. Biotechnology 
1986-93:  Junior High School Scholarship & Ekikrat Scholarship Gov. of 
Uttar Pradesh, India 
 
Experiences: 
2001 – 2003:   CSIR  –  Junior  Research  Fellow,  Division  of  Molecular  and 
Structural  Biology,  Central  Drug  Research  Institute,  Lucknow,  India 
working on project associated with Structural Genomics of Mycobactrium 
Tuberculosis, Advisor: Dr. H. S. Subramanya  
1999 – 2000:  Lecturer, Dr. Virendra Swarup Center of Advance Science and 
Technology, D.A.V. College, Kanpur, India 
 
Academic Teachers: 
Prof. Dr. V.J. Phillip, Prof. Dr. M.V. Joseph, Prof. Dr. P. N. Ravindran, Prof. 
Dr. Gotam K Jarori, Prof. Dr. K.S. Krishanan, Prof. Dr. N. P. Singh, Prof. Dr. 
Vinod Bhakuni, Prof. Dr. C.M. Gupta, Prof. Dr. P. R. Maulik, Prof. Dr. Saman 
Habib, Prof. Dr. Ritu Khurana, Prof. Dr. H. S. Subramanya, Prof. Dr. Raja 
Roy, Prof. Dr. Clemens Glaubitz and Prof. Dr. Harald Schwalbe. 
 
 
 